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Summary 
Tanzania is a country with low access to essential drugs that receives substantial drug donations (DDs) as 
in-kind gifts. To promote good donation practice, to support the ongoing health sector reform in Tanzania 
and to find effective solutions for optimising DD processes, stakeholders’ and recipients’ views on the 
appropriateness and acceptability of DDs are of particular interest. 
 
The aims of this research project were a) to characterise DD processes in Tanzania, b) to explore the 
practice and perception of Tanzanian stakeholders involved in DD processes, c) to identify similarities 
and discrepancies between the views of Tanzanian recipients and Swiss donors and d) to develop 
suggestions for optimising DD processes.  
 
The project methodology employed a participatory stakeholder analysis, a triangulation of methods and 
qualitative research tools. The following stepwise strategy enabled an analysis of the entire DD system: a) 
literature review and document analysis for description of the context, b) a postal, self-administered, 
semi-quantitative questionnaire in Tanzania and in Switzerland for defining problems in DD processes, c) 
key informant interviews in which the interviewees could reflect on the results of the Tanzanian 
questionnaire survey within the context of public health issues and d) a workshop for elaborating practical 
solutions for the optimisation of DD processes in Tanzania. Data were collected from January 2000 to 
October 2002.  
 
Tanzania has to bridge a 30% gap in drug supply. This study found that the acceptance of DDs to fill this 
gap was high. Stakeholders within the country understood that donated drugs were necessary because, 
due to poverty, drugs were either unavailable or not affordable. The prime concern of DD recipients was 
the discrepancy between their needs and the donors’ supply. DDs did not cover recipients' priority needs 
and their quantity was insufficient for sustainable treatment of patients. DDs given from a surplus, as gifts 
from individuals or as single-source DDs were perceived as problematic. However, DDs provided within 
the framework of DD programmes with a known public health effect were welcomed. Tanzania benefits 
from many such programmes. 
 
Tanzania has developed the instruments for an effective regulation of DD processes: national guidelines 
for drug donations and a national essential drug list. The existence of these tools, however, has not 
guaranteed their application. The failure to implement the guidelines for DDs was perceived as being the 
second most important problem in the Tanzanian DD process.  
 
Knowledge of the value of DDs is prerequisite for judging the economic impact of DDs on the drug 
supply, but only 27% of recipients were able to estimate the value of donated drugs. Stakeholders pointed 
out, however, that estimating drug value is difficult when the drugs do not conform to accepted quality 
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standards. This finding demonstrates the need for improved data registration, collection and dissemination 
within Tanzania. With respect to value, for these stakeholders, DD-related transaction costs must also be 
taken into consideration.  
Depending on the form of their involvement, recipients identified additional drawbacks associated with 
DDs, the focus being on structures and processes. The public sector requested more transparency in DD 
processes, the lack of transparency arising from weaknesses in public structures as well as a lack of 
information and accountability. Non-governmental organisations (NGOs) and religious facilities with 
better developed structures addressed problems such as shipment fees and insufficient infrastructure and 
training. These differences call for more collaboration between the private and public sectors and suggest 
that they could learn from each other, as recommended in the Tanzanian Health Sector Reform. 
 
Communication is crucial in the eyes of stakeholders, but was not optimal, whether between donors and 
recipients or among recipients themselves. An important complaint was that donors did not ask what was 
needed in advance and supported a supply-driven donation process.  
 
Tanzanian recipients and Swiss donors coincided in the view that the absence of sustainability and non-
relevance of donated drugs for local needs were the major problems in DD processes. Knowledge about 
donors’ needs was low among Swiss donor organisations. Only one-third of Swiss stakeholders knew the 
WHO guidelines for DDs. Both the Swiss and the Tanzanian stakeholders rated the quality of DDs as a 
problem of minor importance. However, donated drugs often did not comply with requested standards, 
even less so in Switzerland than in Tanzania. 
 
Because this study reflects the situation in 2001, directly after NGOs and PVOs stopped collecting unused 
drugs in Switzerland, donors in the for-profit sector did not understand that unused drugs should no 
longer be donated and failed to recognise that these drugs can burden a recipient. In the eyes of Tanzanian 
stakeholders unused DDs are obsolete. 
 
Suggestions of Tanzanian stakeholders to optimise DD processes were consistent with the core principles 
of the WHO guidelines for DDs: a) meeting local needs (maximum benefit for the recipients), b) 
participatory approach (respecting the wishes of the recipient), c) optimised DD quality (no double 
standard in quality) and d) effective communication between donor and recipient. 
 
The findings of this project contribute to a comprehensive understanding of DD processes in Tanzania. 
They show that the performance of a health system has a major impact on the quality of DD processes. 
Recipients in DD processes need the support that should be provided by the Tanzanian heath sector 
reform plans, which include continuing education of health workers and a better defined responsibility in 
the pharmaceutical sector to overcome problems with the structure and management of DD processes. In 
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addition to improved implementation of DD guidelines by both donors and recipients, the main proposals 
arising from this project are the following: Donors should actively communicate with recipients and 
thereby promote a demand-driven DD process that respects Tanzanian regulations. Recipients on the 
other hand should a) translate the guidelines for DDs into Swahili, b) assure systematic collection of data, 
c) strengthen the collaboration between the public and the private sectors and d) establish an autonomous, 
centralised body for coordination of DDs.  
These findings also call for further research, which might study in more depth drug donations given 
within the framework of programmes, explore the means for better implementation of guidelines for DDs 
and investigate the mechanisms of communication between donors and recipients together with how these 
might be improved. 
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Zusammenfassung 
In Tansania ist der Zugang zu unentbehrlichen Medikamenten („essential drugs“) für einen grossen Teil 
der Bevölkerung erschwert oder nicht möglich. Für viele Geber ist die Spende von Medikamenten eine 
mögliche Strategie, um diese Situation zu verbessern. So erhält auch Tansania eine beträchtliche Menge 
an Medikamentenspenden. In diesem Zusammenhang ist es von besonderem Interesse, die Ansichten von 
Stakeholdern und Empfängern zur Angemessenheit und Akzeptanz von Medikamentenspenden zu kennen 
um a) eine gute Spendenpraxis zu fördern, b) aktuelle Massnahmen der Reformen im Gesundheitswesen 
nicht durch unsachgemässe Medikamentenspenden zu behindern und c) wirkungsvolle Lösungen für eine 
Verbesserung von Spendenprozessen zu finden.  
 
Medikamentenspenden sind in diesem Projekt als Spenden in Form von Naturalien definiert. 
Geldspenden zum Kauf von Medikamenten wurden nicht untersucht. Stakeholder sind tansanische 
Interessensvertreter im Bereich von Medikamentenspenden. Dabei kann es sich um Empfänger und 
Nicht-Empfänger handeln1.  
 
Forschungsziele in dieser Arbeit waren: a) Spendenprozesse in Tansania zu beschreiben, b) Die 
Anwendung von Medikamentenspenden durch Stakeholder, sowie deren Sichtweise über 
Medikamentenspenden zu erforschen, c) Übereinstimmungen und Gegensätze in Verhalten und 
Meinungen von Stakeholdern in Tansania und in der Schweiz zu identifizieren, d) Vorschläge, wie 
Spendenprozesse verbessert werden können, zu erarbeiten. 
 
Die Methodik basierte in diesem Projekt auf einer Stakeholderanalyse mit partizipativem Ansatz, sowie 
auf einer Methodentriangulation und der Anwendung der Instrumente der qualitativen Forschung. Dabei 
wurde ein schrittweises Vorgehen verfolgt, das eine umfassende Analyse des Spendensystems 
ermöglichte: a) die Beschreibung des Kontextes durch eine Literaturrecherche und durch 
Dokumentenanalyse, b) die Erfassung der Probleme von Spendenprozessen in Tansania und in der 
Schweiz mittels einer semiquantitativen, schriftlichen Befragung, c) die Diskussion der Resultate aus der 
Befragung mittels Key Informant Interviews in Tansania, d) die Erarbeitung von praktischen Lösungen 
zur Verbesserung von Spendenprozessen in Tansania in einem Workshop. Die Daten wurden von Januar 
2000 bis Oktober 2002 gesammelt.  
 
Für die Gewährleistung der Medikamentenversorgung fehlen in Tansania 30% der benötigten 
Medikamente. Um diese Versorgungslücke zu überbrücken, war die Bereitschaft der Stakeholder gross, 
Medikamentenspenden zu akzeptieren. Dass Medikamente fehlen und dass sie für die Bewohner in 
                                                     
1 Wenn es sich um Schweizer Stakeholder handelte, wird dies explizit erwähnt. 
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Tansania sehr oft unerschwinglich sind, ist im Kontext der Armut zu betrachten. Für die Empfänger war 
die Diskrepanz zwischen ihren Bedürfnissen an Medikamenten und dem, was effektiv gespendet wurde, 
ein äusserst wichtiges Thema. Spenden haben den wirklichen Bedarf nicht gedeckt und die Menge der 
Spenden war nicht geeignet für eine Langzeittherapie und die nachhaltige Versorgung der Patienten. 
Medikamente, die aus einem Überschuss bei Spenderorganisationen stammen, geschenkte Medikamente 
von Einzelpersonen und einmalige Gaben von Spenden durch Organisationen und Firmen wurden als 
problematisch betrachtet. Hingegen wurden Medikamente geschätzt, die im Rahmen eines Programms 
mit einem klar definierten Ziel gespendet werden. Tansania ist in einige Programme dieser Art involviert. 
 
In Tansania wurden die wichtigsten Instrumente für eine effektive Regulierung von Spendenprozessen 
erlassen, unter anderem Richtlinien für Medikamentenspenden und eine Liste der unentbehrlichen 
Medikamente. Das Vorhandensein dieser Verordnungen garantiert aber noch nicht deren Anwendung. 
Das Versäumnis, die Richtlinien für Medikamentenspenden zu implementieren, wurde als 
zweitwichtigstes Problem in tansanischen Spendenprozessen angesehen.  
 
Kenntnisse über den Wert von Medikamentenspenden sind Grundlage, um ihre ökonomische Auswirkung 
auf die Medikamentenversorgung zu beurteilen. Nur 27% der Empfänger konnte jedoch den Wert der 
Medikamentenspenden, ausgedrückt in lokaler Währung, abschätzen. Stakeholders wiesen darauf hin, 
dass es einerseits schwierig sei, Medikamente von schlechter Qualität zu bewerten. Dieses Resultat zeigt 
andererseits auf, dass die Datenerhebung in Tansania verbessert werden muss. Um den effektiven Wert 
der Spenden angeben zu können, sind ebenfalls Transaktionskosten, wie Transportkosten oder Zolltaxen 
zu berücksichtigen. Weitere Probleme in Spendenprozessen wurden in den einzelnen Sektoren 
unterschiedlich gewichtet. Der öffentliche Sektor verlangte nach mehr Transparenz. ungenügende 
Transparenz basierte in den Augen der Stakeholders auf Fehlen von wichtigen Informationen und auf 
fehlender Verantwortlichkeit. Nichtregierungsorganisationen (NGOs) und religiöse Organisationen 
wünschten sich bessere Strukturen. Dabei wurde speziell auf eine mangelhafte Infrastruktur (wie z.B. 
Probleme mit der Lagerung von Medikamenten, mit unsachgemäss verwalteten Kühlketten), auf zu hohe 
Zollkosten und auf eine mangelnde Ausbildung und Weiterbildung des Personals hingewiesen. Die 
Verschiedenartigkeit der Probleme in den einzelnen Sektoren könnte ein Anreiz sein, vermehrt 
voneinander zu lernen. Eine verbesserte Zusammenarbeit und eine klare Aufgabenverteilung zwischen 
dem öffentlichen und dem privaten Sektor ist auch ein wichtiges Thema in der in Tanzania laufenden 
Reform des Gesundheitswesens, der „Health Sector Reform“.  
 
Kommunikation ist ein entscheidender Faktor in Spendenprozessen; diese wurde aber weder zwischen 
Spendern und Empfängern, noch unter den Empfängern selbst als optimal bewertet. Es wurde 
insbesondere beanstandet, dass Spender nicht im voraus fragen, was im Empfängerland gebraucht wird. 
Dadurch fördern sie einen Spendenprozess, der primär durch das Angebot gesteuert wird.  
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Auch die Spender in der Schweiz waren übereinstimmend mit den Empfängern in Tansania der Ansicht, 
dass fehlende Nachhaltigkeit in Spendenprozessen und eine fehlende Relevanz der gespendeten 
Medikamente für die lokalen Bedürfnisse die wichtigsten Probleme in Spendenprozessen sind. In 
Schweizer Organisationen war das Wissen um die Bedürfnisse der Empfänger klein. Wie in Tansania 
kannte nur ein Drittel der Schweizer Spender die WHO Richtlinien für Medikamentenspenden. 
Tansanische und Schweizer Stakeholders gaben der Qualität von gespendeten Medikamenten einen 
geringeren Stellenwert als den oben genannten Problemen in Spendenprozessen. Dennoch entsprachen 
die gespendeten Medikamente oft nicht den Qualitätsanforderungen und den nationalen Richtlinien. Dies 
war in der Schweiz noch weniger der Fall als in Tansania.  
 
Dieses Projekt beschreibt die Situation in 2001, gerade nachdem in der Schweiz das gezielte Sammeln 
von unbenutzten Medikamenten durch NGOs aufgrund der Empfehlungen der WHO aufgegeben wurde. 
Die Befragung der Stakeholder zeigte, dass Spender vom gewinnorientierten Sektor, wie 
Offizinapotheken und Pharmafirmen, nicht verstanden hatten, weshalb man diese Art von Spenden nicht 
mehr weitergeben sollte, und sie konnten nicht begreifen, dass diese Medikamente dem Empfänger eher 
schaden als nutzen. In den Augen der tansanischen Empfänger sind Spenden von unbenutzten 
Medikamenten obsolet.   
 
Empfehlungen der tansanischen Stakeholder, wie man Spendenprozesse verbessern könnte, stimmten mit 
den Grundprinzipien der WHO Richtlinien für Medikamentenspenden überein: a) die Hilfe muss den 
lokalen Bedürfnissen angepasst sein und sich an den im Empfängerland bekannten Medikamenten 
orientieren, b) die Qualitätsstandards müssen dieselben sein, welche auch in Spenderländern gelten, und 
es darf keine Kompromisse geben, c) der Einsatz von Medikamenten muss die Gesundheitspolitik der 
Empfängerländer berücksichtigen und d) zwischen Spendern und Empfängern soll es einen ausreichenden 
Informationsaustausch geben. 
 
Die Ergebnisse dieses Forschungsprojektes leisten einen Beitrag zu einem umfassenden  Verständnis von 
Spendenprozessen in Tansania. Die Leistungsfähigkeit des Gesundheitssystems eines Landes hat dabei 
einen wesentlichen Einfluss auf die Qualität des Spendenprozesses. Empfänger brauchen eine 
Unterstützung, wie sie in der „Health Sector Reform“ in Tansania gefordert wird: Gut ausgebildetes und 
informiertes Personal und klar definierte Verantwortlichkeiten im pharmazeutischen Sektor können 
wesentlich zur Verbesserung struktureller Probleme und der Probleme mit dem Management von 
Spenden beitragen. Eine verbesserte Implementierung der Richtlinien für Medikamentenspenden sollte in 
Tansania und in der Schweiz erfolgen. Spendern wurde empfohlen, aktiv mit Empfängern zu 
kommunizieren. Dabei sollte auf ein Spendenprozess geachtet werden, der von der Nachfrage geleitet 
wird und die Gesetze und Regulierungen Tansanias respektiert. In Tansania sollten a) die nationalen 
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Richtlinien für Medikamentenspenden in die Landessprache Suaheli übersetzt werden, b) eine 
systematische Datenerhebung eingerichtet werden, die es dem Empfänger ermöglicht den 
Medikamentenbedarf festzulegen, c) eine Zusammenarbeit des öffentlichen und des privaten Sektors 
gestärkt werden und d) eine zentralisierte Koordinationsstelle für Medikamentenspenden geschaffen 
werden.  
Die Resultate aus diesem Projekt zeigen den Bedarf nach einer weitergehenden Forschung, welche auf 
Teilaspekte im Spendenbereich ausgerichtet werden sollte: a) Spendenprogramme sollten vertieft 
analysiert werden, um Problemen, wie sie in dieser Thesis beschrieben werden, besser begegnen zu 
können, b) Möglichkeiten, wie Richtlinien für Medikamentenspenden besser implementiert werden 
können, sollten erforscht werden, c) Kommunikationsabläufe zwischen Spendern und Empfängern sollten 
untersucht und Strategien für eine verbesserte Kommunikation entwickelt werden, die vermehrt neue 
Technologien nutzen. 
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There are not enough drugs for all patients 
Die Medizin reicht nicht für alle Patienten aus 
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1 Introduction 
This research project presents an analysis of the views, knowledge and practices of stakeholders 
(recipients and non recipients) of in kind drug donations (DDs) at the country and local level. It includes 
the elaboration of suggestions for optimised DD processes and the detection of discrepancies between 
Tanzanian recipients’ and Swiss donors’ views and practices. A stimulus for this project was the 
publication of the revised interagency guidelines for drug donations, which were issued in 1996 and 
revised in 1999 through the World Health Organisation (WHO) in cooperation with major international 
humanitarian relief agencies [WHO, 1999]. These guidelines intended to serve as an evidence-based tool 
to be adapted for good donation practice (GDP), as an aid to decision making, as a reference for national 
or institutional guidelines and to empower recipients. The positive impact of these guidelines on the 
quality of DDs and DD processes is well documented [Reich MR, 1999; WHO, 2000c; Autier P et al., 
2002]. Often, however, DDs still failed to take account of recipients’ needs, of existing capacities and 
resources of the recipients’ country. They also did not meet national and international quality standards 
and mismanagement often wasted human and economic resources [Reich MR, 1999; Saunders P, 1999; 
Guilloux A and M Suerie, 2000; Snell B, 2001]. To avoid these failures, DDs have to comply not only 
with globally valid standards but also with requirements at the local level, and they must respect the 
particular needs and interests they intend to serve [WHO, 2000c; Junghanss T, 2001; Weiss MG et al., 
2001]. This study was targeted, to identify the characteristics of DD processes at the country level and to 
support stakeholders to optimise DDs, bearing in mind an improvement of outcomes at the patient level.  
1.1 Drug supply gap 
In the last 30 years, access to essential drugs1 doubled worldwide from an estimated 2 billion people 
worldwide to 4 billions. This gain is a success story for the essential drug concept, which was introduced 
in 1975 by the WHO assembly. WHO defined essential drugs as those drugs that satisfy the health care 
needs of the majority of the population and should therefore be available at all times in adequate amounts 
and in appropriate dosages [Quick JD et al., 2003]. In 1977, the first WHO Model List of Essential drugs 
was launched, containing 208 individual drugs which could provide safe, effective treatment for the 
majority of communicable and non-communicable diseases. This list is revised every two years. In 1978, 
the WHO/UNICEF Conference on Primary Health Care at Alma-Ata included access to essential drugs as 
one of the eight elements of primary health care [WHO, 1978]. In 1979, the WHO Action Programme on 
Essential Drugs was established. The essential drug concept evolved to one of the most cost effective 
actions of present public health care efforts. The concept is flexible and adaptable to many different 
situations. But, access to drugs is not only about adequate resources and has to be seen in a wider context. 
                                                     
1 Although the recent WHO terminology uses “medicine” instead of “drugs”, “pharmaceuticals” or other names, we 
continue using the term “drug”, because of the term “drug donation” that is still mainly used.  
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From the consumers’ perspective access to essential drugs means therefore accessibility (location of the 
service), availability (type and quantity of the drug needed available), affordability (price of drugs 
adapted to patient’s ability to pay) and acceptability of drugs (attitude, social and cultural background of 
patients) [FIP Conference, 2002]. Major achievements of this concept are the development of a national 
drug policy in over hundred countries, ethical criteria for medical drug promotion, objective information 
on rational drug use, improvement of medical training, the establishment of WHO Programme for 
International Drug Monitoring, and publicly available price information [Quick JD et al., 2002; Quick JD, 
2003].  
 
Today, effective drugs exist for treatment or alleviation of nearly every major illness and they offer a 
simple and cost-effective solution to man health problem [Pecoul B et al., 1999]. Despite gains of the 
essential drug concept, still one third of the world population in low-income countries and half of the sub-
Saharan Africa and South-East Asian population lack regular access [Quick JD, 2003]. This lack of 
access to drugs is a direct contradiction to the fundamental principle of health as a human right [Hogerzeil 
HV, 2006].  
 
Major reasons for low access are poverty and resource constraints of individuals and health systems and 
millions are trapped in a vicious cycle of disease and poverty [WHO, 2004c]. Each year 20 percentages of 
deaths are caused by infectious diseases, with the overwhelming majority of these occurring in resource-
poor regions and about half of these deaths in the developing world are due to tuberculosis (TB), malaria, 
and HIV/AIDS. Poor households are caught between high disease burden, inadequate public funding for 
health and high drug prices. They pay 50-90% of needed drugs out-of-pocket [Quick JD et al., 2002].  
 
Barriers concerning access to essential drugs are very complex and relate either to existing drugs as 
well as to the development of affordable new drugs. Some barriers are based on global inequities, arising 
often from multiple market failures[Reich MR, 2000]. Other barriers differ from country to country and 
tackle health systems with inadequate national commitment, human resource inadequacies including 
pharmacists, basic health infrastructure deficiencies, weak political will (lack of accountability and good 
governance), persistent lack of donor assistance and coordination [Ruxin J et al., 2005; UN Millennium 
Development Project, 2005]. Barriers tackle each stage of medicines’ life cycle [Anderson S et al., 2004] 
and comprise unfair financing, high medicine prices, lack of availability due to fluctuating production or 
prohibitive cost, potential consequences of recent trade agreements, poor-quality and counterfeit drugs, 
unreliable delivery systems, irrational use, inefficient combination of private and public supply systems 
[Pecoul B et al., 1999; WHO, 2000b; Quick JD et al., 2002].  
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The complexity of the problems require multiple strategies to negotiate access problems. According to 
WHO, four critical components are to be considered for a sustainable access to essential drugs [Reich 
MR, 2000; WHO, 2000a; Anderson S et al., 2004; WHO, 2004]:  
1. Rational selection and use of drugs: national essential drug list, standard treatment guidelines, 
independent reliable drug information. 
2. Sustainable financing: equitable financing mechanisms, social and private insurances, reduction of 
out-of-pocket spending, targeted external funding with grants, loans, in-kind donations with the aim 
to strengthen local capacity and maintaining effective supply, support of non-governmental 
organisations (NGOs). 
3. Reliable systems: efficient mix of public and private supply services, good pharmacy practice with 
improved warehousing and distribution systems and better control of corruption, quality assurance 
through regulatory control. 
4. Affordable prices: pooled procurement, using the international market through drug tendering, price 
control, generic policies, encouraging local production, differential pricing, Trade Related Intellectual 
Property Rights (TRIPS) safeguards. 
 
The majority of WHO essential drugs are off-patented and subject to generic competition. In this case, 
conflicts are minor and strategies to expand access to those drugs are better tested. But, the incidence of 
HIV/AIDS and chemical resistance against drugs for TB and Malaria demand innovative ideas and access 
to newer drugs. In addition, some life-saving treatments are not available in developing countries because 
drugs for tropical diseases are not profitable enough for drug companies and there is little research being 
carried out. Yet, not all problems are exclusively caused by pharmaceutical companies. Thus, a global 
commitment is needed in research and development (R& D) through public subsidies, private public 
partnerships, protection of product patents and fixed financial incentives.  
 
Access to medicine is a highly political issue and subject to intense lobbying by all principal 
stakeholders. Awareness rising was boosted through rigorous campaigns of NGOs such as Oxfam, Health 
Action International (HAI) and Médecins sans Frontières (MSF), because all theses strategies need 
resolving conflicts of interests between private and public actors [Anderson S et al., 2004]. In recent 
years, first progresses were made and access to essential drugs, especially those for treating HIV, has 
expanded in the developing world. Access to new drugs is thus included in the Millennium Development 
Goal 8 [UN Millenium Development Goals]. Philanthropy and foundations, public private partnerships 
and not-for-profit initiatives are as important initiatives at stake.  
 
Summarised, the global drug supply gap affects especially poor and vulnerable people. Major reasons 
are a) unfair financing, b) substandard and counterfeit drugs, c) irrational drug use, d) unreliable supply 
systems and e) little R&D for new drugs for neglected diseases. Promising developments emerged 
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through global initiatives. In development cooperation (DC), in-kind DDs have been proposed for 
supporting underfunded, weak drug supply systems over the short or middle term, but only if targeted at 
specific diseases and if they do not hinder efforts to develop a sustainable financing mechanism of drug 
supply [WHO, 1998; Reich MR, 2000; WHO, 2004]. 
1.2 In-kind drug donations 
In-kind DDs are defined as manufactured drugs imported free into the recipients’ country. They can be 
classified in two categories. The first category covers DDs in emergency situations such as disasters and 
wars [Berckmans P et al., 1997; Hogerzeil HV et al., 1997; Kale Oladele O, 1999; Autier P et al., 2002]. 
For acute emergencies, waiting for specific requests from recipients is not feasible. WHO has thus 
developed the Emergency Health Kit, a standardised set of drugs and basic equipment for a population of 
10,000 for a period of three months. Its contents are based upon a consensus among major international 
suppliers [WHO, 1998; WHO, 2006a].  
 
The second category, DDs in development cooperation (DC) represents the majority (80%) of all DDs. 
[WHO, 2000c]. DD processes are very complex. The DD supply chain involves a wide range of actors 
from different health systems (governments, companies, private voluntary organisations (PVOs) and 
NGOs, religious organisations). Often these players act as autonomous groups with different bases of 
information, different constituencies, different goals and without common procedures and standards 
[Reich MR, 1999]. Different DD strategies are known in DC [WHO, 1999]. Drugs can be given directly 
to the basic healthcare system of the recipient country and made available through private humanitarian 
institutions (religious, non-governmental, governments and private voluntary organisations), or they can 
be donated by private companies and individuals as so-called corporate DDs. On the other hand, they can 
be single-source DDs or DDs as part of public/private partnerships (PPPs) with a clearly defined public 
health goal [Dull HB and SE Meredith, 1998; Kale Oladele O, 1999; Ombaka E, 1999; Wehrwein P, 
1999; Buse K and G Walt, 2000a; Buse K and G Walt, 2000b; Guilloux A and M Suerie, 2000; Shretta R 
et al., 2000; Shretta R et al., 2001; Peters DH and T Phillips, 2004].  
 
Peer-reviewed literature about in-kind DDs is scarce and research has mostly been carried out in post-
emergency situations after disasters and wars. Letters, news reports and a number of research articles 
have reported that DDs do not comply with common standards and burden the recipients’ health care 
system. In summary, major problems still remain: a) DDs are not relevant for recipients’ need and arrive 
in wrong quantities, b) the quality standard does not comply with standards in the recipient country. c) 
donors ignore regulations of the recipients country and local administrative procedures and d) DDs have a 
high declared value, which result in high taxes and storage overheads [Hogerzeil HV et al., 1997]. 
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The need for guidelines, which could be applied to both categories (DDs in emergency situations and 
DDs in development cooperation) was evident. In 1988, the Christian Medical Commission (CMC) 
published its first "Guidelines for Drug Donations" in order to improve donations to missionary hospitals 
and in 1994, the WHO office in Zagreb compiled detailed guidelines for humanitarian assistance in 
former Yugoslavia [Medicus Mundi, 1989; Hogerzeil HV et al., 1997]. In 1996, the World Health 
Organisation (WHO) issued Interagency Guidelines for Drug Donations in cooperation with major 
international agencies active in humanitarian relief. The pharmaceutical companies represented by 
IFMPA were involved in the development of the guidelines for DDs. They expressed a critical view. 
International Federation of Pharmaceutical Manufacturers & Associations’ (IFMPA) major concerns are 
the restrictions on national essential drug lists, on remaining shelf-life to one year and on special language 
labelling and packaging requirements. These guidelines, revised in 1999, are intended to serve as an 
evidence-based tool to be adapted for good donation practice (GDP), as an aid to decision making, as a 
reference for national or institutional guidelines and to empower recipients [WHO, 1999]. The core 
principles of these guidelines are: a) maximum recipient benefit, b) respect of the recipients' wishes, c) no 
double standard in quality and d) effective communication between donor and recipient. These principles 
are operationalised in 12 guidelines, whose positive impact on the quality of DDs and DD processes is 
well documented [Reich MR, 1999; WHO, 2000c; Autier P et al., 2002]. 
 
In summary, appropriate actions are still needed to cover existing drug supply gaps. Comprehensive 
research on the impact of in-kind DDs in development cooperation at the country and local level was 
scarce. Further knowledge should support the elaboration of suggestions for optimising DD processes and 
empower both, donors and recipients, to apply and adhere to a good donation practice. 
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2 Goal and objectives 
 
 
The goal of this project was to optimise in-kind drug donation processes 
 
 
To approach this goal, by opportunity Switzerland as a donor country and Tanzania as a typical recipient 
country was chosen. Tanzania is one of the poorest countries in the world, with a low rated access to 
essential drugs. Tanzania receives substantial in-kind drug donations (DDs) from abroad. The choice of 
Tanzania and Switzerland was supported through the project’s framework of the Urban Health Project in 
Dar es Salaam and the Swiss Tropical Institute in Basel.  
 
Within this setting we developed the following objectives: 
General objective 1 
To characterise in-kind drug donation processes in Tanzania 
Specific objectives 
1. To collect information on the situation of DD processes in Tanzania  
2. To explore the level of application of tools and guidelines (National and World Health 
Organisation’s (WHO) Guidelines for Drug Donations) as an aid to decision making and taking 
action in the DD processes 
3. To collect stakeholders’ and recipients’ views on problematic areas and gaps in DD processes 
including all strategies of donating drugs in Tanzania 
4. To clarify different interests in donation processes 
General objective 2 
To explore practice and perception of Tanzanian and Swiss stakeholders in drug donation processes 
Specific objectives 
5. To characterise the DD system in Switzerland  
6. To identify similarities and discrepancies in DD processes of Tanzanian recipients and Swiss 
donors 
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General objective 3 
To develop suggestions for optimised drug donation processes 
Specific objectives 
7. To identify possible interventions for the improvement of DD processes in Tanzania 
8. To elaborate practical solutions for optimised drug DD 
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3 Methods 
This research project is based on a stakeholder analysis. This approach enables the researcher to generate 
knowledge about stakeholders in the field of policy and project management and to understand their 
practices and views within a complex system (Figure 1). Varvasovszky defined stakeholders “as actors 
who have an interest in the issue under consideration, who are affected by the issue, or who, because of 
their position, have or could have an active or passive influence on the decision making and 
implementation process” [Varvasovszky Z and R Brugha, 2000].  
 
In-kind drug donations (DDs) are a political issue. The appropriateness of DDs has an impact on the drug 
supply system of a recipient country. The DD process takes place in two environments, and therefore 
understanding the environmental context is necessary for any discussion of the interaction among 
stakeholders (see Chapter 4). The analysis of the different levels of the DD system (Figure 1) used 
various qualitative methods, and the entire study was based on a triangulation of these [Denzin NK, 1977; 
Varvasovszky Z and R Brugha, 2000; Flick U, 2004]. This approach is recommended when a focussing 
on a limited numbers of aspects is to be avoided and was guided by the aim to gather perspectives of 
stakeholders involved in DD processes in order to develop strategies for the optimisation of the DD 
system. Triangulation is the use of different methods to study a single problem from different 
perspectives. According to Flick, triangulation is recommended as a means to produce a more complete 
picture of the investigated problem [Flick U, 2004].  
 
A stakeholder analysis is a participatory approach per se. In this study, stakeholders were involved at 
every level of the project from the formulation of the research question to the dissemination of the results. 
The aim was to follow the principles of the Guidelines for Research in Partnership with Developing 
Countries [KFPE, 1998].  
 
Data collection was carried out between February 2000 and October 2002 and comprised 6 phases:  
Phase 1: Exploratory study in Tanzania 
Phase 2: Literature review 
Phase 3: Elaboration of the study framework 
Phase 4: Description of DD systems and processes – questionnaire surveys in Tanzania and Switzerland 
Phase 5: Data verification and clarification – key informant interviews 
Phase 6: Suggestions for the optimisation of DD processes – a workshop 
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Phase 1:  Exploratory study in Tanzania  
The aims of the exploratory study were  
- to promote participatory collaboration; to build a network; to establish contact with those involved in 
DDs at all levels in Tanzania; and to learn about individual views concerning DDs at the local and 
national level.  
- to determine and establish the study's framework; to pinpoint the study's criteria and to obtain basic 
information to analyse the situation.   
Data collection and analysis 
An unstructured key informant interview was applied guided by several questions: a) Are you involved in 
drug donations? What are your experiences and your perception of drug donations?, b) What, in your 
opinion, are the basic problems in the drug supply system for Tanzania?  
 
The interviewed stakeholders were therefore able to relate whatever aspects of their personal view to the 
problem of concern. Whenever possible, interviewed people were visited more then once. Confidentiality 
was promised to the interviewed person. Data collection was based on snowball sampling. This sampling 
was initiated through contacts in the Dar es Salaam Urban Health Project (DUHP) and the pharmacist at 
the St. Francis Pharmacy in Ifakara. In February 2000, 45 key persons in Dar es Salaam and Ifakara and 
from each sector of the health services were interviewed. Data were structured according to themes and 
used for the development of a later questionnaire.  
Phase 2:  Literature review and document analysis 
Information required for the investigation was: 
- All information about DDs and factors affecting DDs at the global and local level. 
- All information about the factors of the Tanzanian and Swiss health and drug supply system that 
affected DDs.  
- Information about development cooperations in Tanzania and in Switzerland. 
- Information about methods used in this research project. 
 
Aside from direct information through participative collaboration in Tanzania and in Switzerland, which 
granted access to grey literature, further sources to access information were required. For a systematic 
literature review, Medline and Web searches were conducted covering the period from 2000 to 2007. 
Keywords were associated with drug (and medicine) donations (including developing countries, 
development cooperation, drug industry, drug storage, relief work and aid, drug donation programme, 
corporate donation, Private Public Partnership (PPP), World Health Organisation). These keywords were 
adapted to the keywords of Medline search on DDs in publications and afterwards extended [Berckmans 
P et al., 1997; Reich MR et al., 1999]. In addition the term “drug donations” was combined with 
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keywords from the framework of this investigation (Table 1 and 2). The bibliographies of the DD 
publications were additionally followed up.   
 
Documents were retrieved from the Ministry of Health, Medical Store Department, Christian Social 
Services Commission and NGOs in Tanzania. Other sources included the WHO library in Geneva and 
university libraries in Switzerland. Relevant articles, reports, documents, etc were entered in Endnote®. 
Phase 3:  Elaboration of the study framework  
Within the participatory stakeholder analysis, we elaborated a study framework (Tables 1 and 2, Figure 
1). The purpose of this study framework was to enable a systematic data collection and to structure the 
complex information for subsequent data analysis. 
 
Figure 1: Drug Donation System (DD-System) 
Donor PatientRecipient
Donor environment Recipient environment
Perception of stakeholder (from inside or outside the systems)
Resources 
&structure
Resources 
& structure
Resources 
& structure
Donor System Recipient System
Drug Drug
CommunicationCommunication
 
 
The DD system comprises a donor system and a recipient system, both of which provide specific 
environments and resources (Figure 1): The DD processes run within this system and involve a flow of 
drugs from donors to recipients and communication between donors and recipients. This system and the 
processes are viewed from different perspectives by stakeholders within and outside the system. These 
views represent the “perception” of the system, which includes appraisement of outcomes. Various 
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stakeholders can be involved in the donor and recipient systems: governmental organisations, NGOs and 
PVOs, religious organisations, private companies, pharmacies, health facilities and patients Based on this 
systems approach, a first step was to compile a set of determinants (Tables 1 and 2). Indicators were 
elaborated by using a deductive process, enabling the formulation of quantitative and open questions to 
characterise both the DD system and the DD processes. The characteristics and their associated indicators 
were based on experiences from the exploratory study in Tanzania and on other available information 
[Reich MR, ed., 1999] including WHO publications [MSH, 1997; WHO, 1999; WHO, 2000; WHO, 
2000]. 
Phase 4:  Description of DD systems and processes – questionnaire   
  surveys in Tanzania and Switzerland 
Baseline data on the views, practices and knowledge of stakeholders about the DD system at the local 
level were gathered in parallel in Tanzania and in Switzerland. For this purpose, a self-administered, 
semi-quantitative questionnaire was developed using the study framework (Annex 1). The questionnaire 
was grouped in six sections: a) information about respondents (involved in DD processes or not, 
perception about usefulness of DDs), b) information about the donors’ or recipients’ organisation, c) 
quality of DDs in donors’ or recipients’ organisation, d) information about the DD process, e) comments, 
f) personal data about respondents (under strict confidence). The questionnaire contained a set of open 
questions to gather perceptions and opinions (16 in Tanzania/14 in Switzerland), 39/34 quantitative 
questions for basic information followed by 12/13 open questions to elaborate on the quantitative 
questions. The questionnaire was tested in a pilot study to check form and content. Only minor changes 
were necessary. After this pilot study, the English questionnaire was translated into Swahili and 
retranslated in English for validation; the German questionnaire was translated into French and then 
retranslated. Questions for donors and recipients were essentially the same, but took into account their 
position in regard to DDs. 
Data collection 
In Tanzania, questionnaires in English and Swahili were sent out in June 2001 by post with cover letters 
and prepaid envelopes for the return of completed questionnaires. Two months later, a reminder was sent 
out to non-respondents. Data gathering was completed in December 2001. In May 2001, questionnaires in 
German and French were sent out in Switzerland following the same procedure. Italian-speaking 
stakeholders received both the French and the German questionnaires, due to finances not being available 
to develop a questionnaire in Italian. Data gathering was completed by the end of August 2001.  
 
Stakeholders were determined as people from organisations in each sector involved in healthcare (public, 
religious, private-non-profit and private-for-profit) in 2000, which could be involved in DD processes in 
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Tanzania and in Switzerland. In both countries, address lists as complete and updated as possible were 
collected for all groups of recipients and donors, from each level of decision-making and for the entire 
country. Depending on their lengths, all addresses were used from some lists, from others, only a 
randomised sample. 
 
In Tanzania, non-respondents to the questionnaire were assessed. From the non-responding sample, 50 
individuals were selected (randomised and stratified by sectors) and followed-up by telephone call. 
However, financial and time constraints and a lack of personnel prevented follow-up of non-respondents 
in Switzerland. 
Data analysis 
The questionnaire was designed and processed with the software TELEform® Standard Version 7.0 from 
Cardiff Inc. Data quality assurance was done by a double control of the entire dataset. The data were 
transferred to a Microsoft® Access database and analysis was performed with Microsoft® Excel. Chi-
square analyses (2) were performed for the Tanzanian results to assess differences between sectors using 
SPSS 13.0 for Windows. Qualitative data from the open-ended questions were analysed using content 
analysis. In this study, the deductive text analysis was based on the concepts of Mayring ([Mayring P, 
1997; Flick U, 2000]. Key words used in this analysis were derived from important characteristics of the 
DD system as listed in Tables 1 and 2 and from most-cited terms.   
Phase 5:  Data verification and clarification – key informant interviews 
Key informant interviews (KIs) were applied in the next phase of the project.  The aim was to 
contextualize results of the questionnaire survey in regard to public health issues. A semi-structured key 
informant interview was therefore used, based on questions and results of the questionnaire survey. In 
June 2001, the first 230 returned questionnaires in Tanzania were analysed [Gehler Mariacher G et al., 
2007]. From these, key questions were developed for further investigation [Gläser J and G Laudel, 2004] 
(Annex 2). The focus was on five topics: a) main problems with DDs, b) proposals for the optimisation of 
DD processes, c) economic value of DDs, d) coverage of drug supply through DDs, e) in addition, 
strengths and weaknesses of DD processes and the personal opinions of the interviewed stakeholders 
were explored. Our aim with these questions was to cover all important aspects of the DD system (Figure 
1).  
Data collection 
KI interviews were conducted in a) Dar es Salaam as an urban setting, b) Moshi (Kilimanjaro Region) as 
a rural setting with a comparatively high income and education level, c) Songea and Mbinga (Ruvuma 
Region) as rural settings with a comparatively low income and education level (Fig. 2). KIs were 
recipient and non-recipient stakeholders of DD processes who had experiences with DDs, were experts in 
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the social context and were able to transcend cultural positions [Brugha R and Z Varvasovszky, 2000; 
Varvasovszky Z and R Brugha, 2000; Gläser J and G Laudel, 2004]. KIs were recruited from QS 
respondents from each of the three settings. In August 2001 and in January 2002, all KIs were 
interviewed, who were reachable within the limited timeframe of the data collection; KIs were visited 
prior to the interviews, received the interview guide and were informed about the purpose of the study. 
Each KI was asked for consent for the interview to be recorded. All interviews were conducted face-to-
face by the author at the KIs' workplace. Interviews were one hour in duration. Transcripts (in English) of 
the interviews were sent to the KIs for review and agreement.  
Data Analysis 
For the text analysis of the transcripts, the theory of content analysis used in expert interviews was 
applied, which allowed us to focus on specific, substantial aspects of interest in the context of the 
interview guide [Gläser J and G Laudel, 2004]. To analyse the frequency of themes, we used the software 
MAXqda®. (Verbi Software, Udo Kuckartz, Berlin 2002). Each interview was entered as a single file. The 
files were coded and interpreted with the same scheme used for analysis in the QS (Tables 1 and 2).  
Phase 6:  Suggestions for the optimisation of DD processes – a workshop 
In a final phase, results from previous research phases were shared with stakeholders of the project and 
they were asked to elaborate suggestions for optimised DD processes in Tanzania [KFPE, 1998]. In 
October 2002, a one-and-a-half day workshop was organised in Dar es Salaam with the support of the 
WHO. Stratified by sector, 26 participants from the questionnaire survey were selected randomly. Of 
these, 22 were able to accept the invitation. Four further persons with key functions in DD processes also 
participated in the workshop. In group work, for which the participants were randomly assigned to four 
groups, the following topics for improving DD processes, based on stakeholders' recommendations in the 
questionnaire survey for optimising DD processes, were discussed: a) quality of DDs, b) participatory 
collaboration of donors and recipients, c) defining DD needs, d) national regulations. The workshop 
closed with the feedback from the group work, focussing for each topic on a) three main barriers to the 
optimisation of DD processes, b) three main strategies for improving DD processes, c) three main 
suggestions for strategy implementation. The results of the workshop were recorded and disseminated 
to all participants and to the important decision-makers in DD processes.  
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Tables 
Table 1: Characteristics of the recipients’ DD system 
Item numbers of the 
guidelines for DDs  
Determinants Indicator 
WHO Tanzania 
Environment 
Demographics Population   
Epidemiology Morbidity, life expectancy, prevalence of HIV/AIDS, child 
mortality of under fives 
  
Economy Poverty, GDD per capita   
Education Adult literacy rate   
Geography Paved roads   
Health sector and 
DDs 
Sectors involved. Distribution channels for DDs, number of 
pharmacists and educated healthcare staff, public spending for 
health, control of DD importation 
  
National drug policy Guidelines for DDs, laws for importation, Essential Drug List  No. 4.1
No. 4.2a-c 
Resources and structures 
Organisations Characteristics of the organisations   
 Involvement in DD processes   
Staff competence  Accountability    
 Knowledge of GDD   
Documents List of needed drugs  No. 3 
 Quality criteria for DDs   
 Treatment criteria for DDs   
 Availability of GDD   
Financial aspects Shipment and custom fees No. 12  
 Value of DDs   
 Payment for DDs   
 DDs in cash earmarked for buying drugs  No. 3 
Process 
Selection of drugs Expressed need by recipient No. 1  
 DDs part of the EDL of the country or of the WHO No. 2 No. 4.2d 
Management Origin of DDs   
 Coverage of drug supply with DDs   
 Use of DDs   
 Disposal of unwanted drugs   
Transparency Evaluation of DD processes   
Communication Information by donors No. 10 No. 3 
 Collaboration with partner organisations   
 Receipt of invoice documents No. 10  
Quality of the donated drug 
Quality assurance Certificate schemes on the quality of DDs  No. 4 No. 4.2h 
 Shelf-life No. 6 No. 4.2g 
 Unused drugs No. 5 No 4.2j 
Presentation Labelling No. 7 No 4.2f 
Perception of stakeholders  
Satisfaction of 
recipients 
Long-term treatment, implementation of GDD, relevance of DDs, 
shipment and custom fees, transparency in DD processes, 
communication between donor and recipient, infrastructure, training 
of healthcare staff, quality of DDs 
  
Usefulness of DDs    
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Table 2: Characteristics of the donors’ DD system 
Determinants Indicator Item numbers of the WHO DD 
Guidelines  
National drug policy Guidelines for DDs, Essential Drug List (EDL) No. 2 
Resources and structures  
Organisations Characteristics of the organisations  
 Involvement in DD processes  
Staff competence  Accountability   
 Knowledge of GDD  
Documents Quality criteria for DDs  
 Availability of WHO GDD  
 Organisation-owned GDD   
Financial aspects Value of DDs  
 Payment for DDs  
 DDs in cash earmarked for buying drugs  
 Shipment and custom fees No. 12 
Processes  
Selection of drugs Expressed need by recipient No. 1 
 DDs part of the EDL of the country or of the WHO No. 2 
Management Procurement of DDs  
Transparency Evaluation of DD processes  
Communication Information of recipients No. 10 
 Collaboration with partner organisations  
 Mailing of invoice documents No. 10 
Quality of the donated drug  
Quality assurance Certificate schemes on the quality of DDs  No. 4 
 Shelf-life No. 6 
 Unused drugs No. 5 
Presentation Labelling No. 7 
Perception of stakeholders  
Satisfaction of 
recipients 
Long-term treatment, relevance of DDs, shipment and custom 
fees, transparency in DD processes, communication between 
donor and recipient, quality of DDs 
 
Usefulness of DDs   
 
 
Ethical issues 
Approval of the Research Clearance, Tanzania, RC 2000/25 was given in 2000 from the Commission of 
Science and Technology, COSTEC Dar es Salaam. The ethical review was done by the National Institute 
for Medical Research (NIMR) in Tanzania in 2002.  
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PART 4 
RESULTS  
DRUG DONATIONS IN TANZANIA - 
STAKEHOLDERS’ PERCEPTION AND 
KNOWLEDGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Madawa ya Misaada ambayo yamefika – siwezi kusoma lugha zake 
I can’t understand the language of the description of the donated drugs we received 
Ich kann von der erhaltenen Medikamentenspende die Sprache der Beschreibung nicht verstehen 
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4 The environment of the DD systems in Tanzania and in 
 Switzerland 
4.1 Tanzania 
The United Republic of Tanzania, the union of Tanganyika and Zanzibar, is located in East Africa. In 
2001, an estimated 35 Mio people lived in Tanzania with an annual growth of the population of 2.2% 
[UNDP, 2002]. 33% of the population live in urban area. Since 1961, the former English protectorate is a 
Republic, shifting in 1992 from a one-party socialistic republic to a multiparty government with a free 
market economy. The people of Tanzania live in a stable society with rare conflict situations, but poverty 
remains a major challenge. Despite ongoing reforms and improvements such as better access to safe 
drinking water, a higher adult literacy rate and a decreasing poverty line, development indicators are not 
promising. Population growth, lack of manpower, problems with good governance, marginal economic 
growth and the burden of diseases like malaria, tuberculosis and HIV/AIDS have the effect that Tanzania 
depends heavily on foreign aid for health services [SEAM, 2003]. Important indicators are summarised in 
Table 1 and 2 (see 3. Methods).  
Healthcare system 
After the independence in 1961, emphasis was on primary healthcare and health services free to all. In 
that period, population health improved. The oil crisis in the early 1980ies seized also healthcare and the 
health of the population declined. In 1994, the Health Sector Reform (HSR) was launched with the aim of 
improving equity, quality, accessibility and efficiency in the health sector. User fees were introduced and 
private sector participation was promoted. The authority of healthcare is now decentralised to district and 
local levels.  
 
The healthcare system assumes a pyramidal referral pattern: the village post, dispensaries, health centres, 
district hospitals, regional hospitals and referral hospitals. Healthcare is delivered through both the public 
and the private sector, the latter being divided into for-profit and non-profit services [Wyss, K. et al., 
1996]. Non-for-profit organisations include private voluntary (PVOs), non-governmental (NGOs) and 
religious organisations. Christian missions provide 40% of all health services, and working largely in 
rural areas, mostly under the umbrella of the Christian Social Service Commission (CSSC) [Muhume, J., 
2001]. 
 
In 1998, Tanzania adopted the concept of a sector-wide approach (SWAp), which redefined the donors’ 
role. Donors’ funds are now pooled and earmarked for priority activities (basket funding) and donors are 
responsible for synchronising and reviewing their aid [MOH, 1999a; MOH, 1999b; Semali, I., 2003; 
Hutton, G. and Tanner, M., 2004]. 
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Drug supply 
In 1991, the MOH launched the National Drug Policy, revised in 2003 [MOH, 2003]. Tanzania was one 
of the first countries to adopt the essential drug concept and continues to promote it. The National 
Essential Drug List for Tanzania (NEDLIT) and the Standard Treatment Guidelines were published in 
1991 and updated in 1997. In 2001, a draft revision of the NEDLIT became available, which is still valid 
[MOH, 2001]. The NEDLIT stratifies drugs by facility level, adapted to the educational level of the health 
staff. 
 
The WHO rates Tanzania as a country with low access to essential drugs (50-79% of the population). The 
Tanzanian pharmaceutical sector is significantly underfunded [Bürki, O., 2001]. Despite developments 
such as the introduction of cost-sharing and the significantly improved performance of the Medical Stores 
Department (MSD), the parastatal wholesaler for the public and non-profit sector, major structural 
problems still remain, such as the non-availability of qualified pharmaceutical staff, the absence of a 
clearly defined mandate for the staff in the pharmaceutical sector, lack of integration of the 
pharmaceutical sector into the healthcare system and insufficient health worker training in the essential 
drug concept [MOH, 1997; Wiedenmayer, K. and Mtasiwa, D., 2000; Wiedenmayer, K., 2004]. In 2001, 
a study identified gaps in drug availability, primarily in the public sector, and problems with quality and 
affordability of products and services, especially in the private retail sector, were identified. Geographical 
access was not perceived as a problem by the public. In Medical store department (MSD) zonal stores, 
drug stock-outs occurred occasionally. On the other hand, availability does not seem to be a significant 
problem at mission health facilities. The public cannot be assured of good drug quality for a significant 
proportion of drugs on the Tanzanian market [SEAM, 2003].  
 
Drug supply for health centres and dispensaries in the public sector is based on prepacked standardised 
kits as part of the National Essential Drug Programme. The composition of the kits is based on the 
NEDLIT and national morbidity data. The MSD is responsible for purchasing and distributing the kits. In 
2001, 75% of the kit costs were paid by the government and 25% by Danida. Although drugs provided by 
kits do not comply with the definition of in-kind DDs in this study, they are perceived by some health 
workers as drugs donated as gifts in-kind. This may be due to the fact that in the 1980s, kits were 
prepacked and fully financed from abroad, mostly by UNICEF and Danida [Hingora, A., 2001]. In private 
for profit pharmacies nearly every kind of drug is available, but not affordable for most of the Tanzanian 
inhabitants.  
In-kind drug donations  
Tanzania has launched instruments for an effective regulation of DD processes. The main regulations for 
handling DDs are the “Guidelines on donations of drugs and medical equipment to the health sector for 
Tanzania Mainland, 1995”, the “Guidelines for Importation of Pharmaceuticals, 2000” and the NEDLIT 
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[MOH, 1995; MOH, 1997b; MOH, 2000]. Differences between the earlier published Tanzanian 
guidelines on DDs and the WHO-GDD are: 
- Donors should understand Tanzania’s DD policies 
- DDs have to be declared to the MOH for clearance. All importation of any pharmaceutical product 
requires approval by the Pharmacy Board and has to undergo a registration procedure.  
- A financial contribution by the donor should be considered, since it may be more cost effective to buy 
drugs locally. 
The Tanzanian GDD from 1995 are currently undergoing revision and the release of updated GDD is 
expected soon [Muhume, J., 2007]. 
 
The MOH has a regulatory overview. The chief pharmacist (Head of the pharmaceutical services section 
in the directorate of the curative health service) is responsible for the NEDLIT and the Donation Policy. 
The registrar, the director of the Tanzanian Food and Drug Authority, TFDA (before 2003 Pharmacy 
Board) is responsible for implementing the NEDLIT and for policies regarding the importation of drugs 
and is also in charge of the National Drug Quality Control Laboratory. By transferring the authority of 
healthcare to the district and local levels, health sector reforms have also led to a decentralised DD 
process.  
 
Both the public and non-for-profit sectors of Tanzania receive DDs for basic healthcare and as part of 
specific DD programmes. The MSD is mandated to receive and store all in-kind DDs that are given to the 
government. Additionally, the MSD distributes the DDs given in the framework of programmes within 
the country. These DDs are cleared at the port of Dar es Salaam and other harbours together with DDs 
given for the private-for-profit facilities. Christian umbrella organisations have their own clearing offices. 
Local pharmaceutical companies did not receive DDs, but on the contrary were in-country donors of DDs. 
4.2 Switzerland 
Switzerland has a long tradition in humanitarian aid and for many years, Tanzania has been a priority 
country for the Swiss government [SDC] As a nation significantly committed to pharmaceutical research, 
development and production, Switzerland seemed also predestined for involvement in DDs.  
 
Both, the public and the private sector are involved in DD processes. The latter includes the for-profit 
sector (e.g. pharmaceutical companies and community pharmacies) and the not-for-profit sector [religious 
organisations and non-profit organisations such as non-governmental organisations (NGOs) and 
(PVOs)].: 
- In the public sector, the main actors are the government as represented by the Swiss Agency for 
Development and Cooperation (SDC) and the State Secretariat for Economic Affairs (SECO) [SDC; 
SECO]. In 2000, Switzerland committed itself to support the MDGs [MDG; SDC and Strategy 2010]. 
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Focusing on the empowerment of the health systems in low-income countries, the preferred strategy 
of SDC is to eliminate causes rather than making donations and covers optimisation of access to 
essential drugs (MDG 8). Short-term DDs are considered in emergency assistance. But even then, 
local procurement of drugs is preferred [SDC Health Policy 2003-2010]. 
- Two groups of religious organisations have an important impact in health care in DC and DD 
processes. In the first case, major missionary bodies and faith-based organisations, e.g. HEKS and 
Caritas, supported the idea that in a partnership, the recipient should cooperate in needs assessment. 
The second group, they still base their development activity on missionary goals [Holenstein, R., 
1998]. 
- NGO’s importance in DC and DDs has increased, because the complexity of DC requirements 
challenges governmental structures and resources. But, all Swiss NGOs and PVOs that collected, 
sorted out and shipped unused drugs (drugs returned to pharmacies from patients and free samples 
given to health professionals) in a large amount halted this activity after the revision of the WHO 
guidelines for DDs in 1999. In the early 2000s, the organised collection of unused drugs in 
pharmacies came to an end [Gehler Mariacher G et al., 1998; WHO, 1999; Gehler Mariacher G, 
2004].  
- Today, public resources in DC are limited and involvement of the private sector is needed. The 
challenge of this strategy lies in conflicts of interest. One major actor in DD processes, the 
pharmaceutical companies, are involved in many DC contexts, especially in the field of health 
optimisation and poverty reduction. Community pharmacies are the other important players in DD 
processes in the private-for-profit sector. A service of these pharmacies is the cost-free disposal of 
unused drugs. For community pharmacies, it was often not understandable that after 2000 NGOs no 
longer collected these unused drugs for reuse. 
 
The national law on medicine and medical products, issued in 2002, has no specific article for handling 
DDs and there are no DD guidelines for Swiss donors [BAG, 2002]. However, this legislation prohibits 
the export of drugs to foreign countries if those drugs are unauthorised in the target country or if it is 
evident that the drugs will be used for illegal purposes. Before 2002, each canton had its own laws and 
there was no legislation applicable to the entire country. The export of drugs was practically unregulated. 
The Basel Convention, signed by the Swiss government, prohibits the export of unused drugs to any 
country other than OECD states [Basel Convention].  
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PAPER 1 
IN-KIND DRUG DONATIONS FOR 
TANZANIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DUKA LA DAWA: Madawa ambayo unahitaji – yapo nusu tu toka mfuko wa msaada 
PHARMACY: There is only half the dosage of this donated drug for this patient 
APOTHEKE: Wir haben aus der Spendenmedizin nur eine halbe Dosis für den Patienten zur Verfügung 
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PAPER 2 
OPTIMIZING IN-KIND DRUG 
DONATIONS FOR TANZANIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Je, Madawa Ya Misaada hii zimekubaliwa na wizara ya afya ? 
Have the donated drugs been approved by the ministry of health? 
Ist die Spenden - Medizin vom Gesundheitsamt genehmigt worden? 
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6 Optimizing in-kind drug donations for Tanzania    
a case study 
 
 
 
 
Gaby Gehler Mariacher1*, Deo Mtasiwa2, Karin Wiedenmayer1, Rudolf Bruppacher3, Marcel Tanner1, 
Kurt E Hersberger3 
 
1Swiss Tropical Institute, PO Box, 4002 Basel, Switzerland 
2Dar es Salaam City Council, PO Box 9084, City Hall, Dar es Salaam, Tanzania 
3Institute for Clinical Pharmacy, University of Basel, Klingelbergstr. 50, 4056 Basel, Switzerland 
 
 
 
 
 
 
__________________________________________________________________________________ 
 
This paper was published in 
International Journal of Health Planning and Management, September 2007 
 
__________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
Paper 2 - Optimizing in-kind drug donations for Tanzania 
 
 60
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
international journal of health planning and management
Int J Health Plann Mgmt (2007)
Published online in Wiley InterScience(www.interscience.wiley.com) DOI: 10.1002/hpm.901Optimizing in-kind drug donations
for Tanzania—a case study
Gaby Gehler Mariacher1*, Deo Mtasiwa2, Karin Wiedenmayer1,
Rudolf Bruppacher3, Marcel Tanner1 and Kurt E. Hersberger3
1Swiss Tropical Institute, Basel, Switzerland
2Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
3Institute for Clinical Pharmacy, University of Basel, Basel, SwitzerlandSUMMARY
A questionnaire survey (QS) among stakeholders in Tanzania had shown that in-kind drug
donations (DDs) are important to boost the drug supply system. Major problems were their
insufficient quantity for sustainable treatment and the discrepancy between the needs of the
recipients and the donors’ supply. Objectives in this study were to discuss these findings and to
learn from key informants (KIs) how to improve the DD process. Data were collected through
KI interviews in 2001/2002.
A 30% gap in drug supply has to be bridged by DDs. KIs confirmed the importance of the
World Health Organisation and Tanzanian DD guidelines as a tool for good donation practice
and emphasized the role of the government in their implementation. They requested that
donors meet the recipient country’s regulatory requirements. In contrast to QS respondents,
KIs did not view DD quality as a minor problem, and proposed that DD quality should be
adapted to the national quality assurance procedures. DD processes could be improved through
(a) effective implementation of DD guidelines as an aid for decision-making and for quality
assurance, (b) availability of data to improve communication between donors and recipients,
(c) transparency between recipients and donors and (d) clearly defined accountability.
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62BACKGROUND
In development cooperation, in-kind drug donations (DDs) have been proposed for
supporting underfunded, weak drug supply systems over the short or middle term, if
targeted at specific diseases and if they do not hinder efforts to develop a sustainable
financing mechanism of drug supply (WHO, 1998; Reich, 2000; WHO, 2004). To
maintain good donation practice, the World Health Organisation Guidelines for DDs
(WHO GDD) (WHO, 1999) are an essential tool for all stakeholders involved in DD
processes (Table 1). They are valid for all DD strategies in development cooperation
in the form of: (a) DDs given directly to the basic health care system and made
available through private humanitarian institutions (religious, non-governmental and
private voluntary organizations), (b) single-source DDs given through private
companies and individuals and (c) DDs given as part of global public/private
partnerships (GPPPs) with a clearly defined public health goal. The core principles of
these guidelines are: (a) maximum recipient benefit, (b) respect of the recipients’
wishes, (c) no double standard in quality and (d) effective communication between
donor and recipient. These principles are operationalized in 12 guidelines, whose
positive impact on the quality of DDs and DD processes is well documented
(Hogerzeil et al., 1997; Oladele, 1999; Reich, 1999; WHO, 2000; Autier et al., 2002).
However, letters, news reports and a number of peer-reviewed articles have
reported that DDs still do not comply with common standards and burden the
recipients’ health care system. In 2000, a Me´dicins sans Frontie`res study found that
disease-specific DDs cost the donor’s systems four times more than other models, for
example, purchasing lowest-priced quality generics, and burden the recipient system
with unsustainable access to drugs and costs because DDs depend much on the good
will of donors (Guilloux and Suerie, 2000). In a preliminary field investigation in
1999, the Harvard study of health facilities in Armenia, Haiti and Tanzania showed
that DDs were not cost free for recipients, that the impact of DDs varies and that DD
processes were very complex, with problems of communication, logistics and
standards among the organizations investigated (Reich, 1999). On the other hand,
evaluation of the Mectizan Donation Programme in 2004 described an example of
important achievements in public health through DDs in the framework of a GPPP.
The strengths of this programme lay in good governance and management and free
provision of the drug until the disease was under control (Peters and Phillips, 2004).
To achieve appropriate DDs, better understanding of current DD processes at the
global and local level is required. The appropriateness of DDs depends not only onTable 1. Interagency WHO guidelines for drug donations: principles and applications (WHO,
1999)
Core principles Practical application
 Maximum benefit to the recipient  Selection of drugs
 Respect for the wishes and authority
of the recipient
 Quality assurance and shelf-life
 No double standard in drug quality  Presentation, packing and labelling
 Effective communication between
donor and recipient
 Information and management
Copyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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OPTIMIZING IN-KIND DRUG DONATIONS FOR TANZANIAthe motivation, commitment and awareness of the donor, but also on recipients’
motivation, perception and knowledge and on their ability to integrate DDs
effectively into the drug supply system or to refuse unwanted and useless DDs.
Within this context, we were interested in understanding in more depth how
stakeholders in a recipient country (Tanzania) viewed in-kind DDs.Policies relevant to DDs in Tanzania
Tanzania is one of the poorest countries in the world, with a low rated access to
essential drugs, and it receives substantial in-kind DDs from abroad (Reich 1999;
WHO, 2001). The main indicators affecting DD processes in Tanzania are listed in
Table 2. The economic value of DDs for Tanzania was available in 2001/02 only for
single organizations and programmes and thus it was difficult to judge the effective
impact of DDs for the pharmaceutical sector in Tanzania.
Already in the early 1990s, Tanzania had developed instruments for the regulation
of DD processes, all of which are binding for stakeholders involved in DD processes
(Ministry of Health, 1995, 1997b, 2000, 2001, 2003; Ministry of Finance, 2005):
‘Guidelines on the donation of drugs and medical equipment to the health sector for
the Tanzanian mainland’ (published in 1995, currently in revision) are primarily
targeted at donors. These GDD are oriented on the Tanzanian national essential drug
list (NEDLIT, 1991, 2nd ed. 1997). At the time of the interviews, the NEDLIT was
again under review. The NEDLIT stratifies drugs by facility level and adapts drug
supply to the educational level of the health staff in the facilities. The Tanzanian
GDD also say that DDs have to be declared to the MOH for clearance, and all
importation of any pharmaceutical product requires approval by the Pharmacy Board
and must undergo a registration procedure (The Tanzania Food, Drugs and
Cosmetics Act No. 1, 2003). Assistance for the process of importation is given with
the guidelines for Importation of Pharmaceuticals (2000). The ‘Tanzanian
Procurement Act’ (2005) is designed to provide transparent procedures for use in
the procurement of goods and services for the government and its institutions and to
prevent corruption. The Tanzanian GDD, published before the WHO GDD, demand
in addition that donors should understand Tanzania’s DD policies and that a financial
contribution of the donor should be considered, since it may be more cost effective to
buy drugs locally. A list of donor and recipient responsibilities in the DD process is
appended to the Tanzanian GDD.
A health sector reform (HSR) was launched in 1994 with the aim of improving
equity, quality, accessibility and efficiency of the health care system (Ministry of
Health, 1994, 1997a). The supply system was decentralized, with drug provision at
district level and local procurement from the Medical Stores Department (MSD).
Drug supply was financed by cost-sharing schemes and government contributions.
Private sector participation in health care was promoted (Wiedenmayer, 2004).
Within the HSR, in 1998, Tanzania adopted the concept of a sector-wide approach
(SWAp), which redefined the donors’ role. Donors’ funds are now pooled and
earmarked for priority activities (basket funding) and the donors are responsible for
synchronizing and reviewing their aid. Through the transfer of the authority of health
care to the district and local levels, the HSR also led to a decentralized DD process.Copyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
DOI: 10.1002/hpm
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Table 2. Indicators important for the Tanzanian DD system (WHO, 2001; UNDP, 2002;
Muhume, 2001)
Indicator Year Tanzania
Demographic Indicators
Population 2001 35 million
(estimated)
Adult literacy rate at age 15 2000 76%
Population living in urban area 2001 33%
Epidemiological Indicators
Life expectancy at birth, years 2001 44
Under-five mortality rate per 1000 live births 2001 165
Estimated HIV/AIDS prevalence rate 2001 7.8%
Economic Indicators
Population living below USD 1 per day 2001 20%
Poverty line of USD 2 per day 2001 60%
GDP per capita in USD 2001 520
Health Sector
Leading diagnosis for the whole country 1998 Malaria 37%
Acute respiratory
infections 13%
Diarrhoeal
diseases 6%
Expenditure on health as per cent of total
government expenditure
2001 12.1%
Governments expenditure on health, in mio USD 2002 84
External resources for health as per cent of the
government health expenditure
2001 29.5%
Total expenditure on health as per cent of GDP 2001 4.4%
Total number of healthcare facilities 2000 4717
Hospital beds per 1000 2000 9
Physicians for the entire country 2001 355
Nurses for the entire country 2001 5288
Pharmacists for the entire country 2001 42
Pharmaceutical technicians for the entire country 2001 91
Population with sustainable access to essential drugs 1999 50–79%
Government expenditure on drugs as per cent of
total health expenditure
2000 47%
Thereof paid (Muhume, 2001) by
the government 50%
through cost-sharing 20%
through development partners with basket funding 30%
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64Despite the new policy, Tanzania still received substantial in-kind DDs from abroad
(Reich, 1999).Stakeholders’ views on DDs in Tanzania—a situation analysis
The aim of our study project was to gather comprehensive information on the views,
knowledge and practice of stakeholders in Tanzanian DD processes. We used a
qualitative approach, as discussed in the publications of Varvasovszky and Brugha
(2000) to generate knowledge about actors in DD processes and for mappingCopyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
DOI: 10.1002/hpm
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of data and methods. First, in 2001, we conducted a countrywide situation analysis
with a semiquantiative postal questionnaire, involving stakeholders at every level of
decision-making (Gehler Mariacher et al., 2007). We included all strategies of DDs
(according to the Tanzanian GDD) and defined in-kind DDs as products donated by
other countries to the recipients.
An estimated average of 27% of the recipients’ drug supply was covered through
DDs, and 44% of the recipients covered 10% or less of their drug supply with DDs.
The proposals of recipients for optimized DD processes corresponded fully with the
core principles of the WHO GDD (WHO, 1999). The Tanzanian GDD were known to
45% of recipients, the WHO GDD to 30%. In the context of the core principles of the
WHO GDD, our major findings were as follows (Table 3):
Maximum benefit to the recipient. The study showed that DDs were highly accepted
as an important factor for boosting the drug supply system. The monetary value of
DDs to their organization was known to only 28% of the recipients, and best to NGOs
because of the better structure of their organizations. Only 16% of recipients received
donations in cash for buying drugs as recommend in the Tanzanian GDD. The most
important problem for each sector involved in DDs was the insufficient quantity of
DDs for sustainable treatment.
Respect for the wishes and authority of the recipient. An estimated average of 45% of
recipients said that the DDs they received had been exclusively or partly requested.
Almost 65% of DDs were always or partly included in the Tanzanian EDL and 51%
in the WHO EDL.
No double standard in drug quality. The prime concern of DD recipients was not the
quality of drugs, although quality assurance remained an ongoing concern, but the
discrepancy between the needs of the recipients and the donors’ supply. The average
shelf-life of 6 months up to more than 1 year was 60%, and an average of less than 6%
of the DDs were expired. No or only partial labelling of DDs in a local language such
as Swahili or English was reported by 57%. No organization received exclusively
‘unused drugs’.1
Effective communication between donor and recipient. Although recipients con-
sidered that communication was the most important factor to be improved, less than
half (47%) of them had a list of needed drugs. However, 49% of the recipients were
informed in advance by the donor about the composition and the date of shipment.
While this questionnaire survey (QS) gave an overview of the existing situation in
the DD system in Tanzania, the aim of the study reported here was to validate these
findings with a qualitative approach through standardized key informant (KI)
interviews. We were interested in consolidating the views, knowledge and practice of
the recipients of the QS as actors in DD processes. We wanted deeper insight into not
only possible deficiencies in DD processes but also the actions that might be taken to
rectify them. The specific objectives of the work described in this paper were: (a) to1Unused drugs are drugs returned to pharmacies from patients and free samples given to health
professionals.
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OPTIMIZING IN-KIND DRUG DONATIONS FOR TANZANIAhighlight the context of stakeholders’ and recipients’ responses in the QS, (b) to
clarify different interests, (c) to discuss discrepancies and ambiguities in the QS and
(d) to learn about KIs’ recommendations for an optimized local drug supply and for
policy development in DD systems in Tanzania.
METHODS
In June 2001, we analysed the first 230 returned questionnaires in the QS to develop
key questions (Q), which guided us through the semistructured KI interviews2
(Gla¨ser and Laudel, 2004; Gehler Mariacher et al., 2007). We focussed on five topics:
QA–D, emerged from results of the QS. QE tackled the personal opinions of the KIs
(For the entire interview guide see Table 4). Our aim with these questions was to
cover all important aspects of the DD system (Figure 2): coverage of drug supply
with DDs, economic value of DDs, main problems with DDs and proposals for
optimization of DD processes as well as strengths and weaknesses of DD processes.
We conducted the KI interviews in (a) Dar es Salaam as an urban setting, (b) Moshi
(Kilimanjaro Region) as a rural setting with a comparatively high income and
education level, (c) Songea and Mbinga (Ruvuma Region) as rural settings with a
comparatively low income and education level. KIs as stakeholders of DD processes
had experiences with DDs, were experts in the social context and were able to
transcend cultural positions (Brugha and Varvasovszky, 2000; Varvasovszky and
Brugha, 2000).
KIs were recruited from QS respondents from each of the three settings. We
interviewed all KIs who were reachable within the limited timeframe of the data
collection; KIs were stakeholders of the DD system—recipients and non-recipients.
KIs were visited prior to the interviews, received the interview guide and were
informed about the purpose of the study. All interviews were conducted face-to-face
by the first author at the KIs’ workplace. Interviews were 1 h in duration. Each KI
was asked for consent for the interview to be recorded. The transcripts of the
interviews were sent to the KIs for assessment.
For the text analysis of the transcripts, we applied the theory of content analysis
used in expert interviews, which allowed us to focus on specific substantial aspects of
interest in the context of the interview guide (Gla¨ser and Laudel, 2004). To analyse
the frequency of themes, we used the software MAXqda1 (Verbi Software, Udo
Kuckartz, Berlin 2002). Each interview was entered as a single file. The files were
coded and interpreted with the same scheme used for analysis in the QS (Table 5).
RESULTS
Procedure, respondent rates and profile of the KIs
The profile of the 29 KIs, interviewed in August 2001 to January 2002, is given in
Table 6.2The original interview guide is available from the first author.
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Table 4. Topics of the key questions of the interview guide
Topic Question of the interview guide
QA Coverage Very often respondents noted (with the
exception of donation programmes) that
drug donations cover up to 10% of their
annual drug supply. On the other hand,
drug donations are seen as being very
important for the drug supply system in
Tanzania (see Table 3)
QA 1 Coverage of drug supply How is the remaining 90% of the drug
supply covered?
QA 2 Coverage of drug supply
through DDs
Why do you think that 10% coverage by
drug donations is important for the drug
supply system in Tanzania?
QB Value of DDs We received few responses to the question
‘What is the value of the donations received
in 2000?’ How do you interpret this result?
(see Table 3)
– The numbers are too sensitive to be
published
– Donations are perceived as gifts and
not as commercial goods
– It is difficult to estimate the value
of donations
– Other reasons
QC Main Problems To the question: ‘What causes the main
problems in the drug donation processes of
your organization?’ the problems were ranked
as below. How would you interpret this ranking
according to your own experience?
QC 1 Long-term treatment
QC 2 Guidelines for DDs
QC 3 Relevance for local diseases
QC 4 Shipment and custom fees
QC 5 Transparency
QC 6 Communication
QC 7 Infrastructure
QC 8 Training
QC 9 Quality of donated drugs
QD Optimization of DD processes To the open question: ‘In your opinion, what
are the most important actions needed to
optimize drug donation processes?’, we present
you with the five top answers (Figure 1). Do
you think that these proposed actions would
be effective or do you suggest other solutions
for optimizing donation processes?
QE Strengths and weaknesses
of DD processes
What are the three strongest and three weakest
features of donation processes according to
your own experience?
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Table 5. Characteristics of DD systems elaborated in the questionnaire survey (Gehler
Mariacher et al., 2007).
Determinants Indicator Guidelines for DDs
WHO Tanzania
Environment
Demographics Population
Epidemiology Morbidity, life expectancy,
prevalence of HIV/AIDS,
child mortality of under fives
Economy Poverty, GDD per capita
Education Adult literacy rate
Geography Paved roads
Health sector
and DDs
Sectors involved. Distribution
channels for DDs, Number of
pharmacists and educated
healthcare staff, Public spending
for health, Control of importation
of DDs
National Drug Policy Guidelines for DDs, Laws for
importation, Essential Drug List
No. 4.1
No. 4.2a-c
Resources and structures
Organizations Characteristics of the organizations
Involvement in DD processes
Staff competence Accountability
Knowledge of GDD
Documents List of needed drugs No. 3
Quality criteria for DDs
Treatment criteria for DDs
Availability of GDD
Financial aspects Shipment and custom fees No. 12
Value of DDs
Paying for DDs
DDs in cash earmarked for
buying drugs
No. 3
Process
Selection of drugs Expressed need by recipient No. 1
DDs part of the EDL of the
country or of the WHO
No. 2 No. 4.2d
Management Origin of DDs
Coverage of drug supply with DDs
Use of DDs
Disposal of unwanted drug
Transparency Evaluation of DD processes
Communication Information by donors No. 10 No. 3
Collaboration with partner
organizations
Receiving invoice documents No. 10
Quality of the donated drug
Quality assurance Certificate schemes on the
quality of DDs
No. 4 No. 4.2h
(Continues)
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Table 5. (Continued)
Determinants Indicator Guidelines for DDs
WHO Tanzania
Shelf-life No. 6 No. 4.2g
Unused drugs No. 5 No 4.2j
Presentation Labelling No. 7 No 4.2f
Perception of stakeholders
Satisfaction of
recipients
Long-term treatment,
Implementation of GDD,
Relevance of DDs, Shipment
and custom fees, Transparency
in DD processes, Communication
between donor and recipient
Infrastructure, Training of healthcare
staff, Quality of DDs
Usefulness of DDs
G. GEHLER MARIACHER ET AL.
72Because only eight KIs agreed to a recording, notes were taken during all the
interviews. We sent the interview transcript to the KIs for checking. From 19 KIs we
received comments or consensus; 10 did not respond to transcript mailings. None of
the KIs was hesitant about their views becoming publicly known.3
We broke down the views of KIs into three different groups (Table 6) according to
their: (a) sector (public, religious, NGO, private for profit, (b) level (national, district,
local) and (c) function (administrative or working directly with the patient and
supply). All KIs were involved in DDs directly or in decision-making (with 1
exception) and all were very interested in the issue. We did non analyse the level of
influence. Our aim was not to gather data for later policy implementation, but data for
a situation analysis. We excluded from the analysis two KIs who had no or very
limited experiences with DDs.
Each question was addressed by an average of 80% of the KIs. Two KIs from the
private-for-profit sector did not have in-depth experience with every aspect of DD
processes (44% and 31%, respectively, of the questions tackled). Two KIs of bilateral
and multilateral cooperations discussed in-kind DDs within the interview guide
mainly from the perspective of HSR strategies (31/13% of the questions tackled).
Most emphasis was given to personal experiences with DDs (Q E): every KI
answered this question.
Q A: Coverage (discussed by 28 KIs)
The Chief Pharmacist provided numbers for drug supply coverage by the
government, which were confirmed by three other representatives of the public
sector.3Key informants provided us with a comprehensive insight into the problems with DD processes in
Tanzania. We noted here only a few comments. Readers who wish to have a more in-depth view should
contact the first author.
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80KI 4 (Public): The government is able to provide 50% of the requirements. That
means we have a deficit of 50%. We bridge this through other financing options,
the ‘cost sharing’. But not everybody can pay. The maximum we can collect out
of the remaining 50% is only 20%. There remains a gap of 30%, which is covered
by the donors, today called development partners, through the basket funding
(programmes are included in these numbers).
He stated that 70% of the DDs received by the government (except those for
programmes) were for non-communicable diseases, and yet communicable diseases
are the prime cause of morbidity in Tanzania.
Religious hospitals were able to procure up to 70% of their drug supply from the
local market, because the services of the MSD have been significantly improved. An
exception was a rural hospital, which covered a major part of its drug supply through
DDs from Germany. Local NGOs as well as NGOs that were part of donation
programmes covered up to 100% of their drug supply through DDs. Drugs needed
outside the programme had to be purchased on the local market, where affordability
was the major problem. KIs from the private or profit sector did not comment on this
issue.
Coverage of drug supply through in-kind DDs was perceived as very important for
Tanzania by 16 KIs, while five KIs with administrative functions said that Tanzania
was not dependent on DDs. Another five KIs said that Tanzania is too poor to choose
whether or not it should accept DDs. Proposed solutions always focussed on the
optimization of the drug supply system and the fight against poverty. Statements of
KI s reflect very clearly their differences of opinion:
KI 6 (Public) Tanzania is not dependent on donations. This perception should
be given up.
KI 7 (Public): DDs are very important for Tanzania. DDs for programmes as for
example, the TB/Leprosy Programme NTLP have a very important impact.
KI 11 (Rel.) Currently Africa is not able to live without donations and needs
support. The church still needs donations.
KI 12 (Rel.) Tanzania needs DDs because drug supply is not sustainable. The
local industry covers just 12% of the pharmaceutical supply of the country. The
import of drugs is very expensive as well as the registration of drugs.
KI 14 (Rel.) Every little bit counts. In church circles we’re sometimes happy
for anything, although that seems to contradict previous statements. Mission
hospitals are always concerned about how they are going to survive financially.
KI 15 (Rel.) Overall it has to be said that DDs, as they are currently defined, are
obsolete.
KI 28 (PfP) This problem depends on the economy of a country. A poor country
like Tanzania is a prototype of a recipient country and always receives donations.Copyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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Independent of their group, there was a general agreement (14 KIs) that estimating
the value of DDs is difficult. The value of in-kind DDs should be estimated on the
basis of the wholesale price in Tanzania or on the international market price (five
KIs). There was consensus that it is very difficult to calculate the value of a nearly
expired drug and of unused drugs (drugs returned by patients to pharmacies). Four
KIs assumed that recipients are not interested in estimating the value. A further three
KIs from the national level and with an administrative function said that no data
are available. Without such data there is no basis for discussing alternatives to
DDs.
KIs of mission facilities stated that DDs often generated costs: (a) customs
clearance had to be paid, (b) the transport of 1 kg of drugs costs about the same as
1000 aspirins on the local market, (c) the disposal of inappropriate DDs is costly. The
liveliest discussion was on costs due to shipment and custom fees. In 2000, the
government withdrew the exemption for custom fees from NGOs and mission
facilities, stating that DDs were getting into the wrong hands and ending up on the
black market. The director of the Christian Social Services Commission (CSSC)
verified that this was a big problem for mission facilities, but in 2001, taxes were
abolished again, because the CSSC took over responsibility for correct handling at
custom clearance.
KI 9 (Public) Donations are coming into the country through different channels
and not through one specific centre. Therefore it is difficult to estimate the value
of donations countrywide. A centre like a central store for donations should be
founded to optimize the transparency.
KI 19 (NGO) I am working for a DD programme. Everything is very clearly
marked out. It was interesting for me that the people did not want to talk about the
value of their received drugs. I think they may not know it.
KI 21 (NGO) This is a big issue. It would be important to calculate in a case
study the value and then to think about costs and value. A drug has a value and has
a cost. Drugs are an important part of the health system. It is the challenge to
know, but it is difficult to find the information. People are too busy, especially in
NGOs.
A further five KIs (local and district level) thought that the perception of DDs as a
gift without commercial value might explain the absence of data on the value of DDs.
Respondents from NGOs said that a donation has a much more elaborate procedure
behind it than a gift.QC: Main Problems (each KI contributed to some of the Q)
The ranking of main problems (Table 4) was seen by 19 KIs as self-evident and
corresponding to their own experiences. For the purpose of this paper, we focussed
on the four main problems, which were discussed by an average of more than 60% ofCopyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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82the KIs: (a) quantities of DDs are not sufficient for long-term treatment, (b) GDD and
other tools are not implemented, (c) lack of communication between donors and
recipients, (d) poor DD quality.
Long-term treatment (discussed by 25 KIs). For six KIs (working at national level
and in an administrative function) it was understandable that this problem ranked
highest. For another eight KIs (working at the facility level) the quantity of DDs was
insufficient not only in the long term but also for the short term. This was perceived as
an issue of sustainability and leads to an ethical dilemma: if DDs are provided
through charity, recipients become accustomed to them and have high exp-
ectations of their availability. If the DD stops and people have to pay the full
price, they are often not able to do so. KIs from the religious sector were
confronted with the difficulty of drawing up an annual budget for drug supply
because donors do not ask what is needed and recipients are not able to clearly define
their needs.
KI 11 (Rel.) This result confirms the feeling of many people. DDs are always
somehow available, but seldom in the right amount.
KI 27 (NGO) Who identifies the local needs? The process of the need
quantification and the process of priority setting must begin at the district.
When the problems are identified and the priorities known then DDs could make
sense.
Guidelines for DDs (discussed by 20 KIs). KIs from each sector highlighted the
positive impact of GDD on good donation practice. KIs from the public sector,
especially from the MOH stated that GDD were available, but the distribution and
implementation was not enforced. According to religious KIs, Christian facilities
should be aware of GDD because the Christian umbrella organization CSSC was
very active in distributing them and providing training. They suggested that a
translation into Swahili could optimize the impact of GDD. NGOs pointed out that
GDD were seldom neither available nor known and were surprized that this problem
ranked at second place. Three KIs did not know any GDD.
Communication (discussed by 18 KIs). The lack of communication was perceived
by 18 KIs throughout all groups as a major problem in DD processes. Seven
KIs discussed the role of the donors, who seldom clarified recipients’ needs. Two
KIs from the religious sector noted that communication had ameliorated in recent
years:
KI 11 (Rel.) A company wanted to donate vaccines for Hepatitis B. There was a
dialogue between donor and recipient. The company was not ready to donate
more than once. For that reason, MOH did not allow the recipient to accept
donations. This is a positive example of communication in the country andCopyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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shows the desirable.
KI 20 (NGO) It should be the principle that the recipient requests the donation.
The ideal for DDs should be a pull situation not a push situation. People in the
recipient countries are often too shy to say ‘no’. But after all it is also not polite
just to give anything without knowing the situation.
Transparency was strongly associated with communication according to 14 KIs.
The Chief Pharmacist stated that transparency is not only needed between donors and
recipients but at the local level as well and should be based on accountability.
Quality of the donated drug (discussed by 19 KIs). Poor quality was discussed
equally by each sector, but for six KIs, four from NGOs working in programmes, it
was not a major problem. They felt that drug quality was mostly well controlled in
their organization, with a few exceptions. MOH, CSSC, but also NGO
representatives associated the low ranking of this problem to the low educational
level of the staff. Nevertheless, it was claimed that the Pharmacy Board4 has
optimized its work, control and its impact. Independent research on the quality of
DDs was lacking. KIs from each sector working directly with patients (facility level)
quoted examples of poor-quality DDs. Concrete problems were short expiry dates
and inadequate labelling. There was a feeling that donors sometimes wanted to
dispose of leftovers.
QD: Optimization of DD processes (discussed by 25 KIs)
We presented to the KIs the five most important suggestions from the QS for
optimizing the DD system (Figure 1). Nineteen KIs agreed fully with these
suggestions, of which communication was perceived by seven KIs as the most
important factor. Eight KIs had nothing further to add. KIs from the private-for-profit
sector did not discuss this issue.
Focussing on the required optimal quality of DDs (six KIs), the acting registrar and
a representative of an NGO pointed out that if drugs were submitted for
registration—which is officially an obligation (Ministry of Health, 2000)—quality
could be assured. The acting registrar was aware that this is a long-term goal.
Participative collaboration (four KIs) depends strongly on the person who initiates
the DD. For example, a bishop from a rural area, travelling in Europe, would not
necessarily be able to clearly define local needs, a problem discussed by another four
KIs. They highly recommended respecting the NEDLIT. Six KIs underlined the
effectiveness of the national regulations and the duty of the recipient to inform the
donor about them.
QE: Strengths and weaknesses of DD processes (discussed by every KI)
We asked interviewees to define weak and strong features in the entire DD system
(Figure 2). Every KI commented on this question, arguing more in terms of problems
than of weak and strong features.4The Pharmacy Board is today The Tanzanian National Food and Drug Administration.
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Figure 1. Optimization of drug donation processes, results from the QS (Gehler Mariacher
et al., 2007)
G. GEHLER MARIACHER ET AL.
84The role of donors was discussed by 10 KIs (3 public, 4 religious and 3 NGOs and
mostly at administrative level), awareness and attitude being the major concern,
especially for the KIs from the religious sector. Donors were recommended to
conduct a preliminary analysis of how the health care system is organized in
Tanzania and of existing storage and transport facilities. One KI (NGO) stated that
the awareness of companies had improved in response to public discussion of their
role. Other inputs focussed on the non-transparent procurement through donors and
on the call for a definite end to the collection of unused drugs.Figure 2. Drug donation system (DD-system)
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Why do they not bring the money into the country and buy the drugs at MSD?
Like this the labelling, the expiry date etc. would be controlled and the problem
with unused drugs will come to an end.
Very often the Pharmacy Board is not sure, whether the drugs were going to the
recipients or to the black market. Some donations are used as commercial goods.
They were imported as donations but afterwards they were sold in private shops.
The EDL is very well elaborated. It contains drugs that are affordable.
Imported and donated drugs are very expensive. Villagers and old people believe
that a drug that is costly has a better effect and that they are cured after the
treatment. Therefore, it is very important to follow the EDL and not to create
irrational requests.
Major problems within the process between donors and recipients were again
communication (seven KIs) and transparency (eight KIs), both of which are
prerequisite for sustainable donation processes. For NGOs, an additional problem
was maintaining a stable supply. One KI added that in-kind DDs given by individuals
or companies could interfere with programmes. Another KI of the private-for-profit
sector saw a need for monitoring entire DD processes. The inputs were given equally
from each group and each level—but only from two KIs from the religious sector.
The role of recipients was discussed by 22 KIs (9 public, 4 religious, 8 NGOs, 1
PfP). Eight KIs (five NGOs) complained about a lack of education and training of
health care staff, Mission hospital and MOH representatives said that dispensary staff
were not sufficiently trained to handle drugs from abroad. Thirteen KIs perceived
management and logistics as problematic areas. The main focus was on storage and
transport to very rural areas. The acting registrar mentioned that health workers were
not aware of these problems because of their low education level. Single statements
were given on governance (with a special focus on corruption) and on missing data.
The following achievements were highlighted: the Pharmacy Board had done a good
job in the prior 12 months and the MSD has optimized their system, with a positive
knock-on effect on the DD processes. There were no striking different views among
the different groups of KIs.
Rational drug use was the only, but important, problem raised with regard to the
relationship between recipient and patient (seven KIs, four public, two religious and
one NGO). None of the KIs was working directly with patients, and none were from
the local level. Inappropriate DDs cause irrational drug use. KIs asked for a
programme for rational drug use of DDs, adapted to the Essential Drug Programme
and to the education level of the staff employing DDs.
The discussion of patient awareness was somewhat contradictory. Four KIs (three
public, one religious, all administrative function) believed that patients are aware
when they receive DDs and place a higher value on a purchased drug than on a
donated drug, while six KIs (two public, two religious, two NGOs, district and local
level) said that patients sought adequate treatment, trusted in health care staff and did
not care about the origin of the drug.Copyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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86Final remarks
The diversity of themes added by the 24 KIs (all of the public and private for profit,
five religious sector, seven NGOs) through final remarks was striking. The mutual
issue among all the sectors was the time needed for changes to improve the structures
of the health care system. For the KIs, important barriers for an adequate
understanding between recipients and donors included cultural differences and the
recipients’ self-perception that they lack power.
KIs from the public sector merged two concerns: strengths and weaknesses of the
new financial schemes (e.g. cost sharing, basket funding) and the kit system.5 The kit
system was considered as the best solution in a setting with poorly educated health
care staff. The problem is that kits do not consistently match local supply needs. This
fact often stimulated health workers to accept DDs as gifts in-kind. In contrast to the
results of the QS, KIs did not perceive kits as a donation.
KIs proposed further research for better understanding of the impact of DDs in the
context of drug supply at the local level, but also in the context of development
cooperation. Comparative studies should be done in the different sectors and between
urban and rural areas. There is also no independent research on DD quality. More
information is needed about the financial value of DDs and their transaction costs.
There was dissent among KIs about the role of the patient: further studies are needed
to elaborate the attitude of patients towards DDs in order to improve rational drug
use. Finally, more and better statistics on drug requirements and on the
pharmaceutical market in Tanzania are needed if one wants to discuss alternatives
to donations.DISCUSSION
The study was carried out within the health care system of Tanzania and at the local
level in three regions—Ruvuma, Kilimanjaro and Dar es Salaam. Data were
gathered in 2001/02 through KIs selected from a convenient sample of respondents to
the QS (Gehler Mariacher et al., 2007). Not all results might be representative for
other countries. All the interviews were conducted by the first author, who has long
practical experiences with DDs (Gehler Mariacher et al., 1998). While this provided
consistent data collection, the results might be influenced by her experience and
attitude.
The definition of an in-kind DD was comprehensively conceptualized according to
the definition of DDs in the Tanzanian GDD (Ministry of Health, 1995). It was not
always possible to clearly distinguish between in-kind DDs given (a) in the
framework of a programme, (b) as single donations from individuals or (c) as
corporate DDs from pharmaceutical companies. Despite these limitations, detailed
insights of this study should contribute to a better understanding of DD processes at
the local level in Tanzania. Furthermore, the expertise of KIs produced discussions5Drug supply for health centres and dispensaries in the public sector of Tanzania is based on prepacked
standardised kits as part of the National Essential Drug Programme. The composition of the kits is based on
the NEDLIT and on national morbidity data.
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challenges of DDs given to the Tanzanian drug supply system.
By using an interdisciplinary approach of data collection (triangulation), we
amended the data reliability of the QS (Gehler Mariacher et al., 2007). We found
similarities for coverage of the recipients’ drug supply through DDs (27% Q S, 30%
KIs), which corresponded also to the country’s low indicator for access to essential
drugs (WHO, 2001). The ranking of ‘main problems in DD processes’ was perceived
by KIs as rational and understandable.
KIs working in DD programmes stated that the value of DDs was clearly defined in
their own programmes (e.g. Mectizan Donation Programme, Trachoma Initiative).
This result correlated with the high number of NGO responses (57%) in the QS, that
is, by those who were most aware of the monetary value of DDs (Table 3).
KIs concurred with and went into greater depth on the problems in DD processes
raised by the QS: DD processes and DD quality were often not appropriate.
KIs endorsed the proposals for the optimization of DD processes suggested by the
QS respondents and they had little to add. These proposals were consistent with the
core principles of the WHO GDD (WHO, 1999). This agreement between KIs and
the respondents of the QS confirms the importance of the WHO GDD as a tool for
good donation practice, as discussed in previous studies (Reich, 1999; Autier et al.,
2002). Therefore, the core principles of the WHO GDD are suitable for structuring
the discussion below of the problems of DDs identified by our investigation.Maximum benefit of the recipients
The aim of the Tanzanian Essential Drug Programme is to ensure that drugs for
treating the most common diseases are available, accessible and affordable to the
entire population. In 2001/2002, however, the reality was far from ideal. The 30%
gap in the drug supply system is due to ‘poverty, diseases and ignorance’ (KIs 7, 9),
which have accumulated in a vicious circle. To cover this gap, KIs appreciated the
support through DDs within the framework of DD programmes as part of GPPPs with
a known public health effect. However, DDs given from a surplus, as gifts from
individuals or as single-source and corporate DDs were perceived controversially.
KIs working at administrative or organizational levels and KIs from the
private-for-profit sector stated that in-kind DDs from individuals should be
abrogated, since Tanzania should not be dependent on them. For any DD strategy,
maximum benefit depends on sustainability. Corporate DDs could be helpful as long-
or mid-term DDs (for a minimum of one year), while disburdening the annual budget.
Concerns arose about health workers who accepted poor-quality in-kind DDs.
However, treating patients without drugs is perceived as disenchanting. Thus, even a
10% coverage of drug needs through in-kind DDs could be appreciated to ease gaps,
but it might generate an ethical dilemma through a conflict between individual needs
created by poverty and the targets of the health policy. Here, donors were charged
with responsibility, because poverty creates dependency and hinders free
decision-making.
KIs questioned the basis for estimating the monetary value of an in-kind DD,
especially when the drug is nearly expired, not well labelled or lacks a qualityCopyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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88certificate. The pharmaceutical quality of a DD should be optimal if it is to be
compared with the wholesale price of its generic equivalent in the recipient country
(WHO GDD (WHO, 1999)). The Tanzanian GDD do not address the issue of value
(Ministry of Health, 1995). When considering value, DD-related costs have to be
considered as well. The transaction costs evoked through transport, shipment fees
and costs for disposal can be higher than the value of the donated drug. The new tax
for custom clearance was a significant problem in 2001, especially for the religious
sector and the NGOs. Recognizing the problems in recipient countries, the WHO
GDD request that the donor should pay for shipment and custom fees. This is rarely
the case.
KIs offered thoughts to animate the discussion on how to boost the benefit of DDs.
Why not, instead, donate money to support local activities and the HSR strategy?
This would overcome the problem of treating DDs like gifts and the sometimes
questionable motivation of the donors. DDs in cash are also an expressed request of
the Tanzanian GDD in order to support local manufacturers (Ministry of Health,
1995). But earmarked donations in cash were given to only 16% of the recipients in
the QS (Table 3). A second suggestion was to establish a central store for the
management of DDs, to control the importation of DDs and to distribute them to
facilities in need of specific drugs. Third, why should patients not pay for DDs
according to the customary financing schemes? In the QS, 40% of the recipients,
especially in the religious sector, supported this proposal (Table 3). With a revolving
drug fund (RDF), based on a DD, the Christian sector had achieved first positive
results. The RDF gives a chance to the Christian health facilities to build up a sound
basis for a self-reliant drug supply (Kuper and Njau, 1998).Respecting the wishes of the recipient
A consensus was that DDs were often not donated for an expressed need; in the QS
also, 38% of recipients were confronted with this problem (Table 3). KIs assumed
that data on needs were not collected because needs assessment has not been
systematized, as suggested also in the QS results (Table 3). The lack of data on DD
needs was also perceived as a major drawback for decision-making within the
strategy of the HSR (Ministry of Health, 1999; Bu¨rki, 2001), such that recipients had
no power to refuse DDs of questionable quality. These problems result from a lack of
accountability, an issue already raised in the QS (Table 3).
Tanzania has developed all the necessary tools for a good donation practice. KIs
wanted an optimal scenario for DDs following the essential drug list (NEDLIT) and
the standard treatment guidelines (Ministry of Health, 1997b; Wiedenmayer and
Mtasiwa, 2000). Selection criteria should be established with regard to local needs:
DDs should cover the diseases of the country and correspond with the prevalent
morbidity rate. This process should ensure, as KIs stated, ‘the right drug in the right
amount at the right place in the right time for the right patient’. If unknown drugs are
given, problems with rational drug use and, possibly, adverse drug reactions were
anticipated. KIs made quite clear that compliance either with the WHO and/or with
the Tanzanian GDD would support an optimal DD process. But these tools need to be
better implemented and enforced by both recipients and donors. In the Tanzanian DDCopyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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they are mostly not implemented at all.No double standard in quality
The quality of the donated drug was perceived as a minor problem in the QS
(Table 3). We also found a distinction in the views of KIs working in DD programmes
compared to KIs receiving in-kind DDs from individuals and as single-source DDs,
e.g. in their judgement of the quality of DDs. KIs working with patients did not agree:
inappropriate DDs created an extra workload in terms of sorting, storage and
distribution, cause costs for disposal and easily overstretched the capacity of human
resources. Three major DD quality issues were discussed: unused drugs or leftovers,
the labelling of DDs and the expiry date. Unused drugs will boost stockpiling and
encourage pilfering and black market sales. Together with mislabelled DDs, they
were perceived as a reason for irrational drug use, a serious problem in Tanzania.
Problems with a short shelf-life were stressed by the KIs: the donation of expired
drugs is illegal because of the risks and should not be considered a matter of
conscience or morality. Expiry dates are important: weak drug supply systems
burdened by storage, transport and climate problems are challenged to maintain the
quality of DDs (Ette, 2004).Effective communication between donor and recipient
For all KIs, effective communication is prerequisite for a functional DD process. A
participatory approach has to be initiated by the donors. They should act respectfully,
meet the regulatory requirements of the recipient countries as well as the wishes of
the recipients and not undermine the endeavours of recipients to optimize their drug
supply system. Strongly associated with communication is transparency, not only
within the process between donors and recipients but at the local level as well.CONCLUSIONS AND RECOMMENDATIONS
All relevant DD-related national regulations and guidelines of Tanzania for ensuring
a good donation practice are important for supporting recipients at the end of the
supply chain in voicing their specific needs and in refusing poor-quality DDs,
especially within the context of poverty.
DD quality should be adapted to the national quality assurance procedures with
more stringent control at customs, and the recent efforts of the government should be
supported. The idea of a centralized location for the import of DDs should be
assessed.
DDs given as part of GPPPs have a positive impact on the Tanzanian drug supply
system. In other cases, money donations as proposed in the Tanzanian guidelines for
DDs and in the objectives of the HSR are recommended. But DDs cannot always be
restricted to these requirements, and donating money is not the only alternative.Copyright # 2007 John Wiley & Sons, Ltd. Int J Health Plann Mgmt (2007)
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90However, when drugs are donated, the focus has to be on the Tanzanian Essential
Drug List, the NEDLIT.
This study confirmed and reinforced results from previous investigations: DDs
were frequently not given for long-term treatment and did not meet the needs of the
country. The lack of data, of accountability and of informed health workers are major
structural problems in the recipient country. Insufficient transparency, irrational drug
use and weak management and infrastructure (especially storage and transport
problems) are other significant problems. For further improvements, continuing
education of health workers, the provision and distribution of DD-related
information, nationwide communication and clearly defined accountability are
important issues to address.
As one possible approach, we suggest developing standard operating procedures
(SOPs). The SOPs on drug requisition, transportation, storage, distribution and use,
as they exist in the ‘Tanzanian Procurement Act’, could be transposed onto DDs.
There is no substantive reason to handle a DD and a purchased drug as different kinds
of goods. Thus, it should be possible to optimize education and rational drug use, and
improve data collection.
Donors must act respectfully and meet regulatory requirements of the recipient
countries as well as the wishes of the recipients. This could be achieved through a
pull system, with optimized communication as a major tool. The basis should be
transparency within and between donor and recipient systems.
Finally, when discussing optimization of the DD system, we should not forget the
ultimate goal of DDs. Therefore, a participatory approach should be initiated by both
donors and recipients based on awareness and mutual understanding in the interests
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"Researchers should not tell what the problems are, but how they could be solved" (Prof. G.P. Mwaluko, Symposium on 
Drug Donations, National Institute of Medical Research, NIMR, 21.02 2000, Dar es Salaam)  
Abstract 
Background: In a questionnaire survey conducted in 2001, all sectors and levels of the Tanzanian health 
care system showed a high acceptance of in-kind drug donations (DD) for supporting the drug supply.  
Objectives of this study were to disseminate and discuss the survey findings with these stakeholders 
survey and to elaborate practical solutions for optimised DD processes. 
Method: With the support of WHO, in 2002 a one-and-a-half day participatory workshop was organised 
in Dar es Salaam, Tanzania, focussing on a) three main barriers to the optimisation of DD processes, b) 
three main strategies for improving DD processes, c) three main suggestions for strategy implementation. 
Participants were either randomly selected from the questionnaire survey (n=22) or individually invited 
because of their key function in DD processes (n=4). 
Results: Major barriers identified in the recipients’ country were insufficient transparency, and a lack of 
data,  accountability and informed health workers. To address these problems, participants brainstormed 
practical solutions. Recommendations to donors include: a) respect the national drug policy of Tanzania, 
b) communicate actively with recipients during the entire DD process. Recommendation for recipients in 
Tanzania comprise: a) translation of the guidelines for DDs into Swahili, b) strengthen the collaboration 
between the public and the private sectors, c) establish an autonomous, centralised body for coordinating 
DDs given to Tanzania. 
Conclusions: The focus has to be on the drug and not on the donation. Consequently, like all other drugs, 
a donated drug should conform to the national regulations and to recipients’ requirements.  
Introduction 
As a country with low access to essential drugs, Tanzania uses in-kind drug donations (DDs) to bridge 
drug supply gaps [1, 2]. In-kind DDs are manufactured drugs imported free into the recipients’ country. 
Since the early 1990s, the country has developed instruments for the regulation of DD processes and for 
the support of good donation practices by introducing a) an essential drug list, the NEDLIT (1991), b) 
guidelines on DDs (GDD) (1995), c) guidelines for the importation of pharmaceuticals (2000) [3-5]. As 
part of the health sector reform (HSR), in 1998 Tanzania adopted the concept of a sector-wide approach, 
and donors’ funds are now pooled and earmarked for priority activities (basket funding) in the health 
sector. By transferring the authority of health care to the district and local levels, the HSR also brought 
about decentralised decision making in DD processes [6-8].  
In 2001, we conducted a stakeholder analysis with a questionnaire survey to explore the views, 
knowledge and practices concerning in-kind DDs as a strategy to improve access to drugs [9]. When 
considering all DD strategies together, an average of 27% of the recipients’ drug supply was covered by 
DDs. DD strategies in development cooperation are: a) DDs given directly to the basic health care system 
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and made available through private humanitarian institutions (religious, non-governmental and private 
voluntary organisations), b) single-source DDs given through private companies and individuals and c) 
DDs given as part of global public/private partnerships (GPPPs) with a clearly defined public health goal. 
Stakeholders from every sector and different levels of the Tanzanian health care system showed a high 
acceptance of in-kind DDs as an important source for supporting the drug supply within the context of 
poverty. However, if DDs are not appropriate, they burden the drug supply system. The most important 
problem recognised by each sector involved in DDs was the insufficient quantity of donated drugs for 
sustainable treatment, and hence a prime concern of DD recipients was the discrepancy between the needs 
of the recipients and the donors’ supply. On average, 45% of the recipients were familiar with the 
Tanzanian GDD and 30% with the World Health Organisation (WHO)-GDD. 
In 2001/2002, we conducted standardised key informant (KI) interviews to consolidate the views of 
recipients, to clarify different interests and to identify KI recommendations for optimised local DDs [10]. 
Major structural problems identified in the recipients’ country were lack of data, of accountability and of 
informed health workers. Insufficient transparency, irrational drug use and weak management and 
infrastructure (especially storage and transport problems) were other significant problems. For KIs, the 
problem of DD quality equalled that of problems related to DD systems, in contrast to the questionnaire 
respondents who had placed more emphasis on the latter. Both studies showed that the DD problems that 
arose between donors and recipients were mainly caused by communication failures. Donors should 
respect the wishes of the recipients, meet the regulatory requirements of the recipient countries and 
should not undermine — through inappropriate DDs — the endeavours of recipients to optimise the drug 
supply system. The proposals of recipients for optimised DD processes corresponded fully with the core 
principles of the WHO-GDD (Table 1) [11]. 
Against this background, in collaboration with the WHO we organised a participatory workshop with the 
following aims: a) to disseminate and discuss the findings of the questionnaire survey and the KI 
interviews [12], b) to identify possible interventions for the improvement of DD processes in Tanzania, c) 
to elaborate practical solutions for optimised DD processes and d) to increase the validity and credibility 
of our research work. In this paper, we present recommendations elaborated during the workshop and our 
final conclusions. 
Methods 
In October 2002, we organised a one-and-a-half day workshop in Dar es Salaam. Stratified by sector, we 
randomly selected 26 participants from the questionnaire survey. Of these, 22 were able to accept our 
invitation, providing representation from the public sector (2 facility level, 4 administrative level), the 
religious sector (5, 3), NGOs (2, 5) and private-for-profit organisations (1, 0). Four further persons with 
key functions in DD processes also participated in the workshop.  
At the beginning of the first half day, the first author presented the results of the questionnaire survey and 
the KI interviews. Initial presentations were then followed by group work, for which the participants were 
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randomly assigned to four groups. Each group discussed a question for improving DD processes, based 
on the core principles of the WHO-GDD [11] and the recommendations of stakeholders in the 
questionnaire survey for optimising DD processes (Table 1).  
Table 1: Questions tackled in the group work 
Short Title Questions for the group work adapted to the core 
principles of WHO 
Core Principles WHO [11] 
Quality of DDs How do you to assure and control the quality of the drugs 
received? 
No double standard in quality, 
Participatory 
collaboration 
What is required on your side to collaborate in a participatory 
way with the donor and within your own environment? 
Effective communication between 
donor and recipient 
Defining DD needs What tools do you need for defining local needs (covering your 
own facility)? 
Maximum recipient benefit 
National 
regulations 
How can you optimise the impact of GDD and what is required to 
follow the national regulations? 
Respect of the wishes of the 
recipient 
 
The workshop closed with the feedback from the group work focussing on a) three main barriers to the 
optimisation of DD processes, b) three main strategies for improving DD processes, c) three main 
suggestions for strategy implementation. 
Results  
The results of each group are given in Table 2 as they were presented in the plenary. Additionally, we 
summarise the key issues associated with each question, as raised in the plenary discussion. 
Quality of DDs 
It was emphasized that disseminating guidelines and routine inspections at entry points are not sufficient 
to ensure the quality of donated drugs due to three major barriers: a lack of transparency about donors’ 
quality testing of DDs, inability of the recipient to handle inadequate DDs and policy interference 
between donors and recipients. Workshop participants were however, unable to add any new suggestions 
to those previously put forward to improve the quality of donated drugs These include a more transparent 
donation process, engaging qualified staff and development of tools for quality assessment. In addition, 
the suggestion of the WHO representative to blacklist donors who provide inadequate DDs was endorsed. 
Participatory collaboration 
For good collaboration between donors and recipients, informed health workers and information about 
drug needs are prerequisite. Recipients should proactively inform donors about their drug needs and about 
regulations concerning DDs. In this connection, an annual stakeholder meeting at which donors would 
receive first-hand information about the situation in a recipient country might be effective. Clearly, 
modern communication technology should be used to maintain continuous exchange and collaboration. 
The suggestion was put forward to establish a centralised body for handling all DD imports. This body 
could benefit from the long-term experiences of the Christian umbrella “Christian Social Services 
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Committee” with DDs. Existing knowledge from disease control programmes receiving DDs should be 
used instead of starting a project from scratch. Objections raised against such a body were the lack of 
funds and the complexity of planning. 
Table 2: Results of the group work  
Barriers  Strategies  Suggestions for strategy 
implementation 
Quality of DDs   
Differences in donation concepts 
between donor and recipient. 
Educate donors about what you need 
and the quality you require. 
Disseminate current donation guidelines 
– a Food, Drug and Cosmetic Act is 
currently being drafted. 
Inability to make proper use of donated 
items – e.g. if the product/item is not 
labelled in an appropriate language. 
Assure that donations conform to 
government policies and guidelines. 
Communicate Food and Drug 
Administration (FDA) Act proposal. 
  
Lack of reliable information about 
whether or not donors conduct quality 
testing before sending donations. 
Conduct routine visual inspection (by 
pharmacists and Pharmacy Board) once 
DDs are in the country after screening 
at point of entry, e.g. change in colour, 
smell, etc. 
Service delivery points to communicate 
their requirements for acceptable 
products and bulkware. 
Participatory collaboration  
Lack of awareness and/or transparency 
of both donors and recipients about 
- Regulations 
- Guidelines 
- Procedures 
- Recipient drug needs 
- Packaging and shipping. 
Educate/sensitise stakeholders about 
guidelines, procedures and regulations. 
Both the MOH and other users should 
be pro-active in disseminating this 
information 
Establish an independent central 
platform for communication and 
exchange of information, e.g. availability 
and needs  (Could be fully autonomous 
or semi-autonomous). 
Lack of competent staff and lack of 
accurate data on drug requirements. 
Have qualified staff to quantify drug 
needs. 
Organise annual stakeholder meetings 
where donors and recipients can come 
together and discuss various issues 
pertaining to DDs. 
Limited choice of drugs that forces 
recipients to accept what is available 
Establish a centralised body for 
handling all pharmaceutical donations, 
i.e. a national body that will coordinate 
both private and public donations. 
Empower recipients to access currently 
available sources of information both 
online and as hard copies (web sites, 
networks, etc.). 
Defining DD needs   
Having access to appropriate and 
current data is a precondition for 
efficient drug need identification. 
Improve health information system 
through the employment of qualified and 
dedicated/motivated staff. 
Have a clear list of national essential 
drugs. 
No plans for disease 
outbreaks/epidemics. 
Solicit more funds. Donors and recipients should adhere to 
existing guidelines. 
Lack of funds – financial constraints can 
make clearing and transportation of 
donated items difficult to handle. 
Improve networking and collaboration 
with other key stakeholders. 
Prepare post-donation report/feedback 
– could be done at the annual meeting 
proposed earlier or just directly between 
the recipient and donor. 
National regulations   
High costs, e.g. paying experts to 
review guidelines, printing costs, 
distribution logistics and other related 
costs. 
Mass media campaign, including a topic 
on guidelines in seminars and 
workshops and other medical-related 
meetings 
Regular scheduled meetings with 
minutes circulated to all major health 
care providers. 
Non-compliance with regulations and 
policies (e.g. corruption). 
The Permanent Secretary of the MOH 
should strengthen the functions of the 
national therapeutic committee (it is not 
functioning very well at the moment). 
Use of new communication 
technologies, e.g. internet, email, etc. 
Political lobbying is required to enhance 
awareness of problems with DDs. 
Inclusion of guidelines in the training 
curricula of medical and paramedical 
courses, on-the-job training and 
continuous education. 
Establish medical communication and 
information centres in all medical zones. 
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Defining DD needs 
Definition and quantification of drug needs require epidemiological data and information about the 
national supply chain. Similarly, all donors should understand the relevant health care delivery systems 
with regard to the role and functions of the different levels of care, allowing donors to adapt their DDs to 
the specific level of health care, as required in the NEDLIT. 
A longer discussion focussed on the need for qualified and motivated staff to improve data collection. The 
workload of health workers has to be considered, particularly as there are already many reporting 
requirements, but little coordination. An important suggestion was to insert a tool for drug need 
quantification into the GDD. Known seasonal patterns need to be included in the estimates of drug needs. 
The estimated buffer stock for emergency needs should be available at the parastate wholesaler Medical 
Store Department (MSD).  
National regulations 
Tanzania has developed guidelines and regulations for good donation practices. The plenary argued that 
establishing regulations is important, but they make little sense if there is no adherence to them. 
Discussion of guidelines in the curricula of basic or continuous training of health workers as well as the 
monitoring the guideline application was emphasised. The workshop participants addressed a lack of 
political will: a) the national therapeutic committee with its duty to monitor the implementation of 
guidelines has to strengthen its efforts at both the national and the district level, b) the MOH has to 
improve its communication of policies, c) corruption was seen as major obstacle in the DD process 
through unregistered pharmacies, unqualified pharmacists and unethical political lobbying and should be 
better controlled. In this respect, it is important to note that health workers often work in both the public 
as well as the private sector. This fact predisposes to corrupt practices. 
For better use of guidelines, a translation of the most recent Tanzanian GDD [3] into Swahili could be 
useful. The Tanzanian GDD should be reviewed regularly and they should comply with the WHO-GDD 
and other relevant guidelines 
Discussion and recommendations 
Of the 26 randomly chosen invited persons, 22 or their representatives (85%) participated in the 
workshop. Thus, a good mix of opinions from all sectors involved and from all levels of influence in the 
Tanzanian health care system could be collected and discussed. The level and intensity of discussions 
throughout the workshop illustrated the importance of the topic. All participants showed substantial 
interest in elaborating practical solutions for better DD processes. Given the topic and the specific 
questions addressed, the issues raised are certainly relevant for the discussion of DDs in many other 
similar, low-income countries.  
Another important barrier to optional donation practices identified by workshop participants are 
insufficiently trained and poorly informed health workers. This is a general issue for health care systems 
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in sub-Saharan Africa [13], and is already being addressed in the objectives of the HSR in Tanzania [7, 
14, 15]. A lack of transparency, which hinders good collaboration between donors and recipients, was the 
other important barrier perceived by participants. Donor non-transparency about DD quality reduces 
recipients' influence on DD processes. However, participants were aware that there were transparency 
barriers in the recipient country as well, also based on a lack of accountability and a failure in political 
will. Despite all the efforts made in health care delivery systems to improve health information systems, 
the absence of projections of annual drug needs is surprising and was unanimously identified as another 
important barrier. Participants explained that this problem was not only caused by lack of data alone, but 
also by a waste of data. Reasons given were uncoordinated data gathering and the non-systematic 
collection of often irrelevant data. This reveals not only a structural problem, but also problems of process 
and communication. The lack of reliable data about drug needs at a local level results in DDs which are 
mainly supply/offer rather than demand driven.  
The lack of awareness of existing national regulations and guidelines is an important problem for both 
donors and recipients. Although guidelines for drug donations are available even at the local level, they 
are often unknown and disregarded.  
Most of the barriers found in this study were also identified by stakeholders in our previous studies [9, 
10] or have already been discussed in other contexts [16]. This emphasises the importance of these 
barriers and confirms our results with a different approach. 
Practical solutions for improving DD processes 
Participants had concrete ideas about how to overcome these barriers. To improve communication, to 
raise awareness as well as to exchange information between donor and recipients, an regular stakeholder 
meeting as part of broader donor consultations were proposed. Participants also recommended that all 
sectors should collaborate and that stakeholders should learn from the long-standing experiences of the 
Christian Social Commission and of NGOs working in donation programmes. This addresses the 
importance of PPPs.  
The participants proposed the translation of the Tanzanian GDD into Swahili, as suggested in our 
previous studies. A feasible new input is the addition to the Tanzanian GDD of models and tools for 
needs assessment. Modelling drug needs on the basis of routine data collection and including estimates of 
completeness might provide an effective way forward. The tools established by WHO, within the 
Tanzania Essential Health Interventions Project (TEHIP) programme or similar market-modelling 
software could be adapted and validated for DDs. This helps recipients not only in defining DD needs, but 
also in gathering quantification data for a regular drug supply, and could be an instrument to assess needs 
in emergency situations. 
Drug quality was perceived as a crucially important issue. However, suggestions for improvement did not 
satisfy participants’ expectations. It is important to note here that at the same time in 2001, Tanzania was 
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beginning to set up laboratories for quality assurance at the entry points, including the control and listing 
of DDs through the Tanzanian Food and Drug Administration [17, 18]. 
The suggestion of the WHO representative to register donors who provide inadequate DDs in analogy and 
connected to the established global WHO register [19] was a new concept for participants and was 
perceived as helpful. The question was raised as to how to organise such a register without being 
perceived as donor blaming and thus discouraging DDs. 
The idea of a centralised body for collecting all DDs entering the country was the most important 
suggestion. Factors to be considered are: a) access to information, b) clear structures, c) clearly defined 
procedures for all stakeholders, d) support in quality assurance, e) pooling of DDs for distribution and f) 
financing schemes to enable sustainable functioning. Advantages are: a) protection of developing 
countries from drug dumping, b) monitoring of incoming DDs and c) support to the collaboration 
between donors and recipients. Such centralisation could potentially ensure the appropriate distribution of 
donated drugs to those facilities which really need them. In the public sector, the MSD is already 
responsible for taking over all DDs and distributing them among their own clients. However, participants 
wanted an autonomous body for all sectors involved in DDs. Problems could arise in the area of 
accountability in a situation where there is a fairly decentralised health care system and in the costs of 
maintaining such a body. Participants emphasised that it is important to discuss both the consequences of 
the HSR and the impact of the decentralisation of authority on DD processes. But the Tanzanian case has 
shown that improvements are possible [8].  
Conclusion 
Participants were aware of the key problems they face in Tanzania and were motivated to make an effort 
for optimising DD processes. The barriers affecting DD processes raised by the workshop participants 
were similar to those affecting the entire health care and drug supply system: an insufficient number of 
trained health workers, missing accountability, failure in monitoring of and adherence to guidelines and 
regulations, and a weak data reporting system. DD-specific barriers were seen on both the donor and 
recipient sides: non-compliance with national regulations and guidelines, and shortcomings in 
transparency and communication.  
To address these problems, participants brainstormed practical solutions with the goal to optimise the 
Tanzanian DD system. The recommendations to donors entail:  
- Respect the national drug policy of Tanzania and the guidelines for DDs 
- Communicate actively with recipients during the entire DD process 
- Consider that DDs should be demand and not supply driven 
The recommendation for recipients in Tanzania comprise:  
- Translation of the guidelines for DDs into Swahili and addition of models for needs assessment to 
these guidelines  
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- Assure systematic collection of data linked to the general improvement of the health management 
information system 
- Strengthen the collaboration and sharing of experiences between the public and the private sectors 
- Establish an autonomous, centralised body for coordinating DDs given to the Tanzanian health care 
system  
The important area of quality assurance at the entry points and the revision of the GDDs were also 
mentioned, issues which have already been taken up by the MOH, but are not yet fully implemented.  
Within a DD process, both donors and recipients have to keep in mind that the focus has to remain on the 
drug and not on the donation. Consequently, like all other drugs, a donated drug should conform to the 
national regulations regardless of the country's wealth. Transparency and collaboration are prerequisites 
for good DD practices. 
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Abstract 
Background: Switzerland has a long tradition in humanitarian aid, and both the public and the private 
(not-for-profit and for-profit) sector are involved in drug donation (DD) processes. Objectives of this 
study were a) to assess the characteristics of the DD system in Switzerland and b) to collect stakeholder 
and donor views on problematic areas in DD processes including all strategies of drug donation. 
Methods: Using a qualitative approach, data were collected through validated postal questionnaires in 
German and in French sent out in May 2001 countrywide to stakeholders of all sectors and levels of 
decision-making involved in health care in Switzerland. Result: Of 1115 mailed questionnaires, 359 were 
returned (32%) of which 279 (25%) were eligible for analysis. All respondents perceived economic 
aspects and the support of poor people as the most important justifications for DDs. The most 
frequently mentioned negative aspects of DDs were issues which burden the health care system 
of a recipient country. Sustainability of DDs and the non-relevance of donated drugs for local 
needs were viewed by donors as major problems in DD processes. In the donors' view, 
participatory collaboration could have the greatest impact on improving DD processes. Donors had 
little knowledge about guidelines and good donation practices. Quality aspects were of minor importance. 
Donors from the private-for-profit sector (community pharmacies as well as industrial companies) 
reported important donations of unused drugs. Conclusions: In 2001, the views of stakeholders and 
donors about strategies in development cooperation and DD policy largely complied with the then current 
Swiss policies. However, DD practices reflected a strongly supply-driven process with insufficient 
communication between donor and recipient.  
Background 
In-kind drug donations (DDs) are defined as manufactured drugs that are imported free to the recipients’ 
countries. They have been proposed as a support for underfunded, weak drug supply systems over the 
short or middle term, but only if they do not hinder efforts to develop a sustainably financed mechanism 
of drug supply [1-3]. DD processes and systems are complex:  
- Stakeholders in DD processes (donors, recipients, patients) belong to multiple organisations in 
different health care systems embedded in different environments (Figure 1).  
- The settings for DDs are either a rapid response to an acute emergency or a component in 
development cooperation (DC).  
- In development cooperation (DC), many DD strategies are possible: a) targeted DDs are given 
directly to the basic health care system and made available through private humanitarian institutions 
(religious, non-governmental and private voluntary organisations), b) single-source DDs are given 
through large corporations or through individuals, c) DDs are given as part of public/private 
partnerships (PPPs) with a clearly defined public health goal.  
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The World Health Organisation (WHO), in cooperation with major international agencies active in 
humanitarian relief, has issued the Interagency Guidelines for Drug Donations as a globally valid standard 
(Table 1) [4]. However, DDs still do not comply with these standards and burden the recipients’ health 
care system [5-8]. Global standards alone do not assure a good donation process. DDs have to be adapted 
to the needs, capacity and system of the recipients’ health care system [9-11].  
A review of the literature showed that major problems in DD processes have their origin in the interaction 
between donors and recipients [12-15]. In a literature search for 2000, we found, however, only two 
papers which had a specific focus on donors [15, 16]. In a quantitative study, Reich assessed the 
relevance of DDs (listed in the essential drug list of the recipients’ country or a therapeutic alternative) 
and time to expiry of two private voluntary organisations (PVOs) in the USA. In addition, he contacted 
36 companies and 31 PVOs for the analysis of their donations policy [16]. One year after their 
introduction, WHO reviewed experiences with the DD guidelines with a view to their improvement where 
necessary. Donors were included in the evaluation.[15]. With this background and alongside our work on 
recipients' perception of DDs and DD processes [17-19], we sought to deepen knowledge about the 
donors’ point of view, and present here preliminary results about Swiss donor attitudes towards 
problematic areas and gaps in DD processes.  
Switzerland was selected as an exemplary donor country for several reasons: 
- It has a long-standing involvement in DC with developing countries, including Tanzania. 
- DD processes in both the public and the private sector are involved. The latter includes the for-profit 
sector (e.g. pharmaceutical companies and community pharmacies) and the not-for-profit sector 
[religious organisations and non-profit organisations such as non-governmental organisations (NGOs) 
and PVOs].  
 
Our objectives were: a) to assess the characteristics of the DD system in Switzerland and b) to collect 
stakeholder and donor views on problematic areas in DD processes including all strategies of donating 
drugs.  
Swiss DD processes 
Switzerland, as a industrialised and OECD country, has a long tradition in humanitarian aid, fuelled 
largely by humanitarian motives and a sound economy. Secular and religious relief organisations were 
formed in the 19th century [20-22]. The motives of these first-generation relief organisations were to 
cover, inland or abroad, sudden need (e.g. food, medical aid). After the Second World War, all the sectors 
involved rethought their activities in humanitarian and development aid under the influence of the Cold 
War and the conflict in Vietnam [20]. An ongoing discussion about the motives, efficiency and 
effectiveness of the activities led to the current development policy. People from low-income countries 
are now viewed as partners and not as helpless people in need. Solidarity and equity have become guiding 
ideas and development is now understood as a change in the political, social and economic structures in 
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poor countries. Whatever strategy Swiss stakeholders adopted in DC, health issues have been a major 
focus of attention. Drugs have been viewed as a significant tool to relieve distress, and DDs considered as 
a possible strategy to provide these drugs to people in need. As a nation significantly committed to 
pharmaceutical research, development and production, Switzerland seemed also predestined for 
involvement in DDs.  
The Swiss pharmaceutical sector is based on free market principles. The registration of drugs is carried 
out by Swissmedic [23]. The drug market is highly regulated with respect to quality standards and a 
guaranteed and affordable basic drug supply through the mandatory national insurance system. The 
national law on medicine and medical products, issued in 2002, has no specific article for handling DDs 
and there are no DD guidelines for Swiss donors. [24]. However, this legislation prohibits the export of 
drugs to foreign countries if those drugs are unauthorised in the target country or if it is evident that the 
drugs will be used for illegal purposes. Before 2002, each canton had its own laws and there was no 
legislation applicable to the entire country. The export of drugs was practically unregulated. 
In Switzerland both the public and the private sector are involved in DD processes. Each sector has 
pursued specific strategies to donate drugs, based on different motives:   
Public sector: In the public sector, the main actors are the government as represented by the Swiss 
Agency for Development and Cooperation (SDC) [25] and the State Secretariat for Economic Affairs 
(SECO) [26]. The main motive to provide DC and humanitarian aid is one of public concern, that is to 
ensure an efficient multilateral system among small and larger states. In 2000, Switzerland committed 
itself to support the Millennium Development Goals (MDGs) in all multilateral activities and to focus on 
a world without poverty, fear and ecological problems [27, 28]. To reach these goals, SDC seeks 
collaboration with partners in the form of PPPs [11] . Focusing on the empowerment of the health 
systems in low-income countries [29], the preferred strategy of SDC is to eliminate causes rather than 
making donations and covers optimisation of access to essential drugs (MDG 8) [27]. Short-term DDs are 
considered in emergency assistance. But even then, local procurement of drugs is preferred, 
circumstances permitting [30]. 
Less relevant actors work in cantonal administrations and public hospitals, health facilities and 
pharmacies. Their commitment to DD processes is similar to that of community pharmacies (see under 
private-for-profit sector). 
Not-for-profit sector: It is difficult to gain a comprehensive and clear overview of either religious or 
secular, private not-for-profit organisations. In 1998 more than 200 organisations from this sector were 
working in DC [31]: 
1. Religious sector: After the Second World War, religious organisations also rethought their approach to 
development aid. They made a considerable contribution to shaping the debates about north-south 
conflicts. As a result, they became very welcome partners in DC because of their well-established 
structures in countries with low income. Two groups have an important impact in health care in DC and 
DD processes. In the first case, major missionary bodies and faith-based organisations, e.g. Hilfswerk der 
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Evangelischen Kirchen Schweiz (HEKS) and Caritas, supported the idea that in a partnership, the 
recipient should cooperate in needs assessment [20]. This view led to a critical appraisal of DDs. To 
provide donors with a guide, as early as 1988, the Christian Medical Commission (CMC) issued 
guidelines for DDs, which provided the basis for the WHO's later GDD [32]. However, not all religious 
organisations followed this change in paradigm, and as the second group, they still base their 
development activity on missionary goals. Likewise, helping people in need to receive the mercy of God 
has also been the motive of individuals, smaller missions and small PVOs [20]. DDs are often sent by 
individuals to mission facilities without prior knowledge, do not cover needs and do not meet the 
requested standard [13, 33].  
2. NGOs and PVOs have existed since the mid-19th century and are private not-for-profit institutions with 
clearly defined structures, independent of governments but with a wide range of goals. In the face of 
globalisation, the importance of NGOs in DC has increased, because the complexity of DC requirements 
challenges governmental structures and resources. NGOs can better mobilise resources directly from 
people, are often well financed, have approved know-how and are flexible in adapting to local conditions. 
They are therefore welcome partners for government institution like SDC at the political and operational 
level. NGOs, however, are not without critics, and have been accused of a lack of transparency, being 
primarily concerned about their survival or limited in their operational effectiveness by their ideals. [30, 
34].  
Major NGOs in Switzerland were actively involved in designing the contents of the WHO guidelines for 
DDs. When we made preliminary inquiries during development of the questionnaire, the national offices 
of some of these organisations (CARITAS, HEKS; Rotes Kreuz) confirmed that their policy for DDs had 
changed and that they were strictly observing the guidelines’ recommendations. But this provides no 
guarantee that their regional organisations or other smaller PVOs and individuals handle DDs in an 
equally rigorous manner. One important NGO in DD processes in 2001 was Medi Swiss (today Inresa 
Pharma), which was (and is) the only not-for-profit wholesaler in Switzerland providing drugs at cost 
price to relief organisations [35]. 
All Swiss NGOs and PVOs that collected, sorted out and shipped unused drugs in a large amount halted 
this activity after the revision of the WHO guidelines for DDs in 1999 and under the influence of NGOs 
engaged in development policy [4, 36]. In the early 2000s, the organised collection of unused drugs 
in pharmacies came to an end.  
Private-for-profit sector: Today, public resources in DC are limited and involvement of the private sector 
is needed. The challenge of this strategy lies in conflicts of interest. Forms of collaboration are PPPs, 
social investments, corporate social responsibilities and multistakeholder initiatives that incorporate the 
private not-for-profit sector. The experiences of these rather young strategies are not yet well documented 
and the potential for sustainable development through these approaches needs to be assessed. Potential 
problems include: dependency on industry and the market, withdrawal of public responsibility and the 
establishment of “vertical” programmes [37-39].  
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One major actor in DD processes, the pharmaceutical companies, are involved in many DC contexts, 
especially in the field of health optimisation and poverty reduction. Their priorities in research and 
development, issues of patent law and the above-mentioned involvement in PPPs (which represent three-
quarters of all projects), are viewed critically [40-42]. Company representatives have stated that the 
motives for their engagement in DC have been to promote acceptability and reputation. A positive effect 
on risk management was assumed: anticipation of future regulations, a good image vis-à-vis customers 
and attractiveness for personnel [41].  
The supply-driven Swiss pharmaceutical sector produces an oversupply of drugs. As a result, some 
stakeholders in the private-for-profit sector, such as pharmaceutical companies, wholesalers and 
community pharmacies, might feel obliged to engage in charity and philanthropy and to fill drug supply 
gaps in the form of DDs [3, 41]. Swiss pharmaceutical companies still pursue all DD strategies: direct in-
kind DDs, single-source DDs and DDs as parts of programmes [10, 43-47]. 
Community pharmacies are the other important players in DD processes in the private-for-profit sector. A 
service of these pharmacies is the cost-free disposal of unused drugs. A study from 1996 showed that the 
market value of the disposed drugs was about CHF 200 million per year; more than one-third of the drug 
boxes were unopened and another third had not expired [48]. For community pharmacies, it was often not 
understandable that after 2000 NGOs no longer collected these unused drugs for reuse. Such pharmacies 
often continue to pass on unused drugs, if individuals or organisations ask for them. In such case, the 
pharmacists are presumably unaware of the Basel Convention, signed by the Swiss government, which 
prohibits the export of unused drugs to any country other than OECD states [49].  
Methods 
The same questionnaire developed for analysing the views of Tanzanian stakeholders on DD processes in 
2000 was used in a German and a French version [50]. The aim was to gather the Swiss data 
simultaneously with the data from Tanzania. The questionnaire contained 34 numerical questions (Q) for 
basic information followed by 13 open questions to further develop the numbered questions. 
Additionally, it contained a set of 14 open questions to gather perceptions and opinions. The 
questionnaire was validated with a pilot questionnaire to check form and content. Only minor changes 
were necessary after the pilot study.  
Address lists as complete and updated as possible were collected for all groups that might be involved in 
DDs in every sector (public, religious, private non-profit and private for-profit) and from the entire 
country. If an address list exceeded 50 addresses, a random sampling was made. 
In May 2001, 1115 questionnaires in German and French were sent out with cover letters and prepaid 
envelopes for returning questionnaires. Italian-speaking stakeholders received both questionnaires, 
finances not being available to develop a questionnaire in Italian. Two months later, a reminder was sent 
out to non-respondents. Data gathering was completed by the end of August 2001. 
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The questionnaire was designed and processed with the software TELEform® Standard Version 7.0 from 
Cardiff Inc. Data quality assurance was done by a double control of the entire dataset. The data were 
transferred to a Microsoft® Access database and analysis was performed with Microsoft® Excel.  
The discussion of the results follows the same framework for analysis developed for the Tanzanian 
questionnaire [18]. Qualitative data from the open-ended questions were analysed using content analysis. 
In this study, the deductive text analysis was based on the concepts of Mayring [51, 52]. Key words used 
in this analysis were derived from important categories of the DD system as listed in Table 2 and from 
most-cited terms.  
Results  
Respondent rates 
Of the 1115 postal questionnaires sent out countrywide, 359 were returned (32%) and a total of 279 
(25%) were eligible for analysis. Of these, 196 questionnaires were in German and 83 in French. Of the 
not analysable questionnaires, 2 were duplicates, 14 addresses were no longer valid and 64 respondents 
returned the questionnaires empty with the comment that they were not involved in the distribution of in-
kind DDs.  
The response rate to the various questions gave a balanced picture. Out of 31 questions, three-quarters 
had a “no answer rate” of 5% or less. Only open questions (Q5,6; see Table 3) had a “no answer rate” of 
40% or more .Questions on the value of DDs (Q15) and on the essential drug policy of the recipient’s 
country (Q25,26) resulted in more than 50% “I don’t know” answers. It was striking that NGOs had only 
30% no knowledge about the value of DDs. Questions on the labelling of DDs (Q28), quality certificates 
of DDs (Q29) and the information policy (Q22) had a rate of more than 20% “I don’t know” answers. The 
answers were internally consistent. A good example are the answers on WHO guidelines for DDs (Q11-
13). 
Analysis of respondents 
Tables 3 and 4 provide a summary of the characteristics of the respondents for each sector. Of all 
respondents, 39% belonged to the NGO and 37% to the private-for-profit sector. One-third of all 
respondents were from pharmacies (76 community pharmacies and 21 hospital pharmacies).  
Half of all respondents were involved in DDs (Q3), thereof 60% in the religious and private-for-profit 
sector, 43% in NGOs and PVOs and 26% in the public sector. Of all respondents, 45% reported that drug 
supply was the main activity of their organisation (Q2): 90% in the private-for-profit sector, 40% in the 
public sector (pharmacies and pharmaceutical companies) and none in the religious sector. Earmarked 
donations in cash were given by only 14% (Q4). Sectors with a defined mandate in DC had higher rates 
for cash earmarked for DDs: 42% in the religious sector and 21% in NGOs. 
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The perception of DDs for all respondents was assessed with two open questions. Multiple answers were 
possible (Table 5). Of all respondents, 60% answered Q5: “In which situation do you consider DDs 
as useful?” Of all answers, 20% focused on DDs given either in emergency situations or in DC. 
The usefulness for DC was linked to clearly defined need or structured DD processes. Economic 
aspects (15%) and the guarantee of the availability of drugs through DDs (9%) were other 
important factors.  
In Q6 “There are reasons for and against supporting the drug supply system through in-kind 
DDs. Suggest some of them”, 25% respondents perceived economic aspects and a support of 
poor people as the most important features for the usefulness of DDs. A positive impact of 
donations of unused drugs was identified by 11% of donors. In 2001, this issue was being 
debated among pharmacies in Switzerland.  
The most frequently mentioned negative aspects of DDs (37%) were issues which burden the 
health care system of a recipient country: DDs do not respect local circumstances, hamper the 
building up of local competence, often do not meet local needs and boost corrupt practices. Quality 
aspects were not at the top of the list (7% of answers).  
DD System 
Below, we focus on the views and practices of the donors from different sectors. Only in the private-for-
profit sector did some differences emerge, between community pharmacies and pharmaceutical 
companies. Within all other sectors, the results were balanced.  
Structure and resources 
Characteristics of donor organisations differed from those of all respondents (Tables 6 and 7): in the 
public and the private-for-profit sectors, only pharmacies and pharmaceutical companies were among 
donors (Q7).  Among the donors, most of the respondents (82%) reported that they were themselves in 
charge of DDs (Q8) 
Religious organisations (25%) and NGOs (29%) purchased most of their donated drugs from not-for-
profit wholesalers, e.g. Action Medeor, IDA, Echo (Q10). The other important sources were 
pharmaceutical companies, NGOs and pharmacies. The public pharmacies took their DDs from unused 
drugs (23%) and from their own stock (26%). In the private-for-profit sector, community pharmacies 
procured 58% DDs from unused drugs and 18% from their own stock; for the pharmaceutical companies, 
the figures were 58% from their own stock and 37% from unused drugs.  
For 35% of the donors, the main purpose for donating drugs was primary health care, for 21% a request 
from individuals, for 10% secondary health care, for 9% refugee camps and war (Q9). For all sectors, 
these responses were at the top of the list, not always in the same order. It is noTable that for the religious 
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sector and for NGOs, half of the donated drugs were used for primary health care (50%/46%). Only 5% 
of all donors were involved in DD programmes and 6% in DDs earmarked for specific diseases.  
The WHO guidelines for DDs (Table 8) were known to 31% of donors, better in the public sector and in 
NGOs (Q11). In the private-for-profit sector, half of the pharmaceutical companies knew the WHO 
guidelines for DDs, but only one-quarter of the community pharmacies were aware of them. Copies of 
these guidelines were available in 15% of the donor organisations, again more in the public sector and in 
NGOs (Q12). These guidelines influenced DD practices of 26% donor organisation (Q13), and 20% had 
elaborated their own guidelines for DDs, especially in NGOs (25%) and in the private-for-profit-sector 
(21%) (Q14). Looking at the private-for-profit sector, 12% of community pharmacies and 58% of the 
pharmaceutical companies had elaborated their own guidelines for DDs. 
Only 35% of donors were able to estimate the monetary value (Q15) of their donated drugs (Table 9): 
NGOs were best able to estimate the monetary value, 62% giving a positive response, followed by the 
religious sector at 40%; the public and the private-for-profit sector at only 17% each. In the private-for-
profit sector, 8% of the community pharmacies and 33% of the pharmaceutical companies were able to 
estimate the value of DDs. Of all donors, 35% perceived payment by patients for DDs in recipients’ 
countries as justifiable (Q16), with this response higher than the average for religious organisations (47%) 
and NGOs (51%).  
Processes 
The highest proportion of DDs was donated to Africa (31%) and Eastern Europe (27%) (Table 10, Q17). 
An evaluation of DD processes (Q18) was carried out by 21% of the NGOs, 20% of the religious 
organisations and 27% of the public facilities, but by only 3% of the private-for-profit-sector (only 
pharmaceutical companies).  
Of all donors, an average of 41% had received in 2000 concrete order lists for DDs (Q19): 67% in 
religious organisations and 60% in NGOs, but only 27% in the public and 24% in the private-for-profit 
sector. An average of 24% of recipients donated without explicit orders from recipients (private-for-profit 
sector 53%) (Q20).  
Of all donors, 45% always or sometimes informed the recipients about the composition and date of 
shipment (Q22) prior to sending it out: 27% in the private-for-profit, 36% in the public (16% community 
pharmacies and 75% pharmaceutical companies), but 73% in the religious sector and 74% in NGOs. A 
similar picture emerged for invoice documents (Q23).  
Two-thirds of donors donated drugs registered in Switzerland (Q24). More than half of donors could not 
answer the questions on whether DDs were included in the WHO essential drug list or in the essential 
drug list of the recipients’ countries (Q25,26).  
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Quality of DDs 
Questions on quality criteria were based on the minimal requirements of the WHO guidelines for DDs 
[4], which demand a minimum shelf-life of one year or more (Table 11). This requirement was fulfilled 
by only 12% of donors (Q27). The shelf-life of six months up to one year was met by 25% donors; 3% 
donated expired drugs.  
Exploring further the quality requirements in the WHO guidelines for DDs, labelling of donated drugs in 
a local language or at least in a language understood by recipients was given as always or sometimes by 
66% of donors (Q28). A quality certificate was always or sometimes included in 15.5% of the shipments. 
The percentage of “I don’t know” answers to these questions was relatively high (14-23%, Q29). 
Main problems in the DD system 
Problems reported by interviewees in an exploratory study undertaken by us with recipients in Tanzania 
[18] were presented to donors with the request to rate the various statements (Table 12). Multiple answers 
were possible. The most frequently mentioned problem (23%) was the fact that the quantity of DDs was 
not sufficient for long-term treatment with DDs. This problem was followed by: non-relevance for local 
diseases, shipment and custom fees and no communication between donors and recipients, with an 
average of 10% responses each.  
Looking at the sectors, the perception of the importance of problems varied. For the religious sector and 
NGOs, shipment and custom fees were the most important problems in DD processes (27/28%). 
Organisations directly involved in DD processes rated concrete problems higher.  
Low ranked were: poor quality of donated drugs (average 6.5%), the importance of guidelines for DDs 
and other tools for a good donation practice (average 6%) and transparency in DD processes (average 
5%). 
Optimisation of the DD system 
To the open question “In your opinion, what are the most important actions needed to optimise drug 
donations?”, 62.5% of recipients answered, with 148 multiple answers (Figure 2). The proposals do not 
follow the core principles of the WHO guidelines for DDs (Table 1) The most important aspect given was 
participatory collaboration during the entire donation process. Other development-specific aspects were at 
the top and correlate with the view of respondents in Table 6. The quality of donated drugs and 
transparency again rated low. The use of guidelines or other tools for good donation practice were not an 
issue.  
Discussion and conclusion  
This descriptive study gathered for the first time stakeholders’ perceptions and knowledge about in-kind 
DDs donated from Switzerland. Their key views can be summarized as follows: a) sustainability is the 
major problem in DD processes, b) drug quantities are not sufficient for long-term treatment, c) the 
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request of the right drugs for recipients required a demand-driven DD process and d) optimisation of DD 
processes requires improved collaboration among donors and recipients.  
This study has strengths and limitations. One important consideration is that it was undertaken as a 
stakeholder analysis reflecting views for producing knowledge about the position and importance of 
stakeholders in DD processes [53]. The outcome of DD processes at the patient level was not assessed. 
Additionally, this approach can only focus on the system as a whole and cannot provide detailed aspects 
of its inner structure. It is possible to assess differences between sectors, but it is difficult to obtain very 
detailed insight into single DD processes and to draw distinctions between different strategies for 
donating drugs. Another limitation was the financial and time constraint of this study. Our studies were 
focused on DD processes for Tanzania. We did not have the personnel or funds to follow up at the same 
time non-respondents in Switzerland.  
Study sample: The entire range of DD strategies and DDs given from all sectors involved in DD 
processes (public, private-for-profit and private not-for-profit sectors) was covered. The target, based on a 
WHO study on experiences with the GDD [15], of one-third eligible questionnaires was not achieved 
despite sending out a reminder. We thus had a low respondent rate and a high percentage of non-eligible 
respondents, who sent us back the empty questionnaire with the explicit remark that they did “not donate 
drugs". This leads us to suggest that for non-donors, DDs may represent a rather marginal issue and the 
high proportion of 50% donors in this study does not reflect the real situation. 
Nevertheless, donors did fill in the questionnaire accurately, the “no answer rate” was low and the 
answers were concise. Only the open questions yielded a high no-answer rate and it was also difficult to 
assign the discursive responses to our keywords and characteristics (Table 2).  
Perception: Both the settings of DDs for emergency situations and DDs for DC had the same relevance in 
the eyes of stakeholders, both donors and non-donors. Thus the usefulness of in-kind DDs for DC was 
linked to clearly defined needs and to DDs in specific programmes. The most important positive features 
of DDs (economic support of the drug supply system and poverty reduction) or negative features of DDs 
(no respect of local circumstances and hampering the building of local competence) focused on their 
impact on the recipients' health care system and thus correlated with the strategy of the Swiss government 
and the major NGOs in Switzerland to support a change in political, social and economic structures in 
poor countries [28].  
Structure, process and quality: The absence of DD sustainability and non-relevance of donated drugs 
were perceived as major problems in DD processes, followed by a lack of communication between 
donors and recipients and high shipment and customs fees. In other studies, sustainability, coverage of 
local needs and communication have also been discussed as major problems for all DD strategies, and 
only a few specific DD programmes have been described as adequate [1, 5, 7, 12]. The suggestions for 
optimised DD processes were targeted at better collaboration between donors and recipients. This was the 
only case in which donor perceptions coincided closely with the core principles in the WHO guidelines 
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[4]. The quality of DDs and the implementation of DD guidelines were rarely mentioned as either 
problems in DD processes or as targets for optimisation. 
Looking at structural characteristics, the low knowledge about DD guidelines — an average of only one-
third of donors claimed such knowledge — is striking. This may explain why quality aspects, requested 
by the WHO GDDs (shelf-life, labelling, quality certificate) were a minor issue and why DD quality was 
in general of low importance in this study. Other structural and process characteristics revealed 
differences between the not-for-profit sector (religious and NGOs) and the for-profit sector, mainly 
community pharmacies. The not-for-profit sector had better knowledge about DD value, supported better 
the selling of DDs, had a higher quality of DDs, received more concrete lists of orders and procured DDs 
mainly from not-for-profit wholesalers and directly from pharmaceutical companies. A major problem for 
this group were shipment and custom fees. Payment of transport fees by the donor is also required in a 
paragraph of the WHO guidelines for DDs [4]. NGOs and religious organisations are more aware of the 
problems of recipients in the setting of poverty.  
In the for-profit sector, pharmacies procured more than 50% of their DDs from unused drugs. After 
NGOs and PVOs stopped collecting unused drugs, pharmacies were overwhelmed with unexpired and 
complete medication returned from patients [48]. Pharmacists did not understand that “good is not good 
enough” and took up arguments for reusing these drugs. However, pharmaceutical companies also 
donated an important proportion — 38% — of unused drugs. Thus, unused drugs demonstrated a 
comparatively high importance in this study. There is a discrepancy between, on the one hand, the 
recognition of sustainability as an important issue by all stakeholders and, on the other, the opportunistic 
procurement of unused drugs by the private-for-profit sector. DDs of unused drugs are completely supply-
driven donations. Disposed drugs are a problem in a donor country with a market-driven drug policy. It 
seems easier to donate these drugs than to solve the problems locally.. Donors do not recognise that these 
drugs could burden a recipient. Meanwhile campaigns for awareness and education have been launched in 
Switzerland through PsF and the Swiss society of community pharmacists [54, 55]. Unused drugs are 
obsolete. A study could follow up practices, views and knowledge of community pharmacists as well as 
representatives from industrial companies. 
We conclude: 
- In 2001, views of stakeholders and donors about strategies on DC and DD policy largely complied 
with the then current policies of the Swiss government and the core principles of the WHO DD 
guidelines “Maximum benefit to recipients”. However, donors in particular showed an important 
discrepancy between their views and their practices and ignored other core principles of the WHO DD 
guidelines such as quality requirements (e.g. sufficient shelf-life) and knowledge about the needs and 
requirements of recipient countries.  
- Characteristics of DD practices reported by respondents reflected a strongly supply-driven DD process 
with insufficient communication between donor and recipient. 
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- In-kind DDs have to be analysed sector-wise. Each sector has different responsibilities. 
Pharmaceutical companies are not well represented in this study, but today they have a major impact 
in DD processes. They should therefore be more fully integrated in future studies. 
- Because this study reflects the situation in 2001, directly after NGOs and PVOs stopped collecting 
unused drugs, a follow-up of this survey could demonstrate if the WHO guidelines are fully accepted 
today or if there is still a need for awareness-raising campaigns. 
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Figures and tables of the working paper: 
Figure 1: Drug Donation System (DD System) 
 
Figure 2: Optimisation of DD processes 
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Table 1: Interagency WHO guidelines for drug donations: principles and applications [4] 
Core principles 
Maximum benefit to the recipient 
Respect for the wishes and authority of the recipient 
No double standard in drug quality 
Effective communication between donor and recipient 
Practical application 
Selection of drugs 
Quality assurance and shelf-life 
Presentation, packing and labelling 
Information and management 
 
Table 2: Characteristics of the donors’ DD system 
  WHO Guide-
lines for DDs 
Questions in 
table: 
Environment 
National Drug 
Policy 
Guidelines for DDs, Essential Drug List (EDL) 2 8 
Resources and structures   
Organisations Characteristics of the organisations  3,4,6,7 
 Involvement in DD processes  4,7 
Staff competence  Accountability   7 
 Knowledge of GDD  10 
Document Quality criteria for DDs  8 
 Availability of WHO GDD  8 
 Organisation owned GDD   8 
Financial Aspects Value of DDs  9 
 Payment for DDs  9 
 DDs in cash earmarked for buying drugs  4,7 
 Shipment and custom fees 12 30 
Processes   
Selection of drugs Expressed need by recipient 1 10 
 DDs part of the EDL of the country or of the WHO 2 10 
Management Procurement of DDs  7 
Transparency Evaluation of DD processes  10 
Communication Information of recipients 10 10 
 Collaboration with partner organisations  10 
 Mailing of invoice documents 10 10 
Quality of the donated drug   
Quality Assurance Certificate schemes on the quality of DDs  4 11 
 Shelf-life 6 11 
 Unused drugs 5 7 
Presentation Labelling 7 11 
Perception of stakeholders   
Satisfaction of 
recipients 
Long-term treatment, relevance of DDs, shipment and custom 
fees, transparency in DD processes, communication between 
donor and recipient, quality of DDs 
 12 
Usefulness of 
DDs 
  5 
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Table 3: Identification of respondents (N=279) 
Question Sector Description of organisations involved 
Public Sector 
N 42 
Hospitals (Admin.)      7  
Hospital pharmacy    21 
Nursing homes      2 
Federal Office of Public Health (FOPH or BAG)   1 
Cantonal Health Department     3 
Cantonal pharmacy administration and agency 
for therapeutic products     6 
No description       1 
Religious Sector 
N 24 
Interdenominational      3 
Protestant churches       8 
Roman catholic    13 
NGOs 
N 109 
NGO (2 Pharmaciens sans Frontières)  45 
PVO     54 
Foundation      3 
Individuals      6 
No description    1 
1. Which category 
identifies your 
organisation best? 
Private-for-Profit Sector 
N 104 
Pharmaceutical companies   19 
Wholesalers      3 
Community pharmacies   76 
Private hospitals      5 
No description      1 
 
Table 4: Characteristics of respondents (N=279) 
Question Answer All 
Respondents 
Public 
Sector 
 
Religious 
Sector 
 
NGOs 
 
Private-for-
profit 
Sector 
 Single 
Answers 
N 279=100% N 42=100% N 24=100% N 109=100% N 104=100% 
Yes 45.2% 40.5% 0.0% 13.8% 90.4% 
No 54.5% 59.5% 100% 86.2% 8.6% 
2. Is drug supply the 
main activity of your 
organisation? 
No answer 0.4% 0.0% 0.0% 0.0% 0.0% 
Yes 48.7% 26. 2% 62.5% 43.1% 60.6% 
No 50.9% 73.8% 37.5% 56.9% 38.4% 
3. Is your organisation 
involved in DDs as gifts 
in-kind? 
No answer 0.4% 0.0% 0.0% 0.0% 1.0% 
Yes 13.6% 2.4% 41.7% 21.1% 3.8% 
No 66.3% 69.0% 54.2% 55.1% 79.8% 
I don’t know 1.8% 7.1% 0.0% 1.8% 0.0% 
4. Has your 
organisation ever 
donated earmarked 
money in cash to 
recipients for buying  
needed drugs? 
No answer 18.3% 21.4% 4.2% 22.0% 16.3% 
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Table 5: Respondents’ perception of DDs 
Question Answer 
Usefulness of DDs:  
From 168 (60%) respondents, a total of 327 (= 100%) answers were given 
Emergency situations such as disasters, refugee camps, epidemic outbreaks.  20.5% 
DDs for development cooperation, especially when need is clearly defined or for 
programmes (e.g. tuberculosis, HIV/AIDS, chronic diseases, malaria) 
19.9% 
Economic aspects, which included mainly fighting against poverty , but also 
better affordability in general; lack of funds 
15.3% 
Guarantee of drug availability 9.2% 
For their own project 5.8% 
When donors can control that DDs go directly from donors to recipients 4.3% 
5. In which situation do 
you consider DDs as 
useful? 
 
Other features included: usefulness in any situation, well-trained health staff, 
guarantee that DDs will arrive at the right place 
25% 
Positive features of DDs:  
From 156 (56%) respondents, a total of 202 (=100%) answers were given 
Economic aspects such as better affordability of drugs and reductions in costs 
for purchasing drugs  
15.3% 
Support of poor people   11.9% 
Positive aspects of unused drugs 10.9 
Availability of drugs  10.4% 
DDs perceived as positive in any situation 5.9% 
Other features included: supporting local needs, DDs for emergency situations, 
DDs are a human right, controlled DD processes, DDs free of charge, trust 
55.5% 
Negative features of DDs: 
From 156 (56%) respondents, a total 162 (=100%) answers were given 
DDs do not respect local circumstances and hamper the building of local 
competence 
14.2% 
DDs often do not meet local needs 13.6% 
DDs boost corrupt practices 9.9% 
Weak management of drug supply in recipients’ countries 8.0% 
Quality aspects, especially short shelf-life 7.4% 
DDs are not sustainable 6.2% 
6. There are reasons for 
and against supporting 
the drug supply system 
through in-kind DDs. 
Suggest some of them 
Other features included: dependency on donors, transport problems, no control 
in DD processes.   
40.7% 
 
In-Kind Drug Donations from Switzerland – Working Paper 
 
 127
Table 6: Identification of the donors’ organisations 
Question Sector Description of organisations involved 
Public Sector 
N 11=100% 
Hospital pharmacies     10  
No description       1 
Religious Sector 
N 15=100% 
Interdenominational      2 
Protestant churches      4 
Roman catholic       9 
NGOs 
N 47=100% 
NGOs      17 
PVOs     25 
Individuals      5 
7. Which category 
identifies your 
organisation best? 
Private for Profit Sector 
N 63=100% 
Pharmaceutical companies   12 
Pharmacies    50 
No description     1 
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Table 7: Characteristics of the donors’ organisations 
Question Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
 
NGOs 
 
Private 
for-profit 
Sector 
 Single Answers N 136=100% N 11=100% N 15=100% N 47=100% N 63=100% 
Yes 82.4% 81.8% 66.7% 85.1% 84.1% 
No 15.4% 18.2% 33.3% 12.8% 12.7% 
8. Are you the 
person in-charge of 
DDs in your 
organisation? 
No answer 2.2% 0.0% 0.0% 2.1% 3.2% 
Multiple Answers N 251=100% N 20 =100% N 28 =100% N 92 =100% N 111=100% 
For primary 
healthcare 
35.9% 25.0% 50.0% 45.7% 26.1% 
On request of 
individuals 
20.7% 25.0% 17.9% 12.0% 27.9% 
For secondary and 
tertiary healthcare 
9.6% 10.0% 10.7% 13.0% 6.3% 
For refugee camps 
and during wars 
8.8% 5.0% 3.6% 9.8% 9.9% 
For natural disasters 5.6% 5.0% 0.0% 5.4% 7.2% 
As earmarked in-kind 
DDs for specific 
diseases 
5.6% 5.0% 7.1% 6.5% 4.5% 
As partner of a 
programme 
4.8% 10.0% 7.1% 5.4% 2.7% 
For research activities 0.4% 0.0% 0.0% 0.0% 0.9% 
I don't know 4.0% 5.0% 0.0% 0.0% 8.1% 
9. For what 
purposes did you 
donate drugs? 
Other reasons 4.8% 10.0% 3.6% 2.2% 6.3% 
Multiple Answers N 268 
=100% 
N 31 =100% N 36 =100% N 105 
=100% 
N 96 =100% 
Returned sold items 
(unused drugs)  
27.6% 22.6% 13.9% 9.5% 54.2% 
From non-profit 
wholesalers  
16.0% 3.2% 25.0% 28.6% 3.1% 
From the 
manufacturer  
14.9% 22.6% 16.7% 17.1% 9.4% 
Saleable items from 
own stock  
13.8% 25.8% 2.8% 2.9% 26.0% 
From pharmacies  8.6% 3.2% 19.4% 11.4% 3.1% 
From NGOs such as 
Pharmaciens sans 
Frontieres 
7.8% 3.2% 16.7% 13.3% 0.0% 
From hospitals  4.1% 9.7% 2.8% 6.7% 0.0% 
As extra production 
for the donation  
1.5% 3.2% 0.0% 1.0% 2.1% 
I don't know 0.0% 0.0% 0.0% 0.0% 0.0% 
10. Where does 
your organisation 
procure the drugs, 
for donations?  
Other reasons  5.6% 6.5% 2.8% 9.5% 2.1% 
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Table 8: Policies of the donor’s organisations 
Question Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
 
NGOs 
 
Private 
for-profit 
Sector 
 Single Answers N 136=100% N 11=100% N 15=100% N 47=100% N 63=100% 
Yes 30.9% 36.4% 20.0% 36.2% 28.6% 
No 66.9% 54.5% 80.0% 61.7% 69.8% 
11. Are you familiar 
with the WHO 
Guidelines for DDs? 
No answer 2.2% 9.1% 0.0% 2.1% 1.6% 
Yes 15.4% 18.2% 6.7% 25.5% 9.5% 
No 76.5% 63.6% 73.3% 70.2% 84.1% 
I don’t know 5.1% 9.1% 20.0% 2.1% 3.2% 
12. Do you have a copy 
of the WHO Guidelines 
for Drug Donations? 
No answer 2.9% 9.1% 0.0% 2.1% 3.2% 
Yes 26.5% 27.3% 20.0% 31.9% 23.8% 
No 52.2% 36.4% 66.7% 53.2% 50.8% 
I don’t know 9.6% 0.0% 6.7% 6.4% 14.3% 
13. Did these guidelines 
influence practices with 
regard to drug 
donations in your 
organisation? No answer 11.8% 36.4% 6.7% 8.5% 11.1% 
Yes 19.9% 9.1% 6.7% 25.5% 20.6% 
No 72.1% 81.8% 80.0% 68.1% 71.4% 
I don’t know 5.9% 9.1% 6.7% 4.3% 6.3% 
14. Has your 
organisation its own 
guidelines for drug 
donations? 
No answer 2.2% 0.0% 6.7% 2.1% 1.6% 
 
Table 9: Economic aspects of the donor’s organisations 
Question Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
 
NGOs 
 
Private 
for-profit 
Sector 
 Single Answers N 136=100% N 11=100% N 15=100% N 47=100% N 63=100% 
Value known 35.3% 18.2% 40.0% 61.7% 17.5% 
I don’t know 58.8% 72.7% 60.0% 29.8% 77.8% 
15. What is the value of 
the DDs donated in 
2000? 
No answer 5.9% 9.1% 0.0% 8.5% 4.8% 
Yes 35.3% 0.0% 46.7% 51.1% 27.0% 
No 50.7% 63.6% 33.3% 38.3% 61.9% 
16. Do you think is it 
justifiable to sell 
donated drugs? 
No answer 14.0% 36.4% 20.0% 10.6% 11.1% 
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Tabelle 10: DD processes 
Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
 
NGOs Private 
for-profit 
Sector 
Question 
Multiple answers N203=100% N22=100% N22=100% N66=100% N93=100% 
Asia 12.3% 9.1% 9.1% 15.2% 11.8% 
Africa 30.5% 27.3% 45.5% 40.9% 20.4% 
Eastern Europe 27.1% 22.7% 22.7% 27.3% 29.0% 
South America 12.4% 13.6% 13.6% 12.1% 11.8% 
Other Regions 3.4% 4.5% 9.1% 0.0% 4.3% 
I don't know 9.9% 18.2% 0.0% 0.0% 17.2% 
17. To which region 
did your organisation 
send drug donations? 
No donations in 
2000 
4.4% 4.5% 0.0% 4.5% 5.4% 
 Single answers N 136=100% N 11=100% N 15=100% N 47=100% N 63=100% 
Yes 13.2% 27.3% 20.0% 21.3% 3.2% 
No 71.3% 63.6% 46.7% 63.8% 84.1% 
I don’t know 12.5% 0.0% 26.7% 12.8% 11.1% 
18. Has your 
organisation ever 
carried out an 
evaluation of your 
donation processes? No answer 2.9% 9.1% 6.6% 2.1% 1.6% 
Exclusively 22.1% 18.2% 33.3% 44.7% 3.2% 
Partly 47.8% 72.7% 66.7% 44.7% 41.3% 
Never 24.3% 0.0% 0.0% 8.5% 46.0% 
I don't know 5.1% 9.1% 0.0% 2.1% 7.9% 
19. Does your 
organisation base its 
drug donations on an 
order list provided by 
recipients? 
No answer 0.7% 0.0% 0.0% 0.0% 1.6% 
Yes 41.2% 27.3% 66.7% 59.6% 23.8% 
No 47.1% 45.5% 13.3% 29.8% 68.3% 
I don’t know 9.6% 18.2% 13.3% 8.5% 7.9% 
20. Were concrete 
order lists submitted 
to you in the year 
2000?  
No answer 2.2% 9.1% 6.7% 2.1% 0.0% 
Yes 38.2% 18.2% 20.0% 57.4% 31.7% 
No 47.1% 54.5% 66.7% 34.0% 50.8% 
I don’t know 11.8% 18.2% 0.0% 6.4% 17.5% 
21. Does your 
organisation 
cooperate with 
partner 
organisations? No answer 2.9% 9.1% 13.3% 2.1% 0.0% 
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Tabelle 10: DD processes (continued) 
Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
 
NGOs Private 
for-profit 
Sector 
Question 
Multiple answers N203=100% N22=100% N22=100% N66=100% N93=100% 
Always  44.9% 27.3% 53.3% 78.7% 20.6% 
Sometimes 8.8% 9.1% 20.0% 8.5% 6.3% 
Never  19.1% 18.2% 6.7% 8.5% 30.2% 
I don't know 24.3% 27.3% 20.0% 4.3% 39.7% 
22. Does your 
organisation inform 
the recipients 
beforehand about the 
composition and the 
date of shipment of 
the donations? 
No answer 2.9% 18.2% 0.0% 0.0% 3.2% 
Always  38.2% 27.3% 53.3% 61.7% 19.0% 
Sometimes 14.0% 36.4% 26.7% 12.8% 7.9% 
Never  33.8% 18.2% 0.0% 14.9% 58.7% 
I don't know 12.5% 18.2% 20.0% 6.4% 14.3% 
23. Does your 
organisation add 
invoice documents to 
the donated drugs?? 
No answer 1.5% 0.0% 0.0% 4.3% 0.0% 
Exclusively 66.2% 81.8% 66.7% 44.7% 79.4% 
Partly 21.3% 18.2% 20.0% 34.0% 12.7% 
No 2.2% 0.0% 0.0% 2.1% 3.2% 
I don't know 10.3% 0.0% 13.3% 19.1% 4.8% 
24. Does your 
organisation donated 
drugs that are 
registered in 
Switzerland?  
No answer 0.0% 0.0% 0.0% 0.0% 0.0% 
Exclusively 10.3% 9.1% 13.3% 14.9% 6.3% 
Partly 34.6% 54.5% 6.7% 34.0% 38.1% 
No 1.5% 0.0% 0.0% 2.1% 1.6% 
I don't know 50.7% 36.4% 73.3% 46.8% 50.8% 
25. Are the drugs 
donated included in 
the WHO Essential 
Drug List? 
No answer 2.9% 0.0% 6.7% 2.1% 3.2% 
Exclusively 5.1% 0.0% 0.0% 10.6% 3.2% 
Partly 25.0% 36.4% 13.3% 36.2% 17.5% 
No 2.2% 0.0% 0.0% 0.0% 4.8% 
I don't know 61.8% 63.6% 66.7% 48.9% 69.8% 
26. Does you 
organisation donate 
drugs that are on the 
essential drug lists of 
the recipient 
countries?  No answer 5.9% 0.0% 20.0% 4.3% 4.8% 
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Table 11: Quality of donated drugs 
 
Question Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
NGOs 
 
Private 
for-profit 
Sector 
 Single answers N 136=100% N 11=100% N 15=100% N 47=100% N 63=100% 
Min. 1 year a) 11.8% 9.1% 13.3% 23.4% 3.2% 
6 to 12 months 25.0% 9.1% 40.0% 23.4% 25.4% 
Up to 6 months 41.9% 72.7% 20.0% 31.9% 49.2% 
Expired 2.9% 9.1% 0.0% 2.1% 3.2% 
I don't know 14.0% 0.0% 26.7% 10.6% 15.9% 
27. How long is the 
average shelf-life of the 
drugs donated? 
No Answer 4.4% 0.0% 0.0% 8.5% 3.2% 
Always  25.7% 18.2% 46.7% 38.3% 12.7% 
Sometimes 40.4% 45.5% 20.0% 44.7% 41.3% 
Never  9.6% 9.1% 20.0% 4.3% 11.1% 
I don't know 22.8% 27.3% 13.3% 8.5% 34.9% 
28. Are the drug 
packaging text and 
package inserts written 
in a language that will 
be understood in the 
recipient country?  No answer 1.5% 0.0% 0.0% 4.3% 0.0% 
Always  3.7% 0.0% 6.7% 6.4% 1.6% 
Sometimes 11.8% 9.1% 13.3% 14.9% 9.5% 
Never  61.8% 63.6% 46.7% 53.2% 71.4% 
I don't know 20.6% 27.3% 33.3% 19.1% 17.5% 
29. Does your 
organisation add a 
quality certificate to the 
donated drugs? 
No answer 2.2% 0.0% 0.0% 6.4% 0.0% 
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Table 12: Main problems with DDs in donor organisations 
Question Answer All Donors 
 
Public 
Sector 
 
Religious 
Sector 
NGOs Private 
for-profit 
Sector 
 Multiple answers N 284 =100% N 22 =100% N 26 =100% N 95 =100% N141 =100% 
Quantities are not 
sufficient for the long-
term treatment of 
patients 
22.9% 27.3% 15.4% 22.1% 23.4% 
Not relevant for the 
diseases of the local 
population 
10.4% 18.2% 0.0% 1.1% 17.0% 
Shipment and customs 
fee 
10.4% 9.1% 26.9% 28.4% 2.8% 
No communication 
between donor and 
recipient 
10.4% 13.6% 11.5% 6.3% 12.1% 
Insufficient 
infrastructure 
7.5% 4.5% 11.5% 6.3% 7.8% 
Poor quality of the 
donated drug 
6.5% 4.5% 3.8% 2.1% 9.9% 
Guidelines for drug 
donations or other 
tools are not 
implemented 
5.7% 0.0% 11.5% 5.3% 5.7% 
Insufficient training 5.7% 4.5% 3.8% 7.4% 5.0% 
No transparency in 
the donation processes 
5.0% 9.1% 0.0% 2.1% 7.1% 
Others 10.4% 4.5% 15.4% 12.6% 4.3% 
30. What causes 
the main 
problems in the 
drug donation 
processes of your 
organisation? 
None 5.0% 4.5% 0.0% 6.3% 5.0% 
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9 General discussion and conclusion 
The aim of this research project was to gather knowledge about stakeholders’ views and practices with 
regard to in-kind drug donations (DDs) in Tanzania and to develop suggestions for optimised drug 
donation processes. DDs are an important issue in public health, whose purpose as a part of development 
cooperation (DC) is to fill the gaps in access to essential drugs in low-income countries. Informal 
reporting through news and letters regularly mention negative consequences of DDs, although the World 
Health Organisation (WHO) in cooperation with major international agencies active in humanitarian 
relief has issued revised guidelines for DDs [WHO, 1999]. However, peer-reviewed literature on the 
performance of DDs is scarce, especially on the impact of DDs on the drug supply system of a recipient 
country within the framework of DC. This project, therefore, set out to explore in depth a topic relevant to 
contemporary DC, and based on its key findings it has been possible to formulate practical solutions for 
the optimisation of DD processes in Tanzania. 
 
Key findings were that a) in Tanzania, DDs were highly accepted by recipients and stakeholders for 
overcoming drug supply gaps in the context of poverty, b) DDs often did not cover priority needs, c) 
clearly defined accountability, availability of data and better communication between donor and recipient 
could optimise DD processes, d) suggestions of recipients for optimisation of DD processes corresponded 
fully with the principles of the Tanzanian and the WHO guidelines for DDs and e) Swiss DD practices 
reflected a mainly supply-driven DD process.  
 
After presenting the strengths and limitations of this study, the discussion continues with the general 
objectives of the research undertaken and a) provides a characterisation of DD processes in Tanzania, b) 
explores the similarities and discrepancies in the views of Tanzanian recipients and Swiss donors, c) 
makes suggestions for optimised drug donation processes and d) discusses the implications for future 
research and makes recommendations for action. 
9.1 Strengths and limitations  
The project was carried out from 2000 to 2002 within the healthcare systems of Tanzania and 
Switzerland. Due to the lack of research in these areas, a stakeholder analysis and a participatory 
approach were used, which actively involved stakeholders in the design process of this research project. A 
strength of the stakeholder analysis is that it identifies views, knowledge and openness to change. It tends 
not to provide facts. Stakeholders in this context were recipients and donors from each sector involved in 
drug supply and DDs (public, religious, private-non-profit and private-for-profit), covering the entire 
country in each case, and from each level of decision-making. When employing the general term 
stakeholder, Tanzanian stakeholders are meant. Swiss stakeholders are defined as such. Both the 
participatory approach using stakeholders and the involvement of different sectors allowed an appropriate 
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analysis. The definition of an in-kind DD was comprehensively conceptualised according to the definition 
of DDs in the Tanzanian guidelines for DDs, which covers all DD strategies [MOH, 1995]. Thus, this 
approach made it possible to describe the entire DD process for the total range of donation strategies: in-
kind DDs given a) in the framework of a programme, b) as single donations from individuals or c) as 
corporate DDs from pharmaceutical companies. It was beyond the scope of this project to explore the 
extent to which the results obtained might be representative for other countries and for a different time 
frame. 
 
This approach focused on the system as a whole. It was possible to assess differences between sectors, but 
it was difficult to obtain very detailed insight into single DD processes or to distinguish unequivocally 
between different strategies for donating drugs. The outcome of DD processes at the patient level was not 
assessed.  
 
By using tools of qualitative research and the triangulation of methods, a more complete picture of the 
investigated problem was achieved. A stepwise strategy enabled the analysis at the different levels of the 
DD system: a) literature review and document analysis for description of the context, b) a postal, self-
administered, semi-quantitative questionnaire in Tanzania and in Switzerland for defining problems in 
DD processes, c) key informant interviews in which the interviewees could reflect on the results of the 
Tanzanian questionnaire survey within the context of public health issues d) a workshop for elaborating 
practical solutions for the optimisation of DD processes in Tanzania.  
 
Some limitations were encountered when applying these methodological approaches. In Tanzania, 
relevant documents and grey literature were scarce and little printed material was available. In the 
questionnaire survey, some respondents might have been biased because they were themselves recipients 
of DDs. The questionnaire was distributed to the heads of districts, dioceses and facilities who themselves 
selected the respondents, giving rise to an additional selection confounder. Third, the questionnaire was 
sent out in Tanzania either in Swahili or in English according to a specific selection procedure (see 
questionnaire survey in Tanzania [1]). Some respondents did not understand English, but nevertheless 
filled in the questionnaire. All the key informant interviews were conducted in Tanzania by the author 
herself, and while this provided consistent data collection, the results might be influenced by her 
experience and attitudes. 
In Switzerland the target, based on a WHO study on experiences with the guidelines for DDs [WHO, 
2000c], of one-third eligible questionnaires was not achieved despite sending out a reminder. This leads 
to the assumption that for non-donors (the majority among the non-returnees), DDs may represent a rather 
marginal issue. 
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9.2 Characterisation of DD processes in Tanzania 
A discussion about DDs is at the same time a discussion about the health and drug supply system of 
donor and recipient countries. The questionnaire survey in Tanzania [1] and the subsequent key informant 
interviews [2] showed that the performance of a health system has a major impact on the quality of DD 
processes. Accordingly, and in agreement with earlier published studies and reports, the DD system in 
Tanzania was influenced by major contextual factors: poverty, a resource-constrained economy, donor 
dependence as well as a weak infrastructure [Reich MR, ed., 1999]. The primary reasons for the 
acceptance of donated drugs were non-availability and non-affordability of drugs, the root cause of both 
being poverty [1]. Nevertheless, stakeholders — both local health workers and those at organisational and 
administrative levels in both the public and the private-for-profit sector — understood the ideological and 
practical constraints of poverty: it impacts on perception, may hinder a critical view of DDs, creates 
dependency and restricts free decision-making [2].  
 
The debate about whether or not to accept DDs was a marginal issue in this research project: the focus of 
the debate was on the strategy for donating drugs. For any DD strategy, the maximum benefit is only 
achieved by sustainably meeting local needs [2]. Recipients and non-recipients appreciated the support of 
DDs provided within the framework of DD programmes with a known public health effect. Tanzania 
benefits from many such programmes. DDs given from a surplus, as gifts from individuals or as single-
source DDs, were perceived as problematic. These DDs may ease temporary drug supply gaps. However, 
they raise an ethical conflict between individuals, who are not able to afford needed drugs, and the vision 
of the government. Corporate DDs can be helpful as short - or mid-term DDs, where they disburden the 
annual budget. 
Tanzanian context  
Tanzania has developed the instruments for an effective regulation of DD processes. This is important for 
supporting recipients at the end of the supply chain in voicing their specific needs and in refusing poor-
quality DDs, especially within the context of poverty. Stakeholders made a strong appeal to donors to 
respect the essential drug list (NEDLIT). Adherence to the NEDLIT could overcome one of the major 
problems encountered with DDs, i.e. that they are “not meeting local needs”. Indeed, the Tanzanian 
NEDLIT is very well elaborated. It corresponds to the prevalent causes of morbidity in the country, it 
contains drugs that are affordable, it stratifies drugs by facility level and it is adapted to the educational 
level of the health staff. Nevertheless, the mere existence of NEDLIT does not guarantee its application, 
and a failure to implement the “guidelines for DDs and other tools for a good donation practice” was 
revealed by this study as being the second most important problem in the Tanzanian DD process [2]. The 
claim was confirmed by the questionnaire survey, in which less than half the recipients knew either the 
Tanzanian or the WHO guidelines for DDs. Compliance either with the WHO and/or the Tanzanian GDD 
would support an optimal DD process. However, these tools need to be better implemented and enforced 
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by both recipients and donors. In the Tanzanian DD system, the GDD are in fact distributed to the public 
and to the religious sector. Furthermore, in the religious sector, this distribution was even connected with 
continuing education [2], but according to a WHO study, in 2003 this training was still not optimal 
[Banda M et al., 2006] . However, enforcement of the guidelines remains a global challenge. This 
problem of disregard or (apparent) ignorance of DD guidelines is not restricted to the Tanzanian DD 
system, as recently demonstrated by Hechmann [Hechmann R and Bunde-Birouste A, 2007] and Autier 
[Autier P et al., 2002] for Sri Lanka and Mozambique 
Resources and structures 
Dispensary staff were not sufficiently trained to handle drugs from abroad and were prone to accept poor-
quality in-kind DDs. The issue of human resource constraint ran like a red thread through the entire 
project. This is a general issue for healthcare systems in sub-Saharan Africa [WHO, 2006b] and is already 
being addressed in the objectives of the Health Sector Reform (HSR) in Tanzania [Wiedenmayer K and D 
Mtasiwa, 2000; Bürki O, 2001; Wiedenmayer K, 2004]. 
 
The quality of structures must be improved before problems of the DD process can be addressed 
[Mtasiwa D et al., 2003]. In the eyes of workshop participants, a lack of quantitative data was a major 
structural failure [3]. This problem was confirmed by the study, where many of those answering the 
questionnaire could not provide concrete answers on the value of or coverage by DDs [1,2]. Furthermore, 
only half of the recipients had a list of needed drugs, which hinders efficient communication with donors. 
Stakeholders assumed that data on needs were not collected because needs assessment had not been 
systematised [2]. The absence of data on drug needs and on the value of the supply through DDs hampers 
a discussion of alternatives to DDs. This lack was also perceived as a major drawback for decision 
making within the strategy of the HSR, such that recipients had no power to take action in the field of 
DDs [Ministry of Health, 1999a,b; Bürki O, 2001]. In particular, missing data at the local level in 
combination with inadequately trained staff impeded their ability to refuse unneeded DDs or DDs of 
questionable quality. A lack of data also posed problems for accountability, not only between donors and 
recipients but at the local level as well. Another reason for low accountability was that often there was no 
person in charge of DDs in the various organisations involved [1,2]. Perhaps this is a consequence of the 
decentralisation of DD processes.  
 
Knowledge of the value of DDs is prerequisite for judging the economic impact of DDs on drug supply, 
but arriving at reliable estimates of the value of DDs is far from straightforward. Only 27% of recipients 
were able to estimate the monetary value of DDs, and there was general agreement in the study that 
establishing the value of DDs given to Tanzania is difficult, except for programmes with a clearly defined 
budget. The stakeholders asked: How, does one estimate the monetary value of an in-kind DD when, for 
example, the drug is nearly expired, not well labelled or lacks a quality certificate? The pharmaceutical 
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quality of a DD should be optimal if it is to be compared with the wholesale price of its generic 
equivalent in the recipient country, as called for by the WHO guidelines [WHO, 1999]. The Tanzanian 
GDD do not address the issue of value [MOH, 1995]. When considering value, DD-related costs have to 
be acknowledged as well. The transaction costs, evoked by transport, shipment fees and taxes for customs 
clearance, and costs for disposal can be higher than the value of the donated drug.  
Process 
DDs in the framework of DC should be integrated into a country’s drug supply system and must be 
planned as sustainable support. This is a major task in Tanzania, given that an estimated average of 27% 
of the recipients’ drug supply was covered by DDs. There is no substantive reason to handle a DD and a 
purchased drug as different kinds of goods [2]. The management cycle of DDs has to follow the same 
quality standards as the management of purchased drugs. The key informant (KI) study [1,2] found that 
the procurement of donated drugs, mostly given to primary and secondary healthcare institutions, and in 
the framework of programmes lacks transparency. Transparency, however, is prerequisite for a stable 
supply, and its absence undermines the endeavours of recipients to optimise their drug supply system. 
According to stakeholders, transparency in the procurement of DDs is not only a problem between donors 
and recipients but also within the local drug supply system. Distribution failures, such as storage and 
transport problems, reflect problems reported in the literature. Finally, irrational use of drugs is a serious 
problem in Tanzania [Wiedenmayer K, 2004]. If unknown drugs are given, problems with rational drug 
use and, possibly, adverse drug reactions are anticipated.  
 
Crucial for an appropriate DD process is the communication between donors and recipients. Without 
appropriate communication, the supply of requested drugs cannot be improved, local needs are not met 
and transparency is not guaranteed. Communication is basic for a participatory collaboration of donors 
and recipients. According to stakeholders' experience, however, donors did not ask what is needed in 
advance and supported a supply-driven donation process. Stakeholders would prefer a pull approach, in 
which the recipient has a say in the content of DDs. Important barriers for adequate communication 
between recipients and donors include cultural differences and the recipients' self-perception that they 
lack power. 
Quality of DDs 
In the questionnaire survey [1], drug quality was perceived as a minor problem, which may reflect the 
pyramid of need and which reveals the daily challenge to the Tanzanian healthcare system to cope with 
economic constraints and the problems of drug supply sustainability. In contrast, KIs were worried about 
the poor quality of donated drugs [2]. DD quality should be adapted to the national quality assurance 
procedures, with more stringent control at customs, and the recent efforts of the government should be 
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supported. Theoretically, all drugs, including DDs, have to be submitted for registration. This is an 
official obligation, which in practice is difficult to obtain [MOH, 2000]. 
Inappropriate DDs create an extra workload in terms of sorting, storage and distribution. They cause costs 
for disposal and they can easily overstretch human resources. KIs discussed three major DD quality 
issues: unused drugs or leftovers, the labelling of DDs and the expiry date [2]. Unused drugs boost 
stockpiling and encourage pilfering and black market sales. Together with mislabelled DDs, they were 
perceived as another reason for irrational drug use. There was a feeling among many stakeholders that 
donors sometimes wanted to dispose of leftovers. The donation of unused drugs should definitively come 
to an end. The donation of expired drugs is simply illegal, not a matter — because of the risks — of 
conscience or ethics. Expiry dates are important, because weak drug supply systems burdened by storage, 
transport and climate problems are challenged to maintain the quality of DDs [Ette EI, 2004]. 
9.3 Similarities and discrepancies between the views of Tanzanian 
recipients and Swiss donors  
This research project confirmed that improved communication between donor and recipient is crucial if 
DD processes are to be optimised [Hogerzeil HV et al., 1997; Snell B, 2001; Autier P et al., 2002]. The 
results from the questionnaire survey in Switzerland [3] have given first insights into the donor system 
and its possible influence on DD processes. Finally, a comparison of the results from similar 
questionnaire surveys with recipients and donors makes it possible to identify similarities and 
discrepancies in their views and practices that may act as possible barriers to good communication and, 
thus, donation practice. 
Perception 
Swiss stakeholders (once again, both inside and outside the donation system) perceived economic aspects 
and the support of poor people as the most important features determining DD usefulness. In this case, 
Tanzanian and Swiss stakeholder views coincided. Nevertheless, as this project highlighted, many 
problems occur during the DD process that burden the recipient substantially. As revealed by the already 
mentioned Harvard study [Reich MR, ed., 1999], despite a willingness to improve human welfare by 
supporting poor people, cultural barriers and power differentials are important barriers in DC. Thus, 
somewhat in contrast to the recipient perspective, in the eyes of Swiss stakeholders, the most negative 
aspects of DDs comprise issues which burden the healthcare system of a recipient country: DDs do 
not respect local circumstances, hamper the building up of local competence, often do not meet local 
needs and boost corrupt practices. 
Both Swiss and Tanzanian stakeholders appraise the issue — “quantity is not enough for long-term 
treatment” — as the most important problem of all the DD processes. Thus both refer to the problem of 
sustainability of DD processes. In general, Swiss stakeholder agree with the Tanzanians that only DDs 
given within the framework of programmes are useful, because there, need is clearly defined. 
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Swiss context  
Switzerland has no specific law or regulation for handling DDs, which might explain why only 30% of 
Swiss donors knew the WHO guidelines for DDs. This result, however, coincided with that for 
Tanzanian, where recipients were only better informed about their own guidelines. Switzerland does not 
practice the essential drug concept. Nevertheless, both Tanzanian recipients and Swiss donors claimed 
that donated drugs should comply with the WHO or the recipients’ country essential drug list. Despite 
this apparent commitment, only 60% of donated or received DDs were totally or partly included in the 
WHO essential drug list.  
Resources and structure 
Comparable with the findings for Tanzanian recipients, two-thirds of Swiss donors were not able to 
estimate the value of DDs. This result probably reflects the high proportion of donors in the for-profit 
sector (community pharmacies and pharmaceutical companies), which donated unused drugs and were 
uninterested in their value. The Tanzanian result, on the other hand, was associated with a lack of data. 
Another structural problem was the burden of custom fees: In both countries this posed a major problem, 
especially for organisations from the not-for-profit sector. In Tanzania, these organisations simply cannot 
afford to pay customs fees. This issue, however, is dealt with clearly in the WHO guidelines for DDs, 
which state that either donors must bear costs or they should, at least, discuss the responsibility for such 
costs with recipients before making a donation.  
Process  
In the DD process, donors play the role of providers, and are thus directly involved in the selection and 
procurement of the donated drug. Apart from respecting the recipients’ essential drug list and import 
regulations, drugs should ideally only be donated in response to specific requests, but this is not always 
the protocol followed by Swiss donors and not always reality for Tanzanian recipients. In this context, 
both agree that better communication is essential. Without appropriate communication between donor and 
recipient, the supply of requested drugs cannot be improved, local needs are not met and transparency is 
not guaranteed. 
Quality 
Rating the main problems of DD processes, both the Swiss and the Tanzanian stakeholders placed quality 
low on their list. However, donated drugs did not comply with requested standards [WHO, 1999], even 
less so in Switzerland than in Tanzania.  
 
Because this study reflects the situation in 2001, directly after non-governmental organisations (NGOs) 
and private voluntary organisations (PVOs) stopped collecting unused drugs, the donation of unused 
drugs was a major issue. There is a discrepancy between, on the one hand, the recognition of 
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sustainability as an important issue by all Swiss stakeholders and, on the other, the lack of understanding 
by the private-for-profit sector that unused drugs should no longer be donated. DDs of unused drugs are 
completely supply-driven donations and in the eyes of Tanzanian stakeholders absolutely obsolete. 
Unused drugs are a problem in a donor country with a market-driven drug policy, and it has seemed easier 
to donate these drugs than to solve the problems locally. Donors have failed to recognise that these drugs 
can burden a recipient. Meanwhile, campaigns for awareness and education have been launched in 
Switzerland through Pharmaciens sans Frontières (PSF) and the Swiss Society of Community 
Pharmacists [Apotheker ohne Grenzen; Gehler Mariacher G, 2004].  
9.4 Suggestions for optimised drug donation processes 
Suggestions of Tanzanian stakeholders were a logical consequence of the main problems identified [1,2] 
and were consistent with the core principles of the WHO guidelines for DDs [WHO, 1999]: a) maximum 
benefit for the recipients (meeting local needs), b) respecting the wishes of the recipient (participatory 
approach), c) no double standard in quality (quality aspects) and d) effective communication between 
donor and recipient.  
To meet local needs, it is important to instantiate routine data collection. Modern communication 
technology helps to establish and maintain a continuous exchange of information and a participatory 
collaboration of donors and recipients. To ensure their better use, implementation of the existing national 
regulations and guidelines needs monitoring (Workshop [4]). Optimisation of the quality of donated drugs 
requires a more transparent donation process. Stakeholders’ views on barriers for optimising DD 
processes in Tanzania reflected targets of the Health Sector Reform (HSR) and issues raised by 
WHO Health Reports: insufficiently trained and poorly informed health workers as well as a lack of 
accountability and missing data [MOH, 1999; WHO, 2000b]. Results from the Swiss study [3] pinpoint a 
strong need for awareness raising among donors and improved dissemination of the guidelines. 
 
Stakeholders came up with some significant questions: 
a) Instead of DDs, why not donate money to support local activities and the HSR strategy? This would 
overcome the problem of treating DDs like gifts and the sometimes questionable motivation of donors. 
DDs in cash are also an expressed request of the Tanzanian GDD in order to support local manufacturers 
[MOH, 1995]. However, earmarked donations in cash were given to only 16% of the recipients. 
b) Why should patients not pay for DDs according to the customary financing schemes? With a revolving 
drug fund (RDF), based on such payment for drugs coming from DDs, the Christian sector had achieved 
first positive results, according to stakeholders of the religious sector. The RDF helps the Christian health 
facilities build up a sound basis for a self-reliant drug supply [Kuper M and EC Njau, 1998] . 
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9.5 Implications for further research 
This research project confirmed that a donated drug is not sustainable in the long-term and addresses 
symptoms rather than curing underlying problems in a healthcare system. Future research arising from the 
findings should therefore include appraisals of DDs within the framework of programmes, sustainable 
provision of needed drugs, the impact of guidelines for DDs and optimisation of communication between 
donors and recipients.  
DDs in the framework of programmes 
Donating drugs within the framework of programmes was perceived as the best DD strategy. Tanzania is 
involved in many DD programmes. A general question could be: are DD programmes evaluated and, if 
so, by what criteria? A meta-analysis of available reports and evaluations of programmes established in 
Tanzania could generate knowledge about benefits, drawbacks, differences and synergies between 
programmes. Such an analysis could also enable mutual learning from experiences. Possible criteria for 
such an analysis might be: the adoption of Tanzanian standards, such as the guidelines for DDs and 
NEDLIT; sustainability; accountability; collaboration between sectors and between donors and recipients; 
value of DDs; costs emerging at the local level. An issue, which is also important in the context of DD 
programmes, is whether the drug is integrated in basic healthcare or is given only within a strictly vertical 
programme. A further interesting question in this context is whether the donated drug is later integrated in 
the NEDLIT. DDs should be coherent with the national drug policy — only this way will access to 
essential drugs improve [Shretta R et al., 2001]. Furthermore, it would be interesting to compare the 
strategies of donating money for buying drugs versus DDs given within the framework of a programme 
(i.e. money versus programme)  
Sustainable provision of needed drugs  
This study project was carried out within the framework of the Dar es Salaam Urban Health Project 
(DUHP) and work being undertaken at the Swiss Tropical Institute. The purpose of the DUHP was to 
promote long-term improvement of health service delivery at district level [Wiedenmayer, 1998]. Thus, 
one of the DUHP objectives was to assure drug availability and rational drug use in government health 
facilities in Dar es Salaam, which, since April 1992, have been supplied with essential drugs financed by 
decreasing contributions from the Swiss government. Today, the Dar es Salaam drug supply is integrated 
in the government's drug supply system. A case study could describe this positive example of a DD 
process and analyse the transition from a totally DD-dependent supply to a sustainable drug supply 
system under local conditions in a low-income country.  
Guidelines for DDs 
Guidelines for DDs are the global standard for a good DD practice. They were perceived as important and 
helpful for a good DD process [1]. Differences in distribution, implementation and education are a local 
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issue. A comparative study could evaluate the application and impact of the guidelines among sectors and 
gather important information for the outstanding update of the Tanzanian guidelines for DDs [Muhume J, 
2007].  
As mentioned above, Swiss stakeholders had low awareness of guidelines for DDs and current studies 
pinpoint an ongoing lack of donor knowledge about good DD practice. A case study analysing a reform 
process, the implementation of guidelines and the effect of this intervention could raise awareness among 
donors.  
Communication between donors and recipients  
Transparency and collaboration are prerequisite for good DD practices, as is effective communication 
between donor and recipient [1,2,3,4]. Today, instruments of modern technology are globally widespread, 
and information technologies (IT) are generating major contextual changes. Technically, communication 
should no longer be a problem, but this is to sketch an ideal scenario, and many questions remain: how 
are modern technologies used between and among donors and recipients in the DD process, what are 
possible barriers to the application of this technology and how is communication optimised through IT? 
Investigating such questions could be based on operational research or action research for education 
development. 
Stakeholders research recommendations: 
Stakeholders proposed further research for better understanding of the impact of DDs in the context of 
drug supply, not only at the local level, but also in the context of DC [2]: 
- There needs to be independent research on DD quality.  
- More information is needed about the financial value of DDs and their transaction costs.  
- There was dissent among KIs about the role of the patient: further studies are needed to elaborate the 
attitude of patients towards DDs in order to improve rational drug use.  
- More and better statistics on drug requirements and on the pharmaceutical market in Tanzania are 
needed to enable a discussion about alternatives to donations 
Validation of these research findings and generating tools for monitoring: 
The questions to what extent is this research project applicable to other countries receiving DDs in the 
framework of DC, stimulate the proposal to elaborate a few relevant indicators (such as a core indicator 
package) out of this research project. These indicators could provide a simple tool for regularly 
monitoring DD systems and should be applicable to any DD process. The process of elaborating these 
indicators helps at the same time to validate this research project.  
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9.6 The way forward 
The following are practical solutions put forward for optimising DD processes in Tanzania [4]:  
To recipients:  
National Guidelines for DDs:  
- Adapt the Tanzanian guidelines for DDs (published in 1995) to current standards, integrate specific 
recommendations for DDs that are part of private-public partnerships and finalise the current revision.  
- Translate the guidelines for DDs into Swahili and add to these guidelines models for needs assessment  
Private-public collaboration: 
- Strengthen the collaboration and sharing of experiences between the public and the private sectors 
Coordination of DD processes 
- Establish an autonomous centralised body for coordinating DDs given to the Tanzanian healthcare 
system. This proposal of workshop participants has to be discussed carefully. In a resource constraint 
environment, the first recommendation is to use already existing projects and tools.  
Support of recently established actions through the Tanzania Food and Drugs Authority (TFDA): 
- DDs should undergo the same quality assurance at the entry points as imported drugs [SEAM, 2003]. 
- Continue a systematic and comprehensive collection of DD data as recently initiated by the TFDA.  
To donors: 
Participatory collaboration: 
- Conduct a preliminary analysis of healthcare system organisation in Tanzania and of existing storage 
and transport facilities and respect the national drug policy of Tanzania and the guidelines for DDs 
Sustainability: 
- Consider that DDs should be demand and not supply driven 
Respect of local reforms: 
Donate money to support local activities and the HSR strategy and as requested in the Tanzanian 
guidelines for DDs in order to support local manufacturers. 
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Je, Madawa kwa matibabu ya mgonjwa huyu yapo? 
Is there medicine for the treatment of this patient available? 
Ist für die Behandlung des Patienten Medizin vorhanden?. 
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Annex 1: Questionnaires  
Questionnaire - Drug Donations in Tanzania 
Dodoso – Madawa ya msaada Tanzania 
Fragebogen – Medikamentenspenden aus der Schweiz 
Questionnaire – Dons de médicaments en provenance de la Suisse 
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QUESTIONNAIRE
Drug Donations in Tanzania
INTRODUCTION
Aim of the questionnaire
Definitions
Comments on the handling of the questionnaire
1. Please use a blue or black ballpoint.
2. All entries must be clear and readable. Please use Capital Letters.
3. Please put the cross very exactly in the small box. This is necessary because tha data entry will be
computerised.
Right Wrong
 
1. In this study donated drugs are defined as drugs that pass the border of the recipient country as gifts in
kind.
2. Drugs are any chemical compound that is used in the prevention, diagnosis, treatment  or cure of
disease.
3. Excluded from the study are all medical supplies (e.g. needles, syringes, bandages) as well as consumer
goods (e.g. non medicated shampoos,  food supplements).
4. For reasons of space "organisation" is need in this questionnaire to cover firms, individuals and
institutions of all kinds, including religious ones.
SECTION A: BASIC INFORMATION
1 Which category identifies your organisation best?
Mark the category, which describes your organisation the best
Swiss Centre for
International Health
Gaby Gehler Mariacher
Pharmacist
Page 1
Questionnaire/ge2001
Your opinion is important
So that the results of this questionnaire study will be as complete and true-to-life as possible, I depend very
much on your support.
Thank you very much in advance for your collaboration.
Gaby Gehler Mariacher  (E-Mail: Gaby.Gehler@unibas.ch)
The aim of this survey is to collect as much information as possible about drug donations in Tanzania.
Public sector (e.g. Ministry of Health, hospital, dispensary)
Please specify
Religious organisations (e.g. mission hospital, Muslim organisation, diocese, Indian organisation)
Please specify
Please specify
Please specify
Non-governmental and non-profit sector (e.g. private voluntary organisation, nongovernmental organisation,
Privat for-profit sector (e.g. pharmaceutical company, private pharmacy)
individual)
ID
T Z
Please. do
not fill in - -
Nr.
Approval of the research clearance in Tanzania: Ref. No. RCA 2000/25
2709 159
2 Is drug supply a main activity of your organisation?
Yes No
If No:  What is the major function of your organisation?
3 Drug Donations
3.1   Is your organisaton involved in drug donations as gifts in-kind?
Yes No
3.2   Will your organisation be involved in the future in drug donations as gifts in-kind?
Yes No I don't know
3.4    Are you the person in charge of drug donations in your organisation?
Yes No
If  No:  Please note the address of the person in charge at the back page of the questionnaire
If Yes:  Please identify the function of your organisation in the field of in-kind drug donations
 3.3   Has your organisation ever received donations in cash earmarked for buying drugs in 
         addition to drugs in-kind?
Yes No I don't know
If Yes:  What are the  conditions for the earmarked donations in cash?
3.5    In which situations do you consider drug donations are useful?
3.6   There are reasons for and against supporting of the drug supply system through in-kind drug
  donations. Suggest some of them.
Please mark reasons "for" with (+) and reasons "against" with (-)
If you have answered No to question 3.1,
 
please stop here and go directly to the back page of the questionnaire
Page 2
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SECTOR B:    DRUG DONATIONS
4   Which category describes your donors best?
Mark as many as applicable
Public sector (e.g. government)
Please specify
Religious organisation (e.g. Muslim organisation, catholic mission, Indian organisation)
Please specify
Please specify
Please specify
Non-governmental and non-profit sector (e.g. Private volunatary organisation, non-governmental organisation,
Privat for-profit sector (e.g pharmaceutical companies, private pharmacies)
5   Origin of donated drugs
5.1    From which regions did your organisation receive drug donations in 2000?
Asia
Africa
Europe
North America
Other regions
Mark as many as applicable
5.2     From which regions did your organisation receive drug donations before 2000?
Asia Africa Europe North America Other regions
From which countries?
6  Donations from Switzerland
6.1   Did you receive donations from Switzerland in 2000?
Yes No I don't know
In the year 2000 we did not receive drug donations
If Yes: Who are your partners / donors in Switzerland?
Please identify the donors, if possible
I don't know
individual)
From which countries?
From which countries?
From which countries?
Mark as many as applicable
If you tick other regions: Please specify
5.3     Did  you receive drug donations from Tanzanian donors in 2000?
Yes No I don't know
From which countries?
Page 3
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2709 161
6.2   Did you receive donations from Switzerland before 2000?
Yes No I don't know
6.3   Are you in the future expecting drug donations from Switzerland?
Yes No I don't know
7   Needed Drugs
For primary health care
For secondary and tertiary health care
For natural disasters
For refugee camps and during wars
If Yes:  Please specify
As kit
For basic needs if required
As a partner of a programme  (e.g. for the elimination of Leprosy, TB, Trachoma)
As earmarked in-kind drug donations for specific diseases (e.g Diabetes, HIV)
For research activities
I don't know
Other reasons
If you mark other reasons: please specify
On request of individuals
Mark as many as applicable
0-10% 11-50% 51-90% 91-100%
8  What percentage of your drug supply was covered in 2000 by drug donations?
9  Characteristics of the drugs received
approx
.
US$ I don't know
 9.1   What is the value of the donations received in 2000?
Retail price in donor country
Wholesale price in donor country
Ex Factory Price
Price of a non-profit making wholesaler
World market price
7.1   For what purposes did you receive drug donations?
7.2   Do you have a list of needed drugs, which you give to the donors?
Yes No I don't know
9.2   If you know the value, please indicate on what basis this was calculated
I don't know
 9.3   Where did the donor procure the drugs donated to your organisation?
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SECTION C: QUALITY OF DRUG DONATIONS
11.3   Did these Guidelines influence practices with regard to drug donations in your organisation?
If  Yes:  How?
10  Does your organisation cooperate with partner organisations?
If Yes: Who are the partner organisation in the donors' countries?
If possible, please indicate name and address of the main partners
If possible, please indicate name and address of the main partners
If Yes: Who are the partner organisation in the recipients' countries?
Yes No I don't know
11 Guidelines for Drug Donations (WHO)
11.1   Are you familiar with the WHO Guidelines for Drug Donations ?
11.2   Do you have a copy of the WHO Guidelines for Drug Donations ?
Yes No
Yes No I don't know
Yes No I don't know
12 Tanzanian National Guidelines for Drug Donations
12.1   Are you familiar with the "Guidelines on Donations for Tanzania Mainland" of the MOH?
12.2   Do you have a copy of the "Guidelines on Donations for Tanzania Mainland" of the MOH?
13  Expressed Declaration of Needs
13.1  Did you receive in 2000 donations that you specifically asked for?
13.2  Did you receive in 2000 donations that you had not asked for?
14  Essential Drug List
Yes No
Yes No I don't know
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Exclusively Partly No I don't know
Exclusively Partly No I don't know
14.1  Are the drug received included in the  National Drug List of Tanzania?
14.2  Are the drug received included in the  WHO Essential Drug List?
Exclusively Partly No I don't know
Exclusively Partly No I don't know
2709 163
15  Quality Standard of your organisation for donated drugs
15.1  What are the quality criteria for donated drugs which are demanded by your organisation?
15.2  According to you, in what kind of situation is it justifiable to donate expired drugs?
15.3  How long is the average shelf-life of the drugs received?
Please mark the answer that describes the drugs received best
Minimum 1 year
6 to 12 months
Up to 6 months
Expired
I don't know
15.4  Are the donations labelled in a local language?
Always Sometimes Never I don't know
16  Shipment of Drug Donations
16.1  Does your organisation receive a quality certificate (e.g. from WHO) with the donated drugs?
16.2  Does  your organisation receive invoice documents with the donated drugs?
16.3  Who pays for the shipment of drug donations?
16.4  Who pays for the customs clearance of drug donations?
Page 6
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Please. do not fill in
15.5 What percentage of the drugs received did your organisation have to dispose of in 2000?
0-10% 11-50% 51-90% 91-100%
15.6 Does  your organisation  receive "unused" drugs (drugs returned by patients)?
Exclusively Partly No I don't know
15.7 What does your organisation do with unwanted, unusable drugs or with drugs of poor quality?
With unwanted drugs
With unusable drugs
With drugs of poor quality
Always Sometimes Never I don't know
Always Sometimes Never I don't know
2709164
16.5  Is your organisation informed beforehand about the composition and the date of shipment of the
   donations?
16.6  How does your organisation communicate with the donors (e.g. e-mail, fax)?
16.7  How would you rate the exchange of information with the donor?
SECTOR D: DRUG DONATION PROCESSES
The donation process means the whole path taken by donated drugs, from the donor to the recipient
and ultimately the patient.
17  What in your opinion are the main problems with drug donation processes?
18  Do you think that it is justifiable to sell donated drugs?
Please, give reasons for your statement
 20 Has your organisation ever carried out an evaluation of your donation processes?
If Yes: what in short were the results?
21 What, in your opinion, is the function of the pharmacists in donation processes?
Always Sometimes Never I don't know
Yes No
Yes No I don't know
Page 7
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19  Do patients have to pay for donated drugs in your facility?
Always Sometimes Never I don't know
2709 165
SECTOR E: YOUR COMMENTS
24  In your opinion, what are the most important actions needed to optimise drug donations?
25  Was anything not covered in this questionnaire which you feel is important?
26  Does your professional position give you the possibility of taking action?
22  What causes the main problems in the drug donation processes of your orgaisation?
Mark as many as applicable
Insufficient infrastructure (1)
Poor quality of the donations
Insufficient training
No transparency in the donation processes (e.g. how it works, who is in charge)
No communication between donor and recipient
Shipment and customs fees
Quantities are not sufficient for the long-term treatment of patients
Guidelines for Drug Donations or of other tools for a Good Donation Practice are not implemented
Not relevant for the diseases of the local population
None
Others
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
 Which is the most important? Nr.
If you marked others: Please specify
23  Has your organisation special criteria for deciding to treat a patient with donated drugs?
Yes No
If yes: what are the criteria?
27  What does the expression "double standard of drug donations" mean to you?
Page 8
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SECTION F:      PERSONAL DATA
The information on this page will remain confidential and be stored separately.
It is needed in case we need to ask further questions
First Name
Title
Family Name
Organisation, Institution, Company
Your professional position in your organisation
Phone Number Fax Number
e-mail
Date
. .
Your education / your diploma
Address
Do you know organisations, institutions, groups or individuals which are involved in drug donations and
to which this questionnaire could be distributed as well?
Thank you very much - Ahsante sana!
Name and address of the person in charge of drug donations in your organisation
Personal data
Questionnaire/ge2001
Please. do not fill in
2709 167
DODOSO
Madawa ya msaada Tanzania
UTANGULIZI
Dhamira ya dodoso hili
Maana ya maneno
Mikakati ya kujaza dodoso hili
1. Tafadhali tumia pen ya bluu au nyeusi.
2. Andika kwa herufi kubwa, maandishi yanayosomeka.
3. Tafadhali weka alama ya mkasi kwenye kiboksi kidogo. (Hii ni lazima kwani habari hizi zitawekwa
kwenye computa).
Km inavyotakiwa Makosa
 
1. Katika utafiti huu, msaada wa madawa ina maana ni zile dawa zinazoingia katika mipaka ya nchi kama
zawadi au msaada.
2. Dawa ni kemikali zinazotumika kwa ajili ya kuzuia na kutibu magonjwa mbali mbali.
3. Vifaa vya afya ambavyo havikuhusishwa katika utafiti huu ni kama:( sindano, mabomba ya sindano na
bandegi). Pamoja na vitu kama sabuni zisizokuwa za afya, na vyakula.
4. Kwa sababu ya nafasi au mpangilio unahitajika katika dodoso hili, kugusia mashirika,  watu binafsi na
vituo vya aina zote vikihusika pia vya kidini.
SEHEMU A:  HABARI KUHUSU SEHEMU HUSIKA
1 Shirika lako liko chini ya mfumo upi ?
weka alama sehemu inayohusika
Swiss Centre for
International Health
Gaby Gehler Mariacher
Pharmacist
Page 1
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Maoni yako ni muhimu san
Ili matokeo ya dodoso la utafiti huu yawe yamekamilika na ya kweli kama itakavyowezekana, nategemea
sana msaada na ushirikiano wako.
Natanguliza shukrani zangu.
Gaby Gehler Mariacher  (E-Mail: Gaby.Gehler@unibas.ch)
Dhumuni la utafiti huu ni kukusanya habari zinazohusu madawa ambayo yanatolewa kama msaada/zawadi
kwa Tanzania.
Sekta ya serikali (Kama Wizara ya Afya, Hospitali, Zahanati)
Elezea tafadhali
Shirika la dini (kama hospitali ya misheni, shirika la Kiislamu, Dayosisi)
Elezea tafadhali
Elezea tafadhali
Elezea tafadhali
Sekta isiyo ya kiserikali na ya kujitolea (Kama mashirika binafsi ya kujitolea, mashirika yasiyokuwa ya
Sekta ya binafsi ya kujipatia faida (Kama kiwanda cha madawa, Duka la dawa la binafsi)
serikali, mtu)
ID
T Z
usijaze
hapo chini - -
Nr.
Kibali cha utafiti huu kimetolewa Tanzania: Rejea namba RCA 2000/25
6567168
2 Je utoaji wa madawa ndiyo shughuli kuu ya shirika lenu?
Ndiyo Hapana
Kama jibu ni hapana, ni nini shughuli kubwa ya shirika lenu?
3 Dawa za msaada
3.1   Je shirika lako ninahusika na dawa zinazotolewa kama msaada?
Ndiyo Hapana
3.2   Je shirka lako litajihusisha na madawa yanayotolewa kama msaada hapo baadaye?
Ndiyo Hapana Sijui
3.4    Je wewe ni muhusika mkuu wa madawa ya msaada katika shirika lako?
Ndiyo Hapana
Kama jibu ni hapana: Tafadhali andika anuwani ya muhusika mkuu katika ukurasa wa nyuma wa dodoso
Kama jibu ni ndiyo tafadhali eleza shughuli za shirika lako katika madawa yanayotolewa kama msaada.
 3.3   Je shirika lako limepata kupokea msaada wa fedha kwa ajili ya kununulia madawa zaidi ya
   madawa ya msaada?
Ndiyo Hapana Sijui
Kama jibu ni ndiyo: Masharti ya fedha hizo zilizotolewa ni yapi?
3.5    Ni katika hali gani unaona kuwa madawa ya msaada ni muhimu?
3.6   Kuna sababu za kukubali au kupinga upatikanaji wa madawa kwa njia ya madawa yanayotolewa
  kama msaada. Eleza baadhi
Tafadhali weka alama (+) kwa sababu za "kukubali"na alama (- ) kwa sababu za kupinga.
Kama umejibu hapana kwa swali 3.1,
 tafadhal achia hapa na endelea na ukurasa wa mwisho wa dodoso
Page 2
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6567 169
SEHEMU B: DAWA ZA MSAADA
4   Je shirika lako liko chini ya mfumo gani?
Jaza kila ilivyo sahihi
Sekta ya jamii (k.m serikali)
Tafadhali eleza kwa ufasaha
Shirika la dini (k.m Kiislam,Katoliki)
Tafadhali eleza kwa ufasaha
Tafadhali eleza kwa ufasaha
Tafadhali eleza kwa ufasaha
Sekta isiyo ya serikali na isiyouza kwa faida (k.m Shirika la binafsi la kujitolea, Shirika lisilo la kiserikali,
Sekta ya binafsi inayouza kwa faida (k.m kampuni ya madawa, Maduka ya binafsi ya madawa)
5   Dawa za msaada zinakotoka
5.1    Je kutoka maeneo gani shirika lako lilipata dawa za msaada mnamo mwaka 2000?
Asia
Afrika
Ulaya
Amerika Kaskazini
Maeneo mengineyo
Taja kila ilipo sahihi
5.2     Je ni kutoka nchi gani shirika lako lilipata dawa za msaada kabla mwaka 2000?
Asia Afrika Ulaya Amerika Kaskazini Maeneo mengineyo
Kutoka nchi gani ?
6  Misaada kutoka Uswisi
6.1     Je umepokea msaada kutoka Uswisi mnamo mwaka 2000?
Katika mwaka 2000 hatukupata dawa za msaada
Kama jibu ni ndiyo: Ni nani patina/wafadhili wako kutoka Uswisi?
Tafadhali wataje hao wafadhili ikiwezekana
Sijui
Binafsi)
Kutoka nchi gani ?
Kutoka nchi gani ?
Kutoka nchi gani ?
Taja kila ilipo sahihi.
Kama umetaja maeneo mengineyo: Tafadhali eleza kwa ufasaha
5.3     Je umepokea madawa ya msaada kutoka kwa wafadhili wa Tanzania mnamo mwaka 2000?
Ndiyo Hapana Sijui
Kutoka nchi gani ?
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Hakuna
Ndiyo Hapana Sijui
6567170
6.2   Je ulipokea misaada kutoka Uswisi kabla ya mwaka 2000?
6.3   Je unategemea kupata msaada wa madawa kutoka Uswisi hapo baadaye?
7   Mahitaji ya madawa
Kwa ajili ya afya ya msingi
Afya ya daraja la pili na tatu
Kwa matatizo ya dharura
Kwenye kambi za wakimbizi na wakati wa vita
Tafadhali elezea
Kama "Kit"
Kwa mahitaji ya msingi
Kama mshiriki wa programu (kwa kutokomeza Ukoma, Kifua kikuu,ugonjwa wa vikope).
Kama dawa za msaada kwa magonjwa maaluum (Kisukari, Ukimwi)
Kwa shughuli za utafiti
Sijui
Kwa sababu nyinginezo
Kama umetaja sababu nyinginezo: Elezea
Kwa maombi ya watu waaluum
Taja kila ilipo sahihi
0-10% 11-50% 51-90% 91-100%
8  Katika mwaka 2000 ni asilimia ngapi ya madawa mliyokuwa nayo yalikuwa ni ya msaada?
9  Maelezo kuhusu madawa yaliyopokelewa
Kama. Dola za Kimarekani Sijui
 9.1   Je ulipokea madawa ya msaada ya gharama gani katika mwaka 2000?
Kulingana na bei ya reja reja katika nchi mfadhili
Bei ya jumla katika nchi mfadhili
Bei ya kiwandani
Bei ya wauzaji wa jumla bila faida
Bei ya soko la dunia
7.1   Ni kwa madhumuni gani mlipokea madawa ya msaada?
7.2   Je unayo orodha ya mahitaji ya madawa ambayo mnawapa wafadhili?
9.2   Kama unajua thamani yake tafadhali onyesha ni vipi yalifanyiwa mahesabu
Sijui
 9.3   Ni wapi mfadhili anakotoa madawa anayolisaidia shirika lako?
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Ndiyo Hapana Sijui
Ndiyo Hapana Sijui
Ndiyo Hapana Sijui
6567 171
SEHEMU C:  UBORA WA MADAWA YA MSAADA
11.3   Je muongozo huo unaathiri utendaji ukizingatia madawa ya msaada katika shirika lako?
Kama jibu ni ndiyo: Kwa vipi?
10  Je shirika lako linashirikiana na mashirika washiriki?
Kama jibu ni ndiyo ni yapi hayo mashirika washirika wenzio katika kutoa msaada?
Ikiwezekana tafadhali andika jina na anuwani ya hayo mashirika
Ikiwezekana tafadhali andika jina na anuwani ya hayo mashirika
Kama jibu ni ndiyo nii mashirika gani yanayoshiriki kusaidia wale wanaosaidiwa nchini?
11 Muongozo kuhusu madawa ya msaada (Shirika la Afya ulimwenguni "WHO")
11.1   Je una uzoefu wa muongozo wa shirika la Afya ulimwenguni (WHO) kuhusu madawa ya msaada?
11.2   Je unayo nakala kutoka shirika la Afya ulimwenguni (WHO) inayohusu muongozo wa madawa ya
msaada?
Ndiyo Hapana
12 Mungozo wa Taifa la Tanzania kwa madawa ya msaada
12.1   Je una uzoefu na muongozo wa dawa za msaada kwa Tanzania bara, ulioandaliwa na wizara ya Afya?
12.2   Je unayo nakala ya muongozo wa madawa ya msaada kwaTanzania bara ulioandaliwa na wizara ya
    Afya?
13  Maelezo kuhusu mahitaji
13.1  Je katika mwaka 2000 ulipokea madawa ya msaada kulingana na maombi yako?
13.2  Je mnamo mwaka 2000 ulipokea madawa ya msaada ambayo hukuomba?
14  Orodha ya madawa ya lazima
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14.1  Je dawa ulizopokea ni zile ambazo zipo katika orodha ya Taifa ya dawa za lazima?
14.2  Je dawa ulizopokea ni zile ambazo zipo katika orodha ya madawa ya lazima ya Shirika la Afya
   ulimwenguni?
Ndiyo Hapana Sijui
Ndiyo Hapana Sijui
Ndiyo Hapana Sijui
Ndiyo Hapana
Ndiyo Hapana Sijui
Yote Baadhi yake Hapana Sijui
Yote Baadhi yake Hapana Sijui
Zote Baadhi yake Hapana Sijui
Zote Baadhi yake Hapana Sijui
6567172
15  Kiwango cha ubora wa madawa ya msaada katika shirika lako
15.1  Ni sifa gani za ubora wa madawa ya msaada unazohitaji katika shirika lako?
15.2  Kwa maoni yako ni katika mazingira gani unaweza kukubali madawa ya msaada yaliyokwisha
   muda wake?
15.3  Ni wastani wa muda gani uliobakia wa kuweza kuyatumia madawa uliyoyapokea kabla ya
   kumalizika muda wake?
Tafadhali weka alama kwenye jibu ambalo ni sahihi zaidi
Chini ya mwaka mmoja
Miezi 6 - 12
Hadi miezi 6
Muda wake wa kutumika umemalizika
Sijui
15.4  Je dawa unazopata za msaada zimeandikwa kwa lugha inayoeleweka hapa nchini?
Wakati wote Mara chache Hapana Sijui
16  Usafirishaji wa dawa za msaada
16.1  Je shirika lako hupokea cheti cha ubora wa dawa za msaada (k.m. kutoka Shirika la Afya
   Ulimwenguni "WHO") kikiambatanishwa na hizo dawa
16.2  Je shirika lako linapokea stakabadhi ya malipo unapopokea dawa za msaada?
16.3  Ni nani anayelipia gharama ya usafirishaji wa madawa ya msaada?
16.4  Ni nani anayelipia ushuru wa forodha kwa dawa za msaada?
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15.5  Ni asilimia ngapi ya madawa uliyoyapokea ambayo shirika lako lililazimika kuyatupa mnamo 
         mwaka 2000?
0-10% 11-50% 51-90% 91-100%
15.6 Je shirika lako linapokea dawa ambazo hazikutumika (Dawa zilizorudishwa na wagonjwa)?
Mara nyingi Kiasi Hapana Sijui
15.7 Je shirika lako linafanyaje kuhusu dawa ambazo hazitakiwi, hazikutumika au dawa ambazo zina
  kiwango duni?
Kwa dawa zisizotakiwa
Kwa dawa zisizotumika
Kwa dawa zenye kiwango
duni
Mara zote Mara chache Hapana Sijui
Mara zote Mara chache Hapana Sijui
6567 173
16.5  Je shirika lako hupewa taarifa ya aina za dawa za msaada na tarehe ya kusafirishwa kabla?
16.6  Je shirika lako linawasiliana vipi na wafadhili (k.m kwa taarifa umeme, Fax)?
16.7  Je ni kwa kiwango gani mnawasiliana na wafadhili?
SEHEMU D: UTARATIBU WA MADAWA YA MSAADA
Utaratibu wa kutoa msaada ni hatua ambazo zinafuatwa kwa madawa ya msaada, kuanzia kwa
mfadhili, mpokeaji hadi kwa mgonjwa.
17  Je una maoni gani: Ni nini hasa tatizo katika utaratibu wa kutoa dawa za msaada?
18  Je unafikiri ni halali kuuza madawa yaliyotolewa kama msaada?
Tafadhali toa sababu kwa maoni yako
 20 Je shirika lako liliwahi kufanya tathmini ya utaratibu wa kutoa misaada?
Kama jibu ni ndiyo ni nini matokeo yake kwa kifupi?
21 Ni nini maoni yako, kuhusu kazi ya mfamasia katika utaratibu wa kutoa misaada?
Ndiyo Hapana
Ndiyo Hapana Sijui
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19  Je wagonjwa hutakiwa kulipia dawa zilizotolewa kama msaada katika kituo chako?
Mara zote Mara chache Hapana Sijui
Mara zote Mara chache Hapana Sijui
6567174
SEHEMU E: MAONI YAKO
24  Kwa maoni yako ni hatua gani zinazohitajika kuchukuliwa ili kuongeza ubora wa madawa ya
 msaada?
25  Je kuna lolote ambalo halikuongelewa katika dodoso hili ambalo unafikiri ni muhimu?
26  Je wadhifa wako unakuruhusu kuchukua hatua?
22  Ni nini kinachosababisha matatizo katika utaratibu wa madawa ya msaada katika shirika lako?
Chagua mengi kama itakavyowezekana
Muundo hafifu (1)
Kiwango duni
Mafunzo hafifu
Hakuna uwazi katika utaratibu wa kutoa misaada (k.m. unafanya kazi vipi, nani anasimamia)
Hakuna mawasiliano kati ya mfadhili na mfadhiliwa
Gharama ya usafirishaji na ushuru wa forodha
Kiwango cha madawa hakitoshelezi matibabu ya muda mrefu ya wagonjwa
Utaratibu wa madawa ya msaada au njia za utoaji mzuri wa misaada bado havijatekelezwa
Hazilingani na magonjwa yanayopatikana katika jamii ya hapa
Hakuna
Mengineyo
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
 Ni ipi ya muhimu zaidi? namba
Kama jibu ni mengineyo tafadhali fafanua
23  Je shirika lako lina utaratibu maalum wa kufuatwa kwa kumtibu mgonjwa kwa madawa ya
msaada?
Ndiyo Hapana
Kama jibu ni ndiyo ni utaratibu gani
27  Je unaelewaje kuhusu viwango hafifu vya dawa zinazotolewa kama msaada kulinganisha
 na nyinginezo
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SEHEMU F: TAARIFA BINAFSI
Taarifa katika ukurasa huu zitahifadhiwa kama siri na zitahitajika iwapo
tutahitaji kuuliza zaidi.
Jina la kwanza
Cheo
Jina la ukoo
Shirika, Kampuni, Kiwanda
Wadhifa wako katika shirika
Namba ya simu Namba ya Fax
Anuwani ya taarifa umeme
Tarehe
. .
Kiwango cha elimu/Shahada ya juu
Anwani
Je unafahamu shirika lolote, Kiwanda cha dawa au mtu binafsi wanaojishughulisha na madawa ya
msaada ambao unafikiri tunaweza kuwapa dodoso hili kujaza?
AHSANTE SANA
Jina na anuwani ya msimamizi wa madawa ya msaada katika shirika lako
Personal data
Questionnaire/ge2001
usijaze hapo chini
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FRAGEBOGEN
Medikamentenspenden aus
der Schweiz
EINLEITUNG
Ziel des Fragebogens
Definitionen
Hinweise zum Ausfüllen des Fragebogens
1. Bitte schreiben Sie mit einem blauen, schwarzen oder dunklen Kugelschreiber.
2. Alle Angaben müssen klar und leserlich sein. Benützen Sie bitte Blockschrift.
3. Bitte setzen Sie die Kreuze so exakt wie möglich in die Kästchen. Dies ist notwendig, da die 
Datenauswertung elektronisch erfolgt.
Richtig Falsch
 
1. In dieser Studie ist ein gespendetes Medikament als Medikament definiert, das in Form von Ware die 
Grenze des Empfängerlandes passiert.
2. Medikamente sind Zubereitungen von Arzneistoffen, die zur Vorbeugung, Heilung oder Erkennung von 
Erkrankungen dienen.
3. Nicht erfasst werden in dieser Studie medizinische Hilfsgüter (z.B. Spritzen, Nadeln, Verbandsstoffe) 
sowie Konsumartikel (z.B. Nahrungsergänzungsmittel, Shampoos).
4. Aus Platzgründen werden unter dem Begriff Organisation auch Firmen, kirchliche Einrichtungen, 
Institutionen und Einzelpersonen geführt.
TEIL A: ALLGEMEINE FRAGEN
1 Welche Zuordnung passt am besten zu Ihrer Organisation?
Bitte kreuzen Sie die Antwort an, die am ehesten auf Ihre Organisation zutrifft
Swiss Centre for
International Health
Gaby Gehler Mariacher
Apothekerin
Jede Meinung zählt
Damit die Resultate aus der Umfrage möglichst umfassend und exakt sind, bin ich auf Ihre Mitarbeit
angewiesen. Ich danke Ihnen im Voraus dafür.
Gaby Gehler Mariacher  (E-Mail: Gaby.Gehler@unibas.ch)
Mit dieser Umfrage soll soviel Information wie möglich über Medikamentenspenden aus der Schweiz
gesammelt werden. Details finden Sie in der beiliegenden Zusammenfassung des Studienkonzeptes.
Öffentlicher Sektor (z.B. Regierungsorganisation, Kant. Heilmittelkontrolle, öffentliches Spital)
Bitte beschreiben Sie näher
Kirchliche Einrichtung (z.B. Mission, Pfarrei)
Bitte beschreiben Sie näher
Bitte beschreiben Sie näher
Bitte beschreiben Sie näher
Nichtstaatlich nicht gewinnorientiert (z.B. Freiwilligenorganisation, Nichtregierungsorganisation, Einzelperson)
Privat gewinnorientiert (z.B. Offizinapotheke, Pharmaindustrie)
ID
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2 Ist  Ihre Organisation vor allem im Bereich der Medikamentenversorgung tätig?
Ja Nein
Wenn Nein:  Was ist die Haupttätigkeit Ihrer Organisation?
3 Medikamentenspenden
3.1    Ist Ihre Organisation an Medikamentenspenden in Form einer Sachspende beteiligt?
Ja Nein
3.2    Wird Ihre Organisation auch in Zukunft an Medikamentenspenden beteiligt sein?
Ja Nein Ich weiss es nicht
3.4    Sind Sie in Ihrer Organisation Entscheidungsträger im Bereich von Medikamentenspenden?
Ja Nein
Wenn  Nein:  Notieren Sie bitte die Adresse des Entscheidungsträgers auf der letzten Seite des Fragebogens.
Wenn Ja:  Bitte beschreiben Sie genau, in welcher Form Ihre Organisation an Medikamentenspenden
beteiligt ist.
 3.3   Spendet Ihre Organisation zusätzlich zweckgebundenes Geld, damit der Empfänger benötigte
   Medikamente selbst einkaufen kann?
Ja Nein Ich weiss es nicht
Wenn Ja:  An welche Bedingungen sind die Geldspenden geknüpft?
3.5    In welchen Situationen sind Ihrer Ansicht nach Medikamentenspenden nützlich?
3.6   Es gibt Gründe für oder gegen eine Unterstützung der Medikamentenversorgung durch Spenden. 
  Welche Gründe stehen für Sie im Vordergrund?
Bitte bewerten Sie die Gründe mit Plus- oder Minuszeichen
Falls Sie die Frage 3.1 mit Nein beantwortet haben,
 
gehen Sie bitte direkt zur letzten Seite des Fragebogens
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TEIL B: MEDIKAMENTENSPENDEN
4   Welche Zuordnung passt am besten zu den Empfängern der Spenden aus Ihrer Organisation?
Es sind mehrere Antworten möglich
Öffentlicher Sektor (z.B. Gesundheitsministerium, Spital, Dispensarien)
Bitte beschreiben Sie näher
Kirchliche Einrichtung (z.B. Missionsspital, Diözese)
Bitte beschreiben Sie näher
Bitte beschreiben Sie näher
Bitte beschreiben Sie näher
Nichtstaatlich nicht profitorientiert (z.B. Freiwilligenorganisation, Nichtregierungsorganisation, Einzelperson)
Privat profitorientiert (z.B. Private Apotheke, Pharmaindustrie)
5   Regionen, in die Ihre Organisation Medikamente spendet
5.1     In welche Regionen hat Ihre Organisation im Jahre 2000 Medikamente gespendet?
Asien
Afrika
Osteuropa
Mittel- und Südamerika
Andere Regionen
Es sind mehrere Antworten möglich
5.2     In welche Regionen hat Ihre Organisation vor dem Jahre 2000 Medikamente gespendet?
Asien Afrika Osteuropa Mittel- und Südamerika Andere Regionen
Falls Sie Andere Regionen ankreuzen: Bitte beschreiben Sie näher
Es sind mehrere Antworten möglich
In welche Länder?
In welche Länder?
In welche Länder?
In welche Länder?
6  Spenden nach Tansania
6.1   Hat Ihre Organisation im Jahre 2000 Medikamente nach Tansania gespendet?
Ja Nein Ich weiss es nicht
Im Jahre 2000 hat unsere Organisation keine Medikamente gespendet
Wenn Ja: Wer sind die Partnerorganisationen / Empfänger in Tansania?
Falls möglich, geben Sie bitte Namen und Adressen an
Ich weiss es nicht
In welche Länder?
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6.2   Hat Ihre Organisation vor dem Jahre 2000 Medikamente nach Tansania gespendet?
Ja Nein Ich weiss es nicht
6.3   Wird Ihre Organisation in Zukunft Medikamente nach Tansania spenden?
Ja Nein Ich weiss es nicht
7   Für welchen Zweck spendet Ihre Organisation Medikamente ?
Es sind mehrere Antworten möglich
Für die primäre Gesundheitsversorgung (Basisversorgung)
Für die sekundäre und tertiäre Gesundheitsversorgung
Bei Naturkatastrophen
Für Flüchtlingslager und Kriegssituationen
Wenn Ja:  Spezifizieren Sie bitte
Als Kit
Je nach Bedarf
Als Partner von gezielten Programmen (z.B. für die Elimination von Lepra, TB, Trachoma)
Als zweckgebundene Sachspenden für bestimmte Krankheiten (z.B. Diabetes, Aids)
Für  Forschungszwecke
Ich weiss es nicht
Andere
Falls Sie Andere ankreuzen: Bitte beschreiben Sie näher
Auf Anfrage von Einzelpersonen
8  Woher beschafft sich Ihre Organisation die Medikamente, die sie spendet?
Es sind mehrere Antworten möglich
Aus der Verkaufsware des eigenen Lagerbestandes
Aus einer Extraproduktion für die Spende
Aus Retouren bereits verkaufter Ware (ungenutzte Medikamente)
Andere
Falls Sie Andere ankreuzen: Bitte beschreiben Sie näher
Ich weiss es nicht
Beim Hersteller
Gekauft
Gratis erhalten
Von Nonprofit-Grossisten
Gekauft
Gratis erhalten
Von Apotheken
Gekauft
Gratis erhalten
Von Spitälern
Gekauft
Gratis erhalten
Bei Nichtregierungsorganisationen (z.B. Pharmaciens sans Frontières)
Gekauft
Gratis erhalten
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9  Arbeitet Ihre Organisation im Spendenbereich mit Partnerorganisationen zusammen?
Ja Nein Ich weiss es nicht
10  Wert der Spenden
ca. CHF
 10.2   Auf welcher Kostenbasis berechnen Sie den Wert Ihrer Spenden?
Ich weiss es nicht
 10.1   Wie hoch war der Wert der Medikamentenspenden im Jahre 2000?
Es sind mehrere Antworten möglich
Verkaufspreis im Spenderland
Grossistenpreis im Spenderland
Ex Factory Preis
Preis eines Nonprofit Grossisten
Ich weiss es nicht
TEIL C: QUALITÄT VON MEDIKAMENTENSPENDEN
11  Leitlinien für Medikamentenspenden (WHO)
11.1   Kennen Sie die WHO Leitlinien für Medikamentenspenden?
11.2   Sind Sie im Besitz dieser Leitlinien?
Ja Nein Ich weiss es nicht
Ja Nein
11.3   Haben diese Leitlinien Ihre Spendentätigkeit beeinflusst?
Ja Nein Ich weiss es nicht
Wenn Ja:  Wie?
Wenn Ja: Wer sind Ihre Partnerorganisationen im Spenderland?
Falls möglich, geben Sie bitte Namen und Adressen der wichtigsten Partner an
12  Hat Ihre Organisation eigene Leitlinien für Medikamentenspenden?
Ja Nein Ich weiss es nicht
Wenn Ja:  Bitte senden Sie, falls möglich, ein Exemplar mit diesem Fragebogen mit.
13  Bedarf des Empfängers
13.1   Stellt Ihre Organisation Medikamentenspenden aufgrund einer Bestell-Liste des
          Empfängers zusammen?
13.2   Lagen im Jahre 2000 konkrete Bestell-Listen vor?
Ja Nein Ich weiss es nicht
Falls möglich, geben Sie bitte Namen und Adressen der wichtigsten Partner an
Zum Weltmarktpreis
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Ausschliesslich Teilweise Nie Ich weiss es nicht
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14  Registrierung der Medikamente
14.1  Spendet Ihre Organisation Medikamente, die in der Schweiz registriert sind?
14.2  Spendet Ihre Organisation Medikamente, die in der Liste der essentiellen Medikamente der
   WHO aufgeführt sind?
14.3  Spendet Ihre Organisation Medikamente, die in der Liste der essentiellen Medikamente des
   Empfängerlandes enthalten sind?
15  Qualitätsanforderungen Ihrer Organisation an gespendete Medikamente
15.1  Auf welche Qualitätskriterien achtet Ihre Organisation beim Spenden von Medikamenten?
15.2  In welcher Situation ist es Ihrer Ansicht nach gerechtfertigt, verfallene Medikamente zu
         spenden?
15.3  Wie lange sind die von Ihrer Organisation gespendeten Medikamente haltbar?
Es ist nur eine Antwort möglich
Mehr als 1 Jahr
Mindestens 1 Jahr
Mindestens 6 Monate
Verfallen
Ich weiss es nicht
15.4  Sind die Medikamentenpackung  und die Packungsbeilage Ihrer Spenden in einer Sprache
   beschriftet, die im Empfängerland verstanden wird?
Immer Manchmal Nie Ich weiss es nicht
16  Versand der Medikamente
16.1  Fügt Ihre Organisation der Medikamentenspende ein Qualitätszertifikat (z.B. WHO) bei?
16.2  Fügt Ihre Organisation der Spende einen Lieferschein bei?
Immer Bei Bedarf Nie Ich weiss es nicht
Immer Manchmal Nie Ich weiss es nicht
16.3  Wie werden die Versandkosten zwischen Ihrer Organisation und den Empfängern aufgeteilt?
16.4  Wie werden die Zollkosten zwischen Ihrer Organisation und den Empfängern aufgeteilt?
Ausschliesslich Teilweise Nie Ich weiss es nicht
Ausschliesslich Teilweise Nie Ich weiss es nicht
Ausschliesslich Teilweise Nie Ich weiss es nicht
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16.5  Werden die Empfänger über die Zusammensetzung und das Versanddatum der Spende im
   Voraus informiert?
16.6  In welcher Form kommuniziert Ihre Organisation  mit den Empfängern der Spenden (z.B.
   E-Mail, Fax)?
16.7  Wie stufen Sie den Informationsaustausch mit den Empfängern ein?
TEIL D: SPENDENPROZESSE
Als Spendenprozess wird der ganze Weg, den die Spenden vom Spender bis hin zum Empfänger und
zum Patienten durchlaufen, definiert.
17  Was sind Ihrer Meinung nach heute die Hauptprobleme in Spendenprozessen?
18  Ist Ihrer Meinung nach der Verkauf von gespendeten Medikamenten durch die
 Empfängerorganisationen gerechtfertigt?
Ja Nein
Bitte begründen Sie Ihre Aussage
Immer Manchmal Nie Ich weiss es nicht
 19 Wurde von den Spendentätigkeiten Ihrer Organisation je eine Evaluation durchgeführt?
Wenn Ja: Bitte beschreiben Sie kurz die Resultate
Ja Nein Ich weiss es nicht
20 Welche Funktion haben Ihrer Meinung nach Apothekerinnen und Apotheker in
Spendenprozessen?
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TEIL E: IHR KOMMENTAR
22  Wie kann man Ihrer Meinung nach  Spendenprozesse verbessern?
23  Wurde ein wichtiges Thema in diesem Fragebogen nicht behandelt?
24  Welche Möglichkeit haben Sie in Ihrer Position, um etwas zur Verbesserung der
      Qualität von Medikamentenspenden beizutragen?
21  Was sind die wichtigsten Probleme in den Spendenprozessen Ihrer Organisation?
Es sind mehrere Antworten möglich
Fehlende Infrastruktur (1)
Ungenügende Qualität der Spenden
Mangelnde Ausbildung der Mitarbeiter in Spendenprozessen
Mangelnde Transparenz in Spendenprozessen (z.B. wer ist verantwortlich, wie ist das Vorgehen, etc.)
Mangelnde Kommunikation zwischen Spender und Empfänger
Zoll- und Versandkosten
Nicht adäquate Mengen an Medikamenten für eine längerfristige Versorgung der Patienten
Einführung von Leitlinien oder anderen Qualitätsstandards
Medikamente nicht relevant für die Krankheiten der Bevölkerung
Keine
Andere
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
 Welches ist das wichtigste Problem? Nr.
Falls Sie Andere ankreuzen: Bitte beschreiben Sie näher
25  Was verstehen Sie unter dem Begriff "doppelter Standard von Medikamentenspenden"?
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TEIL F: PERSÖNLICHE ANGABEN
Die Angaben auf dieser Seite werden vertraulich behandelt und separat aufbewahrt
Sie dienen für allfällige Rückfragen
Vorname
Anrede, Titel
Kennen Sie Organisationen, Institutionen, Personen oder Gruppen, die sich auch mit
Medikamentenspenden beschäftigen und denen dieser Fragebogen ebenfalls gesendet werden kann?
Name
Organisation, Institution, Firma
Ihre Position in Ihrer Organisation
Telefon Nummer Fax Nummer
E-Mail
Datum
. .
Tag Monat Jahr
Ihre Ausbildung / Ihr Diplom
Adresse
Herzlichen Dank für Ihre Mitarbeit
Name und Adresse des Entscheidungsträgers in Ihrer Organisation
Pers. Angaben
Umfrage/ge 2001
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QUESTIONNAIRE
Dons de médicaments en
provenance de la Suisse
INTRODUCTION
But du questionnaire
Définitions
Instructions pour remplir le questionnaire
1. Merci d'écrire avec un stylo à bille bleu, noir ou foncé.
2. Toutes les réponses doivent être claires et lisibles. Merci d'utiliser les caractères d'imprimerie.
3. Merci de cocher les cases d'une manière aussi exacte que possible, car le questionnaire sera scanné
afin de pouvoir l'analyser.
Juste Faux
 
1. Dans l'étude présente, un médicament donné est défini comme étant un médicament passant, sous
forme de marchandise, la frontière du pays destinataire.
2. Dans l'étude présente, un médicament est défini comme étant une substance ou un mélange de
substances destinés à diagnostiquer, prévenir ou à traiter les maladies.
3. Sont exclus de l'étude présente, les dispositifs médicaux  ( seringues, aiguilles, matériel de pansement,
etc.) ainsi que les biens de consommation (shampooings, compléments alimentaires, etc.)
4. Pour des raisons pratiques, le terme " organisation " comprend également des entreprises, des
institutions, des institutions religieuses et des particuliers.
PARTIE A: QUESTIONS GÉNÉRALES
1 Quelle description correspond au mieux à votre organisation?
Cocher la réponse correspondant au mieux
Swiss Centre for
International Health
Gaby Gehler Mariacher
Pharmacienne
Chaque opinion compte
Votre coopération est importante afin que l'étude du questionnaire soit aussi complète et exacte que possible
et je tiens à vous en remercier d'avance.
 Gaby Gehler Mariacher  (E-Mail: Gaby.Gehler@unibas.ch)
Le but du présent questionnaire est de récolter le plus d'informations possibles sur le don de médicaments
en provenance de la Suisse. Vous trouverez plus de details dans le résumé du projet d'étude.
Secteur public (par exemple organisation gouvernementale, Office cantonal de contrôle des médicaments,
Merci de préciser
Institution religieuse (par exemple mission, paroisse)
Merci de préciser
Merci de préciser
Merci de préciser
Organisation non publique à but non lucratif (par exemple organisation privée à titre bénévole, organisation
Organisation privée à but lucratif (par exemple officine, industrie pharmaceutique)
ID
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A laisser libre
- -
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2 Votre organisation, travaille-t-elle surtout dans le domaine de la approvisionnement de
médicaments?
Oui Non
Si Non, quelle est l'activité principale de votre organisation?
3 Dons de médicaments
3.1    Votre organisation est-elle impliquée dans le don de médicaments sous forme de don en nature?
Oui Non
3.2    A l'avenir votre organisation sera-t-elle toujours impliquée dans le don de médicaments?
Oui Non Je ne sais pas
3.4    Dans votre organisation occupez-vous une position de responsable concernant une activité de don?
Oui Non
Si Non, merci d'indiquer l'adresse de la personne responsable à la dernière page du questionnaire
Si Oui, merci de préciser sous quelle forme votre organisation est impliquée dans le don de médicaments.
 3.3   Votre organisation donne-t-elle en plus de l'argent pour que le destinataire puisse s'acheter
   lui-même des médicaments dont il a besoin ?
Oui Non Je ne sais pas
Si Oui, à quelles conditions le don d'argent est-il soumis?
3.5    Dans quelles situations les dons de médicaments sont-ils utiles?
3.6   Il existe des raisons pour et contre le soutien de l'approvisionnement de médicaments à l'aide de
  dons. Quelles sont, selon vous, les raisons les plus importantes?
Merci d'évaluer les raisons avec plus et avec minus
Si vous avez répondu Non à la question 3.1,
merci de continuer le questionnaire à la dernière page
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PARTIE B: DONS DE MÉDICAMENTS
4   Quelle description correspond le mieux aux destinataires de vos dons de médicaments?
Plusieurs réponses sont possibles
Secteur public (par exemple ministère de la santé, hôpital)
Merci de préciser
Institution religieuse (par exemple hôpital de mission, diocèse)
Merci de préciser
Merci de préciser
Merci de préciser
Organisation non publique à but non lucratif (par exemple organisation privée à titre bénévole, organisation
Organisation privée à but lucratif (par exemple pharmacie, industrie pharmaceutique)
5   Les régions dans lesquelles votre organisation fait des dons de médicaments
5.1     Dans quelles régions votre organisation a-t-elle fait des dons de médicaments en l'an 2000?
Asie
Afrique
Europe de l'Est
Amérique centrale
Autres régions
Plusieurs réponses sont possibles
5.2     Dans quelles régions votre organisation a-t-elle fait des dons de médicaments avant l'an 2000?
Asie Afrique Europe de l'Est Amérique centrale et Amérique du Sud Autres régions
Si vous avez répondu Autres régions, merci de préciser
Plusieurs réponses sont possibles
Dans quels pays?
Dans quels pays?
Dans quels pays?
Dans quels pays?
6  Dons en Tanzanie
6.1   Votre organisation a-t-elle fait des dons de médicaments en Tanzanie en l'an 2000?
Oui Non Je ne sais pas
En l'an 2000 nous n'avons pas fait de dons de médicaments
Si Oui, quels sont les partenaires/ destinataires en Tanzanie?
Merci d'indiquer, si possible, leur nom et adresse
Je ne sais pas
Dans quels pays?
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6.2  Votre organisation a-t-elle fait des dons de médicaments en Tanzanie avant l'an 2000?
Oui Non Je ne sais pas
6.3   A l'avenir votre organisation continuera-t-elle à faire des dons de médicaments en Tanzanie?
Oui Non Je ne sais pas
7   Dans quel but votre organisation donne-t-elle des médicaments?
Plusieurs réponses sont possibles
Pour les soins de santé primaires (médicaments de base)
Pour les soins de santé secondaires et tertiaires
En cas de catastrophes naturelles
Pour des camps de réfugiés et en situation de guerre
Si Oui, merci de préciser
Comme kit
Selon les besoins
Comme partenaire d'un programme déterminé (par exemple pour l'éradication de la lèpre, du trachome)
Pour le traitement de certaines maladies (par exemple le diabète, le sida)
Pour la recherche
Je ne sais pas
Autres
Si vous avez répondu Autres, merci de préciser
Suite à une demande de particulier
8  Votre organisation, où se procure-t-elle les médicaments donnés?
Plusieurs réponses sont possibles
Marchandise de vos propres stocks destinée à la vente
Production spécifique pour le don
En provenance de retours de marchandises ayant déjà été vendues une fois (médicaments non utilisés)
Autres
Si vous avez répondu Autres, merci de préciser
Je ne sais pas
Chez un fabricant
Achetés
Reçus gratuitement
Chez des grossistes à but non lucratif
Achetés
Reçus gratuitement
Chez des pharmacies
Achetés
Reçus gratuitement
Chez des hôpitaux
Achetés
Reçus gratuitement
Chez des organisations non gouvernementales (par exemple Pharmaciens sans Frontières)
Achetés
Reçus gratuitement
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9  Dans le domaine des dons de médicaments votre organisation coopère-t-elle avec des
    partenaires?
Oui Non Je ne sais pas
10  Valeur des dons
Env.
.
CHF
 10.2   Sur quelle base calculez-vous la valeur de vos dons?
Je ne sais pas
 10.1   Quelle était la valeur des dons de votre organisation en l'an 2000?
Plusieurs réponses sont possibles
Prix de vente dans le pays donataire
Prix de grossiste dans le pays donataire
Prix ex factory
Prix de vente d'un distributeur à but non lucratif
Je ne sais pas
PARTIE C: QUALITÉ DES DONS DE MÉDICAMENTS
11  Principes directeurs de l'OMS applicables aux dons de médicaments
11.1   Connaissez-vous les principes directeurs de l'OMS pour le don de médicaments?
11.2   Possédez-vous ces principes directeurs?
Oui Non Je ne sais pas
Oui Non
11.3   Ces principes directeurs ont-ils influencé votre activité de donation?
Oui Non Je ne sais pas
Si Oui, comment?
Si Oui, quels sont vos partenaires dans le pays donataire?
Merci d'indiquer, si possible, le nom et l'adresse des partenaires les plus importants
12  Votre organisation possède-t-elle ses propres directives concernant le don de médicaments?
Oui Non Je ne sais pas
Si Oui, merci de joindre un exemplaire en annexe
13  Besoins du destinataire
13.1   Votre organisation fait-elle des dons de médicaments sur la base d'une commande écrite du
   destinataire?
13.2   En l'an 2000, y avait-il des commandes écrites?
Merci d'indiquer, si possible, le nom et l'adresse des partenaires les plus importants
Prix sur le marché mondial
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Si Oui, quels sont vos partenaires dans le pays destinataire?
Exclusivement En partie Jamais Je ne sais pas
Oui Non Je ne sais pas
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14  Enregistrement des médicaments
14.1  Votre organisation donne-t-elle des médicaments enregistrés en Suisse ?
14.2  Votre organisation donne-t-elle des médicaments se trouvant dans la liste des médicaments
   essentiels de l'OMS?
14.3  Votre organisation donne-t-elle des médicaments se trouvant dans la liste des médicaments
   essentiels du pays destinataire?
15  Critères de qualité de votre organisation pour les médicaments donnés
15.1  Sur quels critères de qualité les dons de médicaments de votre organisation sont-ils basés?
15.2  Selon vous dans quelles circonstances le don de médicaments échus est-il justifié?
15.3  Durant combien de temps les médicaments donnés peuvent-ils encore être utilisés?
Une seule réponse est possible
Plus d'une année
Au moins 1 année
Au moins 6 mois
Périmés
Je ne sais pas
15.4  L'emballage et la notice d'emballage portent-ils des inscriptions dans une langue couramment
   utilisée dans le pays destinataire?
Toujours Quelquefois Jamais Je ne sais pas
16  Envoi des médicaments
16.1  Votre organisation joint-elle un certificat de qualité (par exemple de l'OMS) avec l'envoi des
   médicaments?
16.2  Votre organisation joint-elle un bulletin de livraison?
16.3  Comment les frais d'envoi sont-ils partagés entre votre organisation et les destinataires?
16.4  Comment les frais de douane sont-ils partagés entre votre organisation et les destinataires?
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Exclusivement En partie Jamais Je ne sais pas
Exclusivement En partie Jamais Je ne sais pas
Exclusivement En partie Jamais Je ne sais pas
Toujours En cas de besoin Jamais Je ne sais pas
Toujours Quelquefois Jamais Je ne sais pas
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16.5  Les destinataires sont-ils préalablement mis au courant de la composition et de la date d'envoi
   des médicaments?
16.6  Comment votre organisation communique-t-elle avec les destinataires des dons (par exemple
   E-Mail, fax)?
16.7  Comment décririez-vous la qualité de l'échange d'information avec les destinataires des dons?
PARTIE D: PROCESSUS DE DON
On entend par processus de don tout le chemin parcouru de l'envoi.
17  Selon vous, quels sont les problèmes majeurs dans les processus de don?
18  Selon vous, la vente de médicaments donnés par les organisations destinataires
 est-elle justifiée?
Oui Non
Merci de justifier votre réponse
 19 Votre activité de donation a-t-elle déjà été sujette à une évaluation?
Si Oui, merci de décrire brièvement les résultats
Oui Non Je ne sais pas
20 Selon vous, quelle fonction les pharmaciennes et pharmaciens occupent-ils dans les
processus de don?
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Toujours Quelquefois Jamais Je ne sais pas
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PARTIE  E: VOTRE COMMENTAIRE
22  Selon vous comment peut-on améliorer les processus de don?
23  Y a-t-il un sujet important qui n'a pas été traité dans ce questionnaire?
24  Quelles possibilités avez-vous dans votre position de contribuer à l'amélioration de la
 qualité des dons de médicaments?
21  Quels sont les problèmes majeurs dans les processus de don de votre organisation?
Plusieurs réponses sont possibles
Infrastructure insuffisante (1)
Qualité insuffisante des médicaments
Formation insuffisante des coopérateurs dans les processus de don
Mauvaise transparence dans les processus de don (qui est responsable, quelle est la démarche etc.)
Mauvaise communication entre donataire et destinataire
Frais d'envoi et de douane
Quantités de médicaments inadéquates pour un traitement des patients à long terme
L'introduction de directives ou d'autres garanties de qualité dans les processus de don
Pas significatif pour les maladies de la population
Aucun
Autres
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
 Quel est le problème le plus important? N°
Si vous avez répondu Autres, merci de préciser
25  Qu'entendez-vous par le terme "double standard de dons de médicaments"?
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PARTIE F: DONNÉES PERSONELLES
Les données figurant sur cette page sont confidentielles et elles seront gardées séparément.
Elles sont importantes pour d'éventuelles questions ultérieures
Prénom
Titre
Connaissez-vous des organisations, des institutions, des particuliers ou des groupes de personnes qui
s'occupent également de dons de médicaments et à qui ce questionnaire pourrait également être envoyé?
Nom
Organisation/Institution/Entreprise
Position dans votre organisation
Téléphone Fax
E-Mail
Date
. .
Jour Mois Année
Formation/Diplômes
Adresse
Merci beaucoup pour votre coopération
Nom et adresse de la personne responsable d'une activité de don dans votre organisation
Données personelles
Enquête/ge 2001
A laisser libre
23295194
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Annex 2: Question Guide  
Key Informant Interview: “Drug Donations – Is the Patient in Focus?” 
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Key Informant Interview: “Drug Donation - Is the Patient in Focus?” 
 
Date:….………………………………….…      Interview partner:………………………………………… 
Goal of the key informant interview 
The goal of the key informant interviews is to deepen the information obtained by the „Drug Donations“ 
survey (May – August 2001, in Tanzania and in Switzerland) and to discuss the preliminary results.  
Concept of the study 
The overall goal of the study is to analyse structures and process cycles of relevant drug donations. The 
advantages and disadvantages of different donation processes will be examined and main determinants for 
good patient-oriented donation processes will be ascertained. Based on these results, models for optimised 
donation processes will be developed. Results of this study will be discussed with reference to the 
Tanzanian drug and health care systems. 
List of questions 
We have done a short analysis from the first 230 returned questionnaires (approx. 20% of the sent 
questionnaires) from Tanzania. We have found the following preliminary results: 
 
A: Identification of main problems 
 
1 On the question: „What causes the main problems in the drug donation processes of your 
organisation?”, problems mentioned are listed in the figure below.  
How would you interpret this ranking according to your experiences?  
 
Problems in Drug Donation Processes
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The respondents pointed out as many problems as observed in their health facilities. Facilities that do not 
receive donations, did mostly not answer this question in general. Please note that the data presented 
above are compiled from preliminary results and are not definitive. 
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Identification of the Numbers of Problems according to the number of answers 
1 Quantities are not sufficient for long-term treatment of 
patients 
2 Guidelines for Drug Donations or other tools are not 
implemented 
3 Shipment and custom fees 
4 No transparency in the donation processes 
5 Not relevant for the diseases of the local population 
 
6 No communication between donor and recipient 
7 Insufficient infrastructures 
8 Insufficient training 
9 Poor quality of drugs 
10 Others 
11 None 
 
 
2 The following flow-chart reproduces a simplified donation process.  
What are the 3 strongest and 3 weakest features of donation processes according to your 
experiences?  
 
 
Donor 
 
 
Recipient 
 
 
Patient 
 
 
Procurement 
 
 
Communication 
Transport and 
custom fees 
Transparency 
 
 
Logistic 
Training 
Storage 
Management 
 
 
 
Distribution  
Rational 
prescribing of 
donated drugs 
 
 
Use of donated 
drugs 
Attitude towards 
donated drugs 
 
 
 
   Other areas: ……………………………….. 
 
 
B: Suggestions for optimising drug donation processes  
 
To the open question: „In your opinion, what are the most important actions needed to optimise drug 
donation processes?“, the five top answers were:  
 
1. To improve the communication between recipients and donors 
2. To assure the quality of donated drugs 
3. To support participatory collaboration in the donation process 
4. To meet local needs by donations 
5. To comply with national regulations of the recipients country and to follow and distribute 
“Guidelines for Drug Donations” 
 
Do you think that these proposed actions would be effective or do you suggest other solutions for 
optimising donation processes? 
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C: Particular questions 
 
1 Very often respondents noted (with the exemption of donation programmes) that drug donations 
cover up to 10% of their annual drug supply. On the other hand, it is discussed that drug donations are 
very important for the drug supply system in Tanzania.  
a. How is the remaining 90% of the drug supply covered?  
b. Why do you think that also a 10% coverage by drug donations is important for the drug 
supply system in Tanzania? 
 
2 To the question „What is the value of the donations received in 2000?“ we did not get many 
answers. How do you interpret this result? 
- The numbers are too sensitive to be published 
- Donations are perceived as gifts and not as commercial goods 
- It is difficult to estimate the value of donations 
- Other reasons 
 
D: Final remarks by the respondent 
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